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ABSTRACT
Polymer micro- and nanofluidic systems, with their critical dimensions, offer a potential to
outperform conventional analysis techniques and diagnostic methods by enhancing speed,
accuracy, sensitivity and specificity. In this work, applications of microfluidics have been
demonstrated to address the existing challenges in stroke diagnosis, by mRNA expression
profiling from whole blood within <20 min. A brief overview of various biomarkers for stroke
diagnosis is given in chapter 1 followed by design and testing of individual microfluidic modules
(chapter 2 and 3) required for the development of POC diagnostic strategy for stroke. We have
designed and evaluated the performance of polymer microfluidic devices for the isolation of
leukocyte subsets, known for their differential gene expression in the event of stroke. Target cells
(T-cells and neutrophils) were selected from with greater purities, from 50 µl whole human
blood by using affinity based capture in COC devices within a 6.6 min processing time. In
addition, we have also demonstrated the ability to isolate and purify total RNA by using UV
activated polycarbonate solid phase extraction platform.
Polymer-based nanofluidic devices were used to study the effects of surface charge on the
electrodynamic transport dynamics of target molecules. In this work, we report the fabrication of
mixed-scale micro- and nanofluidic networks in poly(methylmethacrylate), PMMA, using
thermal nanoimprint lithography using a resin stamp and surface modification of polymer
nanoslits and nanochannels for the assessment of the associated electrokinetic parameters –
surface charge density, zeta potential and electroosmotic flow. This study provided information
on possible routes that can be adopted to engineer proper wall chemistry of polymer
nanochannels for the enhancement or reduction of solute/wall interactions in a variety of relevant
single-molecule studies.
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CHAPTER 1.BIOMARKERS FOR POINT-OF-CARE DIAGNOSIS OF
STROKE: A LITERATURE REVIEW
1.1

Stroke Introduction
Stroke is a major cause of neurological disability and mortality affecting more than 15

million people worldwide. It is the third leading cause of death in the United States after
coronary heart disease and all cancers combined. In the United States alone, 795,000 cases are
reported annually with approximately 75% being classified as incident cases.1, 2 It is predicted
that the mortality rate of stroke will almost double by 2020 simply because, the ageing
population is more susceptible to stroke.3 Mortality due to stroke and their higher incidence may
be linked to a number of factors which are classified into modifiable and non-modifiable risk
factors. Modifiable risk factors include high blood pressure, diabetes mellitus, cardiac diseases
(such as atrial fibrillation, heart failure), high cholesterols, cigarette smoking, alcohol
consumption, obesity, sedentary lifestyle, and unhealthy dietary habits which account for 60% of
all strokes.4 The other 40% of stroke cases are mediated by non-modifiable risk factors such as
age, gender, ethnicity and genetics.
Strokes are classified as diseases of the brain vasculature that share a clinical syndrome,
which exhibits the rapid onset of a focal cerebral disturbance. The World Health Organization
defines clinical stroke syndrome as “rapidly developing clinical signs of focal (or global)
disturbance of cerebral function lasting more than 24 hours or leading to death with no apparent
cause other than that of vascular origin.”5 This definition includes stroke both due to infarction
and hemorrhage. Stroke accounts for 16% of all cardiovascular diseases (see Figure 1.1) and 24% of the healthcare costs worldwide, 6 and has a devastating impact on public health. Hence, it
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is imperative to identify early risk factors of stroke to predict the recurrence of the disease and
for primary prevention.

Figure 1.1 Deaths from cardiovascular diseases, U.S, 2010 (Adapted from National Heart, Lung
and Blood Institute, Disease Statistics)
1.2

Subtypes of Stroke and Pathophysiology
Stroke can be broadly classified into two subtypes, ischemic and hemorrhagic (see Figure

1.2). Both forms of stroke are neurological deficits causing impairment of language, motor
function, cognition, vision and affect and are caused by interruption of cerebral blood flow
resulting in a temporary or permanent change in one or more regions of the brain. The functional
changes associated with or resulting from (termed as pathophysiology) both subtypes are
different and complex depending on the nature of the lesion (area of damaged brain tissue).
Therefore, it is crucial to understand the biochemical mechanisms involved, to clearly delineate
the type, diagnosis, and prognosis of stroke.
1.2.1 Ischemic Stroke (IS)
Ischemic stroke accounts for 84% of all strokes. 7 IS can be further categorized into i)
intracranial thrombosis (large vessel and small vessel types, see table 1.1) primarily caused by
2

impairment of blood flow to the brain due to blockage of cerebral arteries and ii) extracranial
embolisms caused due to blockage of blood vessels resulting from a clot (embolus).

Figure 1.2 Subtypes of stroke. (A) Image of brain showing ischemic stroke. Blue area indicates
deprivation of blood supply and the inset shows blockage of blood vessels due lack of blood flow
to the affected area. (B) Hemorrhagic stroke showing an area of bleeding (in red). Inset shows
the leakage of blood caused by rupture of blood vessels. Reproduced with permission from
(www.alilamedicalmedia.com)
Table 1.1 Etiology of stroke

The onset of ischemic stroke initiates a series of neurochemical events, which are referred to as
an ‘ischemic’ cascade shown in Figure 1.3.
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Figure 1.3 (A) Summary of neurochemical changes that trigger the initiation of ischemic cascade
(B) Ischemic penumbra : a brain region of low perfusion in which cells have lost their membrane
potential terminally (‘core’) is surrounded by an area in which intermediate perfusion prevails
(‘penumbra’) and cells depolarize intermittently (‘peri-infarct depolarization’). Reproduced with
permission from reference [8, 9].
During ischemia, brain damage or neuronal death is caused by the failure of energy
producing compounds, like adenosine triphosphate (ATP), thereby causing a lack of glucose and
oxygen to the brain; thus, cellular homeostasis is not supported. The inadequate energy
production also affects the functioning of the ion gradient by the loss of potassium ions causing
cytotoxic edema (neuronal swelling). Numerous other complex mechanisms are involved in the
brain tissue causing ischemic stroke (see Figure 1.3A). They include the release of glutamate and
aspartate neurotransmitters in the brain, calcium channel dysfunction, and production of reactive
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oxygen species or oxygen radicals activating proteases and lipases that damage cellular and
extracellular elements.9, 10 All these processes result in either the immediate death of a part of
the brain parenchyma (core) or partial injury (penumbra) with the potential of recovery with
therapeutic intervention (see Figure 1.3B). The duration, severity, and location of ischemia are
the main factors which determine the extent of brain damage.
1.2.2 Hemorrhagic Stroke (HS)
Hemorrhagic stroke, which is responsible for about 16% of stroke cases, occurs due to a
ruptured aneurysm (abnormal bulging on the wall of arteries) in the brain causing blood leakage
into the surrounding tissue.11 Hemorrhage due to ruptured brain arteries is of two types,
intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH). 12 ICH originates from the
rupture of weakened cerebral vessels; most commonly, small arteries or arterioles causing a
blood leakage within the parenchymal cerebral space. This forms a localized hematoma (cavity
filled with blood) building up the pressure. The primary cause of ICH can be attributed to
hypertension. SAH on the other hand, is triggered by bleeding of the ruptured arteries into the
subarachnoid space further leaking into cerebral spinal fluid (CSF) blocking its circulation. This
causes extensive damage to brain cells and therefore, SAH is the most deleterious type of stroke.
The treatment for this type of stroke usually requires medications, which reverse the bleeding
that has occurred and might even require surgical drainage in some cases. A report from
Andersen et al. demonstrated the higher severity of stroke and mortality rates associated with HS
(49.2%) when compared to IS (25.9%).13
Stroke mimics (SMs) are non-stroke conditions (false positives) that present symptoms
similar to stroke and therefore, SMs are most often confused with stroke. SMs are defined as
diseases caused by neurologic symptoms which resemble a stroke, and their frequency varies
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from 1.2 to 25%14, 15 depending on the clinical evaluation. They are reversible with no significant
brain damage. The most common type of stroke mimics are migraine, 16 demyelinating disease,
tumors,17 meningitis,14 glucose level abnormalities like hypoglycemia, non-cerebrovascular
diseases such as epilepsy18 (caused by focal dysfunction), dementia, 19 and transient global
amnesia.20 Misdiagnosis of stroke has serious ramifications and therefore SMs must be excluded
for proper identification of stroke subtype and treatment management. A recent prospective
study of more than 300 patients with suspected stroke found 31% had SMs at the time of final
diagnosis.21 Libman et al. were able to correctly identify and diagnose stroke in 81% cases,
finding 19% to be SMs.22 The possibility of a stroke in case of SMs are ruled out by
neuroimaging methods, discussed in the next sections.
Transient ischemic attacks (TIAs), also known as mini-strokes, are defined as events caused
by transient interruption of blood flow to a part of brain and can be typically resolved within a 24
h time window. Unlike an actual stroke event, there is no severe damage to the brain cells in
TIAs. However, it is likely that the occurrence of stroke is preceded by a TIA, and studies show
that 35% of TIA patients have a chance of stroke within five years.23, 24 Also, the presence of
TIA conditions leads to recurrent strokes. Therefore, confirming the probability of stroke or TIA
versus SMs is extremely important.
1.3

Clinical Diagnosis of Stroke
The longer the treatment for stroke is delayed, the lesser the benefits from it. Hence, the

phrase “time is brain.” One of the most critical elements in stroke diagnosis is the time of onset.
In most cases, the arrival of the patient to the hospital is delayed due to the limited awareness of
signs and symptoms of the disease. Rapid assessment of patients suspected with stroke is
therefore highly crucial to accommodate the therapeutic treatment for any subtype of stroke by
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excluding SMs within a fairly short time window. Incidents of acute myocardial infarction are
also noticed in some of the stroke patients and as a part of the initial evaluation;
electrocardiography should be performed in such cases. The major challenges associated with
stroke diagnosis are the lack of imaging resources, lack of neurologic training in emergency
clinicians, exclusion of SMs and misdiagnosis, and the limited time window for effective
treatment.
1.3.1 Stroke Assessment Scales
Stroke scales are evaluation tools used to provide quick and quantitative assessments of the
severity of neurologic deficits including motor, sensory, visual and cognitive impairment,
functional outcome, global outcome due to stroke condition.25 These scales also provide
prognostic information and serve as a baseline to compare the progress or deterioration. Prehospital stroke scales are therefore critical for early recognition ultimately saving valuable time
in triage (priority of the treatment based on severity) and treatment of the patient.
Initial attempts were made to develop a unified scale but due to the complex nature and
heterogeneity of stroke, separate scales were developed. 26 Based on the type of information
collected about the patient, they are divided into the following sub-categories. i) Global outcome
scales such as the modified rankin scale, and the glasgow outcome scale, which provide a broad
overview about the neurologic disability ii) Physical deficit scales, such as the National Institutes
of Health Stroke Scale (NIHSS), which provides information about the deficit with the result
scores attached to severity based on the neurologic examination iii) Activities of daily living scales,
such as the barthel index , which measure the functional outcome and recovery useful in studies of

rehabilitation.27-30
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Stroke scale chosen must be simple, easily and expeditiously administered, and sensitive to a
patient’s condition.31 Although currently, existing scales do not satisfy all the criteria, NIHSS is
considered to be the best scale and is widely used in most stroke studies as it is a highly
reproducible numeric scale that can be completed within 5-8 minutes. It can be used both by
neurologists and non-neurologists. Higher scores in this 15-point assessment scale indicates
greater deficit. Compared to other scales, this scale has proven intrarater and interrater reliability
and has predictive validity for stroke outcome.32-34
It should be noted that these scales cannot be used in isolation in order to reach a decision
about the treatment method. The important metrics for the use of these scales in diagnosis are
validity and reliability. The diagnostic accuracy of most of these scales is about 80%, although
their sensitivity and specificity differ to some extent. It is important to understand that clinical
sensitivity and specificity differ from analytical sensitivity and specificity. Clinical sensitivity
refers to the percentage of people with the disease, identified positive for the disease by a given
assay whereas clinical specificity provides negative predictive value of the disease as determined
by the assay.35 Majority of these scales are used to measure severity and predict stroke outcome,
but they are not capable of distinguishing stroke subtypes. They might provide better results
when used in conjunction with brain imaging or blood biomarkers.
1.3.2 Neuroimaging Methods
Neuroimaging has become an invaluable tool for the initial and accurate diagnosis of stroke
and its subtypes. The advent of various imaging techniques have enabled clinicians to understand
the cause of the disease (etiology) and functional changes associated with the disease
(pathophysiology) of stroke and guide future therapy and provide the utmost benefit to the
patient by confirming the diagnosis. Stroke imaging serves two purposes: first to diagnose or
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confirm the occurrence of stroke by ruling out SMs and, second, to assess the location and
amount of potentially salvageable brain tissue and irreversibly infarcted tissue.
1.3.2.1 Computed Tomography (CT)
The most commonly used modality for imaging is CT because of its wide availability in most
clinical settings and quick acquisition times compared to other imaging methods. CT is the
“criterion standard” for stroke evaluation and the primary diagnostic test to detect ischemic
lesions and rule out ICH. Types of CT include noncontrast head CT (NCCT), CT angiogram of
the head and neck (CTA), and perfusion CT (PCT).36 NCCT is usually performed to identify
early signs of stroke and also exclude or confirm hemorrhages. It’s wide availability and the
speed of image acquisition makes it useful for initial evaluation of suspected stroke patients. 37
The limitation of an NCCT scan is that subtle signs due to the disease are missed in the first few
hours of stroke, resulting in about 40% false negative rates.38 The utility of CT for stroke has
been enhanced by the advent of newer generation CT scanners such as for CTA and PCT. 39
CTA provides information about vessel occlusion such as the site and length of the occlusion,
and gives a clear picture of cerebral blood vessels. 40 PCT requires a rapid injection of
intravenous contrast and repeated imaging of sections of the brain. Based on the total amount and
speed that blood flows to different vascular territories of the brain this technique can help in the
assessment of potential areas of salvageable tissue in the ischemic penumbra.41, 42 Ezzedine et al.
demonstrated the improvement of diagnostic accuracy by combining these two neuroimaging
modalities when compared to the use of NCCT alone. 39
However, the limitations of CT are exposure to ionizing radiation, side effects associated
with the use of intravenous contrast agents, inability of the scanners to image entire brain for
perfusion imaging as current scanners are limited to 2-4 cm wide area of the brain.41, 43
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1.3.2.2 Brain Magnetic Resonance Imaging (MRI)
MRI is another widely used neuroimaging method for the evaluation of stroke. This method
is associated with high cost, limited availability, and lengthy image acquisition times, but,
considered to be extremely sensitive in detecting ischemic lesions. MRI can also detect or
exclude ICH with an accuracy comparable to CT.44 It has also been shown that the sensitivity of
MRI is 83% and that of CT is 26% for the diagnosis of any stroke subtype. 45 Diffusion weighted
imaging (DWI), perfusion weighted MRI (PWI), magnetic resonance angiography, and fluid
attenuated inversion recovery, are some of the imaging techniques under the MRI umbrella.46
Images from DWI give information about the onset of ischemia, which may not be
sometimes seen using NCCT. Once a hemorrhagic stroke has been excluded by CT, DWI
improves stroke detection from 50% to more than 95%. 47, 48 PWI helps in the identification of
hypoperfused regions of the brain by using a contrast agent and like PCT, it can identify the
ischemic penumbra. Perfusion imaging of the entire brain is one of the main advantages of
PWI.48 DWI/PWI mismatch values detect the tissue subjected to infarction by subtracting the
volume of tissue restricted to diffusion from DWI and the volume of tissue that is poorly
perfused from PWI. Information about penumbra from DWI/PWI mismatch helps to identify
patients in need of tissue plasminogen activator (tPA), a clot buster drug or thrombolytic agent
(also known IV rt-PA or alteplase, usually given through a catheter inserted into a vein in the
arm).49-51 Despite significant advances in MRI techniques, implementation of MRI becomes
difficult due to longer scanning times, high costs, non-applicability in patients with
claustrophobia, and also impracticality in an emergency setting.
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1.4

Therapeutics for Stroke
Neurons in the low blood flow area of the penumbra are at a greater risk with elapsing time

leading to neuronal cell death. This is linked to the short therapeutic time window which refers to
time between the onset of symptoms and the treatment. For ischemic stroke, one therapeutic
measure is the restoration of cerebral blood flow to the affected region (reperfusion) to limits the
neurologic deficit. The most common therapy is thrombolytic therapy, which restores blood flow
to the damaged ischemic tissue by dissolution of the clot and reduce the neuronal tissue
damage.52 Another approach is neuroprotection, which involves the use of drugs to protect the
brain against neuronal dysfunction; their efficacy is limited due to the associated side effects, and
additional trials are still ongoing. 8 However, the combination of thrombolysis and
neuroprotectants may offer more advantages in the clinical management of stroke. 53
1.4.1 Recombinant Tissue Plasminogen Activator (rt-PA)
Currently, the only FDA (Food and Drug Administration) approved drug for ischemic stroke
is recombinant tissue plasminogen activator (rt-PA). It works by attaching to the fibrin in the
blood clots, and then activates the production of plasmin, which causes the clots to disintegrate.
This unblocks the blood vessel and restores the blood flow. The findings of a National Institutes
of Neurological Disorders and Stroke trial have shown a complete neurologic recovery in about
31 – 50% of patients treated with rt-PA in three months.54 However, rt-PA must be administered
within a narrow time window of 3-4 h from the onset of stroke symptoms. As large number of
patients arrive after the currently approved 3 h time window, administering a proper treatment
remains difficult. Therefore, some studies have been conducted on the expansion of the effective
therapeutic time window, but the results showed that increasing the time length between
symptom onset and treatment from 4-6 h made the rt-PA treatment less beneficial compared to
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treatment within 3 h.55-57 Moreover, this thrombolytic therapy (rt-PA) is contraindicated in HS
patients which might lead to threating outcomes. While the phenomenon about the increased risk
of hemorrhage with rt-PA administration is yet to be clearly elucidated, a CT scan must be
performed to check for the possibility of HS before administering rt-PA and patients with the
risk of HS are excluded. Due to this delay, the treatment can only reach 3-5% of patients with IS
in the United States.58,

59

So far, there is no FDA approved treatment for hemorrhagic stroke.

Other treatment methods for IS include perfusion enhancing approaches such as administration
of aspirin and heparin,60 use of anticoagulants (warfarin), antiplatelet agents, antihypertensive
agents and telemedicine.61
1.5

Role of Blood Brain Barrier (BBB) in Brain Injury
Understanding the physiology of the BBB is very crucial in developing an effective

diagnostic and therapy for several brain diseases, especially stroke. The BBB plays an essential
role in brain homeostasis. The BBB is a dynamic barrier, which protects the central nervous
system (CNS) from unwanted and neurotoxic substances circulating in blood and allows for the
transport and permeability of required nutrients. Any disruption or leakage of this barrier causes
brain dysfunction and stimulates natural immune or inflammatory responses. 62, 63 The BBB is
comprised of endothelial cells forming the capillaries of the brain with tight junctions Fthat
restrict the movement of molecules into the brain and maintain the cell polarity (which refers to
diversification of cell shapes through asymmetric cell divisions of stem cells that are crucial
proper functioning of differentiated cell types64). Other components of the BBB include
pericytes, astrocytes, and microglia, which support the permeability of this barrier and are
involved in the immune responses of the central nervous system (see Figure 1.4). 65 All these
together form a complex neurovascular unit. The BBB plays a major role in the immune system
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of the brain and any changes in the brain’s microenvironment caused by diseases like stroke
generates inflammatory responses due to activation of microglial cells and programmed cell
death (apoptosis) occurs.66, 67

Figure 1.4 Cellular constituents of the blood–brain barrier. The barrier formed by capillary
endothelial cells, surrounded by basal lamina and astrocytic perivascular endfeet. Astrocytes
provide the cellular link to the neurons. The figure also shows pericytes and microglial cells
which form the important components of a neurovascular unit. Reproduced with permission from
reference [65].
Breakdown of the BBB and damage of endothelial cells following brain injury increases the
permeability of the barrier and allows for the passage of biomarkers from the neurons and glial
cells (neuron supporting cells) into peripheral blood. 68 There is also evidence of leukocyte
infiltration into circulation in humans 48-72 h after stroke, and it has been hypothesized that the
accumulation of these leukocytes is the primary cause of tissue damage and prevents blood flow
after restoration.69 Specifically, neutrophil penetration into brain tissue causes significant damage
due to the release of oxygen free radicals and proteolytic enzymes. 70-73 Also, certain biomarkers
like matrix metalloproteinase-9 (MMP-9) are shown to play a biphasic role in stroke by
13

disrupting the blood brain barrier during the initial phases of the stroke event and promote
vascular growth during recovery phases. 74 Although the exact mechanisms and roles of different
cells in stroke is still unclear, better investigation of the BBB would pave the way for novel
therapeutic approaches.
1.6

Biomarkers for Stroke
Biomarkers are measurable indicators of any biological processes that may be used to

diagnose a disease, monitor its activity, predict its course, or assess response to treatment. 75, 76
Cells, genes, hormones, enzymes, or changes in biological function can be considered as
biomarkers.77 Development of a proper diagnostic test for stroke through biomarker
identification has remained a challenge for a variety of reasons, including the complexity of the
ischemic cascade and presence of the blood-brain barrier; efforts are ongoing in this field of
study. As discussed in the previous sections, neuroimaging techniques can be used as initial
evaluation tools depending on their availability in the clinical setting to identify the type of
stroke. Reaching a clinical decision may sometimes be limited by the experience of the medical
staff. An adjunctive test along with the neurological assessment becomes important especially in
cases where brain imaging appears normal. A rapid diagnostic test will, therefore, be extremely
helpful for pre-hospital screening, and can guide the intervention of thrombolytic treatment.
Biomarkers have the potential to provide insight into the mechanisms of brain injury and,
diagnostic information to improve patient management. They are also useful in the investigation
of prognosis and response to a therapy. The major challenge associated with finding promising
biomarkers for stroke diagnosis is due to their prolonged release following the event of stroke
and their inability to perfuse through the BBB.78 To date, no molecular diagnostic test exists for
stroke and no marker has proven to be clinically sensitive and specific to diagnose either
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ischemic or hemorrhagic stroke. One should note that analytical sensitivity and specificity are
distinct from clinical sensitivity and specificity. High analytical sensitivity does not always
guarantee high clinical sensitivity.35
Clinical sensitivity =

and provides information on the positivity of

the disease as determined by the assay. Clinical specificity =

and

provides information on the negativity of the disease as determined by the assay. Whereas,
analytical sensitivity refers to the ability of the assay to detect the lowest possible concentration
of an analyte in a given sample and analytical specificity is assay’s ability to identify a target
substance.35
There is no individual clinically useful biomarker for stroke, such as troponin or creatinine
phosphokinase for the diagnosis of coronary syndrome, B-type/brain natriuretic peptide (BNP)
for congestive heart failure, or D-dimer (DD) for pulmonary embolism, which have been used in
point-of-care platforms.79-81 Detection of ideal biomarkers in the case of neuronal injury is very
complex compared to heart diseases, due to the physiological differences between the brain and
the heart, such as cellular heterogeneity in the brain (multiple cell types and cells with
differentially localized elements such as axons and cell bodies). Also, the BBB limits the access
of markers in sufficient quantities to the vasculature, but there is direct vasculature access in
heart. Furthermore, complex biochemical pathways occurring in the ischemic cascade makes
biomarker isolation difficult. The validity of clinical judgment is also diminished by SMs . While
a significant amount of research has yet to be conducted on the benefits of single marker vs.
multi-marker panels, researchers postulate that multi-marker panel testing would increase
clinical sensitivity for accurate diagnosis. 82
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Investigations done by the scientific community suggest that an ideal biomarker or a panel of
biomarkers should be able to address the following diagnostic questions: (i) Does the patient
have stroke; (ii) Is it IS or HS; (iii) Is there a need for initiation of thrombolytic treatment with
the observed symptoms; and (iv) Is there a risk of recurrence? These questions can be addressed
by finding an ideal biomarker that can be released into blood in a fair amount of time in
detectable quantities, and the concentration levels should correlate with the volume of infarct.
Some practical considerations in the choice of these biomarkers include cost, factors that affect
the measurement, and the ease of obtaining the biomarkers. Ideal properties of biomarkers for
clinical utility are summarized in the Table 1.2
Table 1.2 Ideal properties of biologic markers. Adapted from Biomarkers Definitions Working
Group [Reference 76].

1.7

Types of Protein Biomarkers for Stroke
This section highlights the biomarkers relevant to ischemic stroke. Compared to ischemic

biomarkers, very little research has been carried out on hemorrhagic biomarkers due to fewer
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cases of HS. Biomarkers can be classified into several categories: (i) Imaging biomarkers that
measure the changes in the nervous system through brain imaging; (ii) Molecular biomarkers;
and (iii) Pharamacodynamic biomarkers, indicative of certain pharmacological responses useful
in drug development.83 Biomarkers based on drug development can be described as diagnostic
(defining the population within a specific disease) and prognostic (correlated with outcome). The
subsequent sections will focus mainly on molecular biomarkers in which measurements are made
on biological fluids like blood, plasma, serum, or CSF. The onset of any brain disease triggers
the release of several biomarkers into CSF and subsequently into the blood stream. Nevertheless,
not all the biomarkers released may be specific to stroke.

Figure 1.5 Categorization of potential biomarkers according to their role in ischemic cascade.
Markers for neuronal injury, lipid peroxidation, inflammation and homeostasis are illustrated.
Reproduced with permission from reference [84].
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Advances in proteomics and genomics have helped in the identification the potential
biomarker candidates. Among several current approaches, proteomics has attracted attention as
proteins are readily available in most of the body fluids and, studies offer an insight into both the
structure and function of proteins in relevance to stroke. Protein biomarkers are mostly studied
due to the better understanding of their relation with pathophysiology of ischemic stroke. Some
of the biomarkers involved in ischemic injury include those associated with glial activation,
inflammation, oxidative stress; thrombus formation, neuronal injury, and endothelial dysfunction
(see Figure 1.5).85, 86
1.7.1 Glial Biomarkers
During the initial events in the ischemic cascade, glial cells are activated, and inflammation
is generated in response to ischemia. The most extensively studied markers specific to glial
function are S100B, glial fibrillary acidic protein (GFAP), and myelin basic protein (MBP).
S100B is an acidic calcium binding protein in astrocytes and glial cells; increased concentrations
of S100B stimulate the cytokine production. In ischemic stroke, serum levels of S100B are
elevated within 12 h from symptom onset with continuous increase even after three days. 87 Even
in primary hemorrhagic stroke, higher S100B concentrations have been observed, predicting
higher morbidity.88,

89

It has also been shown that S100B correlates with the volume of

infarction, neurologic outcome, and its elevated levels in serum are believed to be due to BBB
dysfunction.90,

91

S100B cannot be considered as a stroke-specific biomarker as its levels in

serum and CSF are found to increase in other neurological disorders (trauma, Alzheimer’s
disease, and schizophrenia), extracranial malignancies (schwannoma,
neuroblastoma) and also due its delayed release. 92, 93
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melanoma and

GFAP is an immediate filament protein present in astrocytes and to a lesser extent in
ependymal cells. It is a marker of glial cell lineage and has been reported to increase in stroke
attacks with peak levels after 3 days. 94, 95 A study by Foerch et al. showed that GFAP is the
strongest candidate for detecting hemorrhagic stroke due to its significantly increased levels
observed in 81% of ICH patients compared to 5% of IS patients. Although increase in serum
concentration of GFAP is found to be correlated with volume of infarcted brain as well as S100B
concentration, its delayed release of 6 h after symptom onset limits its use in stroke diagnosis. 96,
97

MBP is a hydrophilic protein that plays an important role in the structure of myelin sheaths. 98
Increased levels of this protein are found in CSF are found in cases of stroke and multiple
sclerosis.99 Detectable levels of CSF MBP in IS subjects are observed after one week and levels
decreased after three weeks.95 The increased concentrations of MBP correlated with higher
NIHSS scores and large lesion volumes. 100 The limiting factor for the application of MBP as a
diagnostic marker of stroke is its latency in response to a stroke event.
1.7.2 Neuronal Biomarkers
During stroke, certain neuronal markers are upregulated and released into the CSF and bloodstream as a result of CNS cellular responses. Increased levels of these neuronal isoenzymes
signal damage to the brain parenchyma. 101 Several neurobiochemical markers that evaluate
neuronal injury have been identified and some of them are listed below (see Table 1.3).
Neuron-specific enolase (NSE) is a glycolytic enzyme specific for neurons. NSE levels are
detectable between 4-8 h of onset of stroke with peak levels after 24 h. 102

Some of the

limitations in using this biomarker include latency in release and less sensitive serum levels to
brain tissue damage, although the sensitivity is high in CSF. 103 There is no clear explanation in
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the literature on the variation of CSF and serum NSE levels but serum NSE levels were
significantly measured in case of greater injury. 104 Sensitivity may be the limiting factor for its
clinical use.
N-methyl-D-aspartate (NMDA) receptor is an excitatory amino acid receptor and is a
tetramer of two NR1 and two NR2 subunits.105 A pilot study found increased serum levels of
NMDA NR2 antibodies in patients with transient ischemic attack when compared to controls and
even higher levels in IS subjects. These elevated levels correlated with NIHSS score and lesion
volume.106 Ongoing research is focusing on measuring NMDA receptor and its utility as a
potential stroke biomarker.
Another neuronal biomarker, fatty acid–binding protein (FABP), is a cytosolic protein
involved in transporting long chains of fatty acids. FABP is expressed in various tissues and
rapidly released into circulation. In the central nervous system, heart-type FABP is present in
glia and brain-type FABP is present in neurons at elevated levels within 2-3 h of stroke onset.
Detection of this marker in a variety of other brain injury conditions does not make it strokespecific.107-109 FABP is also classified as a glial biomarker in some reports.
1.7.3 Inflammatory Biomarkers
One of the factors believed to cause neuronal death during the ischemic cascade is
inflammation, which causes increased levels of inflammatory markers. These biomarkers are
associated with increased infiltration of leukocytes. Biomarkers such as tumor necrosis factoralpha (TNF-α),110 MMPs,111 vascular cell adhesion molecule 1 (VCAM-1), C-reactive protein
(CRP),112 intercellular adhesion molecule 1 (ICAM-1),113 interleukin-6 (IL-6),114 (Table 1.3) are
some proteins involved in inflammation. All of these biomarkers have shown only moderate
clinical utility, either due to low sensitivity or specificity. 115
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Table 1.3 Summary of all protein stroke biomarkers and their functions

Protein

Glial biomarkers

Inflammatory
biomarkers

Neuronal
biomarkers

S100B

[88,96]

GFAP

[96]

IL-6

Cytokine involved in acute-phase response

[116]

CRP

An acute-phase reactant involved in
atherothrombosis and ischemic injury

[117]

MMP-9

Proteolytic enzymes that degrade collagendisrupting endothelium and plaque matrix

[118, 119]

VCAM-1

Immunoglobulin involved in leukocyte–
endothelial cell interaction

[120, 121]

TNF-α

Cytokine involved in inflammation and acutephase response

[116]

ICAM-1

Immunoglobulin involved in leukocyte–
endothelial cell interaction

[120]

ApoC-I
ApoC-III

Lipid metabolism

[122]

NSE

Neuronal marker; a neuronal glycolytic enzyme

[90, 123]

FABP

Cytosolic protein involved in long chain fatty
acid transportation
Glutamate excitotoxic response

[107-109]
[106]

vWF

A glycoprotein involved in coagulation, platelet
adhesion, and factor VIII binding

[124]

D-dimer

Marker of acute thrombosis; a breakdown
product of fibrin blood clot

[125]

NDKA

An RNA-binding protein; elevated in
neurodegenerative disease
Transfers phosphate between nucleosides

BNGF

A growth factor involved in
neuronal growth and differentiation

PARK7
Other
biomarkers

Ref.

Astrocyte marker; an intermediate filament
protein role in cell structure, blood
brain barrier, communication

NMDA

Thrombosis
biomarkers

Description and Function
Astrocyte marker; a calcium-binding protein
involved in cell cycle progression &
differentiation
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[126]
[126]
[82]

1.7.4 Evaluation of Protein Biomarkers for Clinical Utility in Stroke
Several studies have been conducted to evaluate the clinical utility of various stroke relevant
protein biomarkers, which involves measuring biomarker performance and its statistical
association with clinical state of interest to know more about the disease. As mentioned
previously, due to the heterogeneity of stroke and no individually useful biomarker, researchers
have evaluated multiple biomarker panels to obtain additional information useful for early
management.
The potential utility of five blood-borne marker panel consisting of MMP-9, S100B, B-type
neurotrophic growth factor (BNGF), von willebrand factor (vWF), and monocyte chemotactic
protein (MCP) was demonstrated by Reynolds et al. Within 9 h of onset of cerebral ischemia,
they distinguished IS from healthy controls with a sensitivity of 93% and a specificity of 93%
based on 75 samples, indicating the use of this marker panel in conjunction with CT imaging. 82
A pilot study Lynch et al. used 26 blood-borne biomarkers including MMP-9, VCAM-1, S100B
to differentiate IS from controls with a sensitivity and specificity was 90% within 24 h of
symptom onset.121 However, initial control subjects employed in this study were very less (65)
Identification of high levels of S100B and low levels of soluble form of receptor for advanced
glycation endproducts (sRAGE) blood biomarkers in ICH patients compared to IS patients,
suggested the use of these two biomarkers to distinguish between IS and HS according to
Montaner et al.127 Within 6 h of symptom onset, the increased levels of plasmatic biomarkers,
apoliprotein CI (ApoC-I) and apoliprotein CIII (ApoC-III) could distinguish between HS and IS.
ApoC-I provided 94% sensitivity and 73% specificity and ApoC-III 94% sensitivity with 87%
specificity. In this study, ApoC-III marker was also used to distinguish stroke (both IS and HS)
from controls with a specificity and sensitivity of 97% and 58%, respectively. 122 A recent study
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compared the performance of a biomarker panel (BNP, D-dimer, MMP-9, and S100B) to the
cincinnati prehospital stroke scale administered by an emergency room triage nurse in
diagnosing stroke.128 The potential utility of this biomarker panel was supported by additional
studies demonstrating the adaptability of this panel to point-of-care setting.129, 130
Although, some of the aforementioned studies showed good clinical sensitivity and
specificity; reliability, validity and ease of obtaining results still remains an issue. Moreover,
comparison between patient and healthy controls, typically results in overestimation of
sensitivity and specificity of these protein biomarkers. 131
1.8

Gene Expression Profiling of Peripheral Blood
Quantitative assessment of genes expressed in cells or blood samples is known as gene

expression profiling. Gene expression profiling has been applied to various disease states like
inflammatory disease,132 toxic exposure,133 multiple sclerosis,134 and renal carcinoma.135 These
studies demonstrated a promising approach and formed the basis for gene expression profiles of
white blood cells for finding diagnostic and prognostic biomarkers and providing mechanistic
insights into stroke. A disease can be identified by grouping clusters of up-regulated and/or
down-regulated genes and monitoring the changes in mRNA expression levels of the cells as a
response to the injury.
Biomarkers based on mRNA levels, especially in blood, are an emerging and exciting area of
research in medicine. mRNA biomarkers offers several advantages when compared to protein
biomarkers. mRNA levels are chosen to be monitored as they can detect genes with a low
expression level in protein.136 Currently known coding RNAs have been well described and
available on a single platform rather than identifying for best candidate biomarkers using
proteomic approaches.137 Moreover, mRNA is induced more quickly in response to injury when
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compared to protein expression. Also, mRNA expression analysis offers high throughput as tens
of thousands of genes can be analyzed at the same time. 138
One of the challenges of biomarker use is obtaining samples from the appropriate tissue.
Peripheral blood, therefore is a good source of mRNA for use in clinical trials, as plentitude of
information can be obtained from expression profiling by studying thousands of genes
simultaneously.139 Blood, being a biological fluid circulating through every part of the body, has
the potential to reflect any physiological changes during a disease state. It is also an easily
accessible source of tissue to identify the biomarkers for any disease, especially in a clinical
setting, as tissue biopsy is practically infeasible for neurological disorders. 139

Figure 1.6 Leukocyte interactions with intravascular elements relevant for stroke in humans.
Leukocytes (neutrophils, lymphocytes, and monocytes), platelets, red blood cells, and other cells
interact with each other and with endothelial cells in normal vessels. Leukocyte interactions with
endothelial cells, platelets, atherosclerotic plaque, blood clots, and intravascular molecules
(cytokines, chemokines, hormones, others) account for some changes of gene expression
following stroke. Leukocytes also signal to these other cell types, which also account for changes
of gene expression. Reproduced with permission from reference [143].
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Cell types involved with disease specific responses are mostly blood derived-mononuclear
cells (lymphocytes and monocytes); hence, peripheral blood mononuclear cells (PBMCs) are
highly significant in stroke.140 As discussed previously, there is an infiltration of leukocytes
during stroke that generates an inflammatory response. Each cell type has a unique gene
expression profile, and the change in their expression as a result of any physiological or
pathological change(s) can be studied from peripheral blood. 141 Although the exact role of
leukocytes in brain injury is yet to be clearly understood, it is hypothesized that leukocytes
interact with cells from every tissue, endothelial cells of the vasculature, foreign organisms or
cells, injured cells and every element within blood (see Figure 1.6).142 In addition, leukocytes
have a complement of expressed RNAs that reflect a combination of the genetics of these cells as
well as the interactions of those cells with their environment.
Two approaches that can be adopted for expression profiling are: (i) Extraction of RNA from
isolated pure fractions of PBMCs; and (ii) Stabilization of whole blood and extraction of RNA
from the whole blood cell lysate. Advancements in microarray technology utilizing porous glass
and plastic membranes facilitated the study of thousands of genes obtained from a single RNA
sample simultaneously.144, 145 The verification of gene regulation is most commonly performed
using real time/quantitative polymerase chain reaction (qPCR). Strict methods of RNA isolation
are very critical specially when comparing ischemic and healthy subjects. PAXgene based tubes
(for blood collection) are used for stabilization of whole blood, and the additive contained in
them prevents any RNA degradation and further alteration in transcriptional profile. However,
sensitivities less than 50% were reported using this approach. 146
A pilot study of gene expression in humans using peripheral blood was first conducted by
Moore et al. They identified a 22 gene-panel which distinguished ischemic stroke from controls
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with 78% sensitivity and 80% specificity.140 Further studies with whole blood using an 18 genepanel showed a change in gene expression of monocytes and neutrophils. 147 Prior to this, studies
by the same group suggested that differences in gene expression observed in white blood cells of
rat subjected to various brain specific stimuli might serve as a genomic fingerprint for various
diseases.148 Barr et al. identified a panel of 9 genes from 64 samples using whole blood to
distinguish stroke subjects from controls. 149 These studies demonstrated a proof-of-concept and
open the possibility for gene expression studies to identify the genes as biomarkers for
differentiating stroke subtypes.
1.8.1 MicroRNA Biomarkers
MicroRNAs (miRNAs) are a class of small, noncoding RNAs that target and regulate the
expression of complementary mRNAs. miRNA-based diagnostic assays were developed for
diseases such as lung cancer and pancreatic adenocarcinoma.150,

151

Emerging studies on

circulating micro RNAs (miRNAs) in several cardiovascular and other diseases demonstrate the
potential of miRNAs as biomarkers. Some of the attractive features of miRNA include; i)
detectable levels of miRNAs in plasma and serum; ii) ability to withstand freezing and thawing
cycles; iii) stability at high pH and temperatures; and iv) reproducible detection in healthy
individuals and expression levels are tissue specific. 152-154
Initial studies in IS rat models have demonstrated the elevation of miR-124 in plasma with
peak levels at 24 h. Furthermore, miR-210 decreased levels in IS were believed to be an
indication of severity of brain damage, which were further confirmed in a rat model. 155 A recent
study also revealed that elevated expression of circulatory miR-145 expression in peripheral
blood of IS patients compared to controls, but the source of miR-145 could not be identified.156
However, there remains a need for standardized quantification procedures and validation studies
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for miRNA profiling, but it would be interesting to explore the role of circulating miRNAs in
diagnosis and prognosis of stroke.157
1.9

Approaches for Stroke Biomarker Detection and Validation
Major components of successful biomarker development include discovery, qualification,

verification, clinical validation and use in clinical trials (Figure 1.7). In the discovery phase of
development, large sets of biomarker candidates are identified based on knowledge of the
pathophysiology of the disease and differential expression between diseased and normal states. 75
In the verification phase, the potential for success of a marker is determined by its clinical
specificity and sensitivity. Surviving biomarkers from the verification phase are then considered
for validation in a clinical environment. Validation is a lengthy process requiring a large cohort
of patients and robust clinical evidence obtained from several independent studies. 158 The major
challenge during this phase is recruitment of properly matched controls (age, gender,
demographics etc.) for comparison with the patient samples. 159
Advancements in -omic approaches (proteomics, genomics, metabolomics) have made it
possible to identify the expressional or functional changes of a protein, DNA or mRNA
expression during a diseased state and screen for useful biomarkers. 160 Proteomic approaches
have been used for the identification of potential biomarkers because the phenotypic diversity
among common genes can be determined by bioenzymatic functions of proteins. 161 Whereas,
genomic approaches like DNA or RNA microarray technology measures genome-wide mRNA
expression changes or DNA sequence changes (i.e., mutations), variations in biological/clinical
samples during developmental stages, drug treatments, and disease states. 162
Ideal biomarker detection strategies should be able to detect biomarkers present in limited
quantities in complex biological/clinical samples. Multiplexed immunoassays and quantitative
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mass spectrometry are two broader analytical platforms for the identification of biomarkers.
These techniques have radically improved the speed and precision of biomarker identification
and measurement in biological fluids and other samples. The type of analytical technique chosen
depends on the question to be addressed and availability of biological fluid for study. After the
discovery and verification, robust immunoassays must be developed and optimized to evaluate
their potential clinical utility. Some of the most widely used, label-based and label-free
approaches and their usefulness in identification and validation of stroke biomarkers will be
discussed here.

Figure 1.7 Representation of biomarker pipeline. Hypothesis-driven approaches and other high
throughput technologies suggest thousands of candidate biomarkers from which a set of putative
markers undergo systematic testing to establish the consistency of the association between
marker and disease (qualification) and to study the sensitivity and specificity of the indicator in a
larger number and a broader range of samples (verification). Few candidates after verification
process undergo a lengthy and rigorous clinical validation. Reproduced with permission from
reference [163].
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1.9.1 Immunoassays
1.9.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
ELISA is the most routinely employed technique for quantification and identification of
proteins, peptides, antibodies and hormones. This plate-based immunoassay detects binding of
the antigen and antibody is using an enzyme linked to a secondary antibody, which turns the
colorless antigen-antibody complex into a colored product when enzyme substrate is added (see
Figure 1.8).

Figure 1.8 Schematic representation of the sandwich ELISA in which the target molecule is
anchored to the substrate by capture antibodies and recognized by primary antibodies. The
enzyme is linked to the immunocomplex through interactions between enzyme-decorated
streptavidin and biotinylated secondary antibodies Enzymatic biocatalysis generates a coloured
compound. P – product S – substrate. Reproduced with permission from reference [164].
In the direct ELISA, antigen is detected using an enzyme-conjugated primary antibody
whereas; unlabeled primary and conjugated secondary antibodies are used in indirect detection.
The most sensitive and robust format of ELISA is the sandwich assay. In this assay, the analyte
to be measured is bound between the capture and detection antibodies. (see Figure 1.8). The
most commonly used enzyme labels are horseradish peroxidase and alkaline phosphastase. These
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enzymatic labels produce a detectable signal that is directly correlated to the binding of antibody
to an antigen and the colorimetric output is usually measured by spectrophotometer. ELISA can
be used for testing a few samples as well as high throughput screening with automated
procedures.
A pilot study by Stejskal et al. used sandwich ELISA method to evaluate clinical utility of
the visinin-like protein (VILIP-1), a CNS-abundant protein biomarker for brain injury and
several neurogenerative diseases, released into the circulation as a consequence of neuronal
destruction.12 Serum and CSF levels of VILIP-1 were found to be elevated in IS patients within 3
h of stroke onset, compared to healthy subjects. This study was able to achieve 100% clinical
sensitivity and specificity for stroke diagnosis. However, it cannot be completely assumed that
this protein will serve as a single biomarker for stroke as it still needs a larger cohort of patient
samples for further validation.165 Another ELISA-based study using organ samples of mouse
models enabled the measurement of VILIP-1 concentrations <100 ng/L and identified it as
potential candidate for an acute blood-borne biomarker of IS.161
Further ELISA studies, in a large cohort of European and American populations, for stroke
biomarker detection have shown increased concentrations of PARK7 (also called DJ-1) and
nucleotide diphosphate kinase A (NDKA) in plasma samples after 3 h onset of a stroke event
compared to a control population and remained increased up to 5 days after the initiation of the
event. The authors hypothesized that the possible reason for overexpression of both PARK7 and
VILIP-1 in plasma could be due to soluble protein produced by the injured neurons reaching the
blood at the site of the lesion. 126 Zimmerman et al. used ELISA to detect heart-FABP in the
serum of stroke patients and healthy controls. Clinical sensitivity and specificity were reported to
be 68% and 100%, respectively.166
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A new type of immunoassay, elongated oligonucleotide-linked immunosorbent assay
(EOLISA), for protein biomarker detection has been reported by Han et al. This method utilized
elongated DNA nucleotides (80-mer), a complementary RNA oligonucleotide and RNase H for
signal amplification (see Figure 1.9). This assay was evaluated for detection of FABP spiked into
healthy human serum samples. When compared to conventional ELISA, EOLISA showed 10fold higher detection sensitivity (0–1 ng mL-1 range.).167 Due to the improved sensitivity, this
proposed immunoassay is expected to be potentially useful in clinical analysis of biomarkers.

Figure 1.9 Illustration of EOLISA, a sandwich format which utilizes the biotinylated DNA strand
and the fluorogenic RNA probes appended with a fluorophore and a quencher at each. At the
signal amplification step, RNase H cleaves only the RNA part after forming RNA/DNA
heteroduplexes, resulting in fluorescence recovery due to the release of fluorophore from the
quencher. The iterative cycle of DNA/RNA duplexation and degradation of RNA by RNase H
leads to the fluorescence signal amplification. Reproduced with permission from reference [167].
Newer ELISA-based technologies like Searchlight® and Fastquant® allow for operation
with low final volumes, decreased analysis time and simultaneous analysis of multiple samples
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unlike conventional ELISA-based methods.168 Although ELISA is still considered as a gold
standard method for biomarker detection, some challenges still exist. Diagnostic assay
development using ELISA is limited due to the lower concentrations (lower than detection limit
of ELISA) of biomarkers in biological samples at the early of the disease 169 and the availability
of high-quality capture molecules, e.g., antibodies.
1.9.1.2 Microarray-based Assays
Microarray technologies have been extensively used to evaluate changes in gene expression
associated with onset and progression of a disease. 170 They permit simultaneous screening of
thousands of genes and allow i) in-depth understanding of genome-wide expression changes in
health and disease ii) prediction of clinical outcome iii) identification of diagnostic or prognostic
biomarkers.144, 171
In microarray studies, the term “probe” describes the nucleotide sequence attached to the
microarray surface; typically employed probes are DNA, antibodies or aptamers. Target refers to
what is hybridized to the probes.172 Based on the length of the probe utilized, DNA microarrays
are classified into i) cDNA microarrays (500-2500 bp double-strand cDNAs) and ii)
oligonucleotide microarrays (20-90 single-strand nucleotide molecules). For these microarrays to
be reliable tools, they must possess probe sequences that hybridize with high sensitivity and
specificity, thereby allowing precise detection of their intended targets. Gene expression
profiling using microarrays is performed according to the following steps described. mRNA
samples extracted from biological samples and reverse transcribed. 173 Targets are then prepared
by labeling mRNA samples with fluorescent dyes on the array. At the hybridization step, each
labeled nucleotide molecule (mRNA, cRNA, or cDNA) in targets hybridizes with a probe
complementary to its sequence on the array surface and forms a probe-target hybrid. An image is
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then using laser-induced fluorescent imaging. The principle behind the quantification of
expression levels is that the amount of fluorescence measured at each sequence specific location
is directly proportional to the amount of mRNA with complementary sequence present in the
sample analyzed. Signal intensities stored in image files can be transformed to numerical
intensity values for every probe on the array by appropriate algorithms.
Using peripheral blood mononuclear cells, a panel of 22 genes were found to be 80%
sensitive and specific for the diagnosis of stroke. The gene list was generated from a starting
number of 22,283 gene probes, and reproducible gene expression was found within 24 h after IS
and validated using qPCR.140, 174 Barr et al. recruited 67 stroke patients and 25 control subjects
and performed gene expression profiling of peripheral blood. They identified 9 genes based on
the 2-fold expression differences between stroke and healthy subjects as determined by the
statistical analysis. Significant changes on mRNA expression four genes were then validated
using qPCR which revealed the up-regulation of arginase 1, lymphocyte antigen 96, MMP-9 and
down-regulation of chemokine receptor 7.149 However, the exact role of all these genes in
ischemic stroke has not been specified.
Gene expression profiling of purified leukocyte populations (obtained from healthy donors)
using DNA microarrays containing 18,000 genes enabled the identification of cell-type-specific
gene patterns. Clustering analysis of these leukocytes revealed global expression levels of Tcells, B-cells and neutrophils from healthy donors and also variation of gene expression between
cell types within an individual. This finding suggested that subtle variations of gene expression
in peripheral blood cells can help in gaining an insight into any type of disease to develop
diagnostic biomarkers.175
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In order to circumvent the problems of translating a qualitative microarray approach into a
clinical setting, Adamski et al. used a new approach, high-throughput reverse transcription qPCR
which offers high throughput diagnosis, reduced background noise, this high sensitivity, allows
simultaneous screening of 96 transcripts from nL sample volumes for detecting complementary
DNA (cDNA) copies. Whereas, traditional qPCR is time consuming and offers low throughput.
As specific leukocytes are involved in pathogen recognition, innate, adaptive, cellular, and
humoral immune responses and tissue repair,141,

147, 176

gene expression among leukocytes

subsets were measured by extracting mRNA. Stroke related genes associated with white blood
cell differentiation activation and differentiation, 139 IL1R2, S100A9, F5, ETS2, C3AR1 were
shown to up-regulate their expression in stroke patients relative to healthy controls. (see Figure
1.10).177

Figure 1.10 Comparison of cell count–based and control gene analytic methods by two
independent approaches. The first was absolute, based on the cell count and normalized to the Cq
value of the corresponding transcript for the commercial complementary DNA. The second was
relative, measured relative to the average of the three selected control genes (FDFT1, FUT4, and
CD3E). Reproduced with permission from reference [177].
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Data analysis was performed based using cell counts and also control genes. Both the results
were in agreement with each other but cell count method was chosen to overcome the expression
alterations in control genes in different leukocyte subsets or in different disease states.
Furthermore, expression level of each gene can be assessed independently using cell count
method instead of relying upon standard control gene expression
1.9.2 Mass Spectrometry (MS) Techniques
MS is a label-free analytical technique used to measure the mass-to-charge ratio (m/z) of ions
and serves as a means of generating semi-quantitative data for measuring abundant proteins.
These technologies usually combine one or more means of high-resolution protein separation
techniques. Regularly used techniques for the expression analysis of proteins are matrix assisted
laser desorption ionization time-of-flight (MALDI-TOF) MS, Surface-enhanced laser desorption
time-of-flight (SELDI-TOF) MS, and liquid chromatography combined with tandem MS (LC–
MS–MS). Three basic analysis steps are involved in these approaches: (i) Sample preparation;
(ii) sample separation and analysis; and (iii) data analysis, which include protein identification,
quantification, and statistical analysis. Some studies for identification of stroke biomarkers are
outlined below.
Capillary electrophoresis (CE) is used to separate molecular species by their mass to charge
ratio in a small capillary filled with an electrolyte. This separation technique has high resolution
and is used to fractionate and analyze samples before MS. Stroke-specific peptides were
identified by performing CE-MS from 4,453 urinary proteins and peptides. 178 Dawson et al.
developed a 35 biomarker model, consisting of proteins such as FXYD domain-containing ion
transport regulator 4 (regulator of Na-K-ATPase), polymeric-immunoglobulin receptor (protein
transport across BBB) and several other proteins related to stroke severity. This panel showed a
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clinical sensitivity of 56% and specificity of 93%. Although their results show association of the
biomarkers with stroke, the study can been improved further and by also comparing TIA and
healthy controls instead of TIA and those having cardiovascular risk factors. 178
MALDI-TOF-MS is a powerful tool for the analysis of proteins and peptides and a sensitive
technique for the detection of compounds of interest below sub-femtomole (<10-15 mol)
levels.179,
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In MALDI, a matrix absorbs energy from a laser, often a 337 nm N 2 laser, and

causes ionization of the matrix followed by proton transfer to the analyte. 181 TOF analyzers are
commonly associated with MALDI due to their robustness, high data acquisition rate and
sensitivity and a great mass range (1-300 kDa).182 MALDI-TOF analysis was previously used to
identify biomarkers for accurate diagnosis of myocardial infarction.183

Figure 1.11 MALDI-TOF spectra of serum samples collected from ischemic stroke patients and
healthy controls. Serum-free Hb peaks (α and β chains, 15.1 kDa and 15.8 kDa are labeled. 186
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A pilot study by Huang et al. suggested the use of serum free hemoglobin (Hb) as a novel
biomarker for stroke due to the differential expression of Hb (α-chain and β-chain) in sera of IS
patients compared to controls (see Figure 1.11). Serum free Hb is a marker of hemolysis
associated with stroke and atherosclerosis.184,
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MALDI-TOF-MS analysis showed that the

clinical sensitivity of diagnosing IS with this approach was 70.2% and specificity was 85.3%.
However, clinical utility of this marker will be better understood by studying its correlation with
outcome and severity.186
SELDI-TOF-MS is a variant of MALDI-TOF-MS and particularly used for analyzing low
molecular weight proteins.187 SELDI is an affinity-based MS method in which the sample is
applied to a chromatographic surface so that it selectively binds to a subset of molecules from a
crude preparation whereas in MALDI the sample has to be purified before application to the
plate.188 SELDI-TOF analysis was used to correlate overexpression of 6.63 kDa protein, ApoC
III in plasma samples of stroke patients. ApoC III is a protein expressed in the liver and is known
to inhibit lipoprotein lipase on the surface of vascular endothelial cells.189,
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. Summary and

figures of merit for all biomarker studies using immunoassays and MS approaches is listed in
Table 1.4.Some challenges associated with SELDI-TOF-MS and MALDI-TOF-MS concern
reproducibility, which is critical for reliable differential diagnosis, their inability to detect high
molecular weight proteins (>100 kDa).
Other approaches documented for the detection and validation of biomarkers for stroke
included the use of a chemiluminiscence immunoassay and micellar electrokinetic
chromatography coupled to laser induced fluorescence (MEKC-LIF). The presence of the most
studied proteins in stroke, NSE and S100B, were detected using chemiluminiscence duplex
immunoassay technique. It involved the detection of S100B, NSE with alkaline phosphatase and
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horseradish peroxidase labels respectively; capture antibodies against markers coupled to
magnetic beads. Detection limit for S100B was found to be 0.005 ng/mL, and NSE was 0.20
ng/mL achieved in a single experiment without any crosstalk.191
Table 1.4 Summary of biomarker studies of stroke using various immunoassays and mass
spectrometric analysis
Technique

Biomarker

Sandwich ELISA

PARK 7
NDKA

Sample
Type
Plasma

Sensitivity
(%)
84.9

Specificity
(%)
96.7

72.6

96.7

Ref.
[126]

Sandwich ELISA

VILIP-1

Serum

100

100

[1]

ELISA

H-FABP

Plasma

68

100

[166]

CE-MS

35
Biomarkers
Serum free
hemoglobin

Urine

56

93

[178]

Serum

70.2

85.3

[186]

MALDI-TOF-MS

MEKC-LIF method based on the derivatization with 3-(2-furoyl)quinoline-2-carboxaldehyde
was optimized to separate and detect primary amines from plasma. MEKC-LIF was used to
simultaneously detect

five amine biomarkers,

homocysteine, excitatory amino acid

neurotransmitters principally including glutamic acid, polyamines such as putrescine, spermine,
and spermidine, from plasma samples of neuroimaged ischemic stroke patients with limits of
detection 0.2–2.1 nM (at S/N=3), showing about 800 fold higher sensitivity compared with the
usual concentration levels of these analyses in human plasma under normal or
pathophysiological conditions.192
1.9.3 Nanotechnology and Lab-on-a-Chip (LOC) Approaches
An analytical platform integrating proteomics and nanotechniques is termed as
“nanoproteomics”. The advent of several new nanomaterials has enabled the detection of novel
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biomarkers for various diseases like cancer, cardio vascular diseases, infectious, and autoimmune
diseases using nanoproteomic approaches. 193 Detection strategies such as gold nanoparticles, 194196

silicon nanowires and nanoparticles,197,

198

carbon nanotubes,199,

200

nanomechanical

resonators,201 quantum dots202, 203 have been extensively applied to cancer biomarker detection
but none of these methods have been applied for stroke biomarker studies so far due to the lack
of promising biomarkers specific only to stroke.

E)

Figure 1.12 Design of the LOC detection area (left panel) consisting of magnetoresistive
spinvalve sensors and each sensor is made up of multiple alternating magnetic and nonmagnetic
metal layers of 1 to 10 nm each. The resistance of the spinvalve sensor changes in response to an
external magnetic field which can be measured as output voltage change. (A) detection area
consists of two rows of 12 sensors (B, D) each sensor is made of 9 spinvalves that are electrically
connected in parallel (C) sensing area is covered with gold on which magneto-sandwich assay is
build up (E) scheme of magneto-sandwich assay on the spin valve sensing area; coated with a
self-assembling monolayer of alkane thiols, onto which the primary antibody is immobilized.
Secondary antibody binds to the proteins added and forms a link with magnetic beads added in
the final stage. 205
The study for stroke diagnosis using LOC has been conducted by Belgian researchers. They
built a magnetoresistive spin valve based detection platform (see Figure 1.12) for detecting low
abundant stroke diagnostic marker like S100BB (a subtype of S100B and a ββ-homodimer).

39

S100BB is a glial protein which is released into CSF and blood between 48-72 h of stroke
onset.88 This protein predicts BBB disruption.204 The concentration of S100BB is 1-100 pg/mL
in blood and this LOC platform was able to achieve a detection of upto 27 pg/mL. 205 However,
details about target analyte and sample processing have not been mentioned.
1.10 Point-of-Care Testing (POCT)
POCT refers to the diagnostic testing outside the central lab, without the need for trained
personnel and lot of laboratory processing. The main objective of POCT is to provide immediate
results and render better patient management by minimizing the time between testing to
diagnosis and treatment.206 The analytical targets for POC testing include proteins, nucleic acids,
metabolites, drugs, human cells, and microbes from samples such as blood, saliva, urine, or other
bodily fluids or (semi) solids.
Table 1.5 Desirable characteristics of point-of-care assay

For time sensitive medical conditions like stroke, developing a POC diagnostic device offers
possibilities to accelerate stroke management by reducing times for transport, analyses, or
transmission of results further reducing the healthcare costs. The need for easy-to-use medical
technologies in low resource settings can be addressed by developing POC diagnostic tools. Two
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types of POCT formats in use are benchtop analyzers and handheld portable devices. They
require only basic instructions to use and provide easily interpretable results.207 The desirable
characteristics for such a device are outlined in Table 1.5 (Adapted from Cardiac markers: point
of care testing [Reference 206]).
Triage stroke panel is a currently existing POC testing strategy based on a panel of
biomarkers associated with IS to provide diagnostic information in patients with suspected
stroke. It is a rapid, point-of-care fluorescence immunoassay used with the triage meters for the
rapid, quantitative measurement of BNP, D-dimer, MMP-9, and S100B in whole blood or
plasma specimens. The Triage meter plus (Biosite Incorporated, San Diego, CA) is a battery
powered portable fluorometer that display digital results in a turn-around-time of 20 min, by
conversion of fluorescence measurements into electrical signals.208
To eliminate the confusions in interpretation of clinical data due to multiple markers,
Biosite® has developed an algorithm called MultiMarker Index™ (MMX). The MMX value,
derived from individual analyte values, function like an analyte that is sensitive and specific to
the disease. It has a receiver operating characteristic curve, and the MMX value cutoff can be
chosen based on clinical needs. The clinical performance of this triage stroke panel assay has
been assessed in few studies128, 130, 209, 210 and it has been shown that utility and diagnostic of this
marker panel when combined with other diagnostic methods. However, further validation studies
are required before their use in clinics.
1.11 Conclusions
Advances in stroke research have clearly demonstrated that “time is brain” and immediate
medical intervention is necessary due to the narrow time window (3 h). With the existing
diagnostic methods, time required to perform neuro-imaging and the limited availability of
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neuro-imaging instruments prompt the need for a rapid diagnostic test that is capable of
providing results within a few hours of stroke onset.
Identification of clinically relevant markers is a challenge as not all biomarkers are
legitimate therapeutic targets. A single biomarker however, cannot be ideal for use as a
standalone diagnostic test due to the complexity in etiology of stroke. Substantial efforts are
ongoing to identify different biomarkers associated with stroke. In order to improve clinical
outcome, development of a multi-biomarker panel, which can indicate the brain damage by
correlating to the volume of infarction and quick release into the blood/biological fluids upon
stroke onset adds valuable and time-sensitive diagnostic information in the early evaluation of
stroke.
Pilot studies conducted, identified protein biomarkers that distinguished stroke from controls
and HS from IS suggesting their potential to provide rapid assessment and personalized patient
care in acute stroke. It is very important to realize that a direct comparison cannot be made
between clinical sensitivities and specificities obtained from different biomarker studies. This is
because of large variance in factors such as the recruitment of control subjects, samples obtained
within various time windows from symptom onset and total number of samples analyzed.
Therefore, further validation studies in large cohort of patients are required for determining their
clinical utility and cost effectiveness. Compared to the use of protein biomarkers, mRNA
profiling of peripheral blood has the potential to improvement of accuracy of stroke diagnoses
and to accommodate stroke therapy as the recent studies by Baird et al,139 Tang et al147 and
Moore et al140 provide an evidence on the reproducibility of peripheral blood gene expression
signatures and also constant gene expression levels for atleast a week.
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Also, the absence of a widely available and rapid diagnostic test for stroke remains a
significant limitation in the evaluation and treatment of this disease. Therefore, stroke biomarker
detection could benefit immeasurably from the application of microfluidic based technology for
mRNA expression profiling and detection of stroke biomarkers to further create a portable and
fully automated POC diagnostic tool for rapid blood-based diagnostic testing. This would reduce
turn-around-time to assist physicians in making proper diagnostic decisions.
1.12 Outline of the Dissertation
This work consists of 5 chapters focusing on microfluidics and nanofluidics. A summary of the
contents of each chapter is presented below.

The major focus of this work is to develop a portable, automated instrument which would
serve as a near patient technology for the diagnosis of ischemic and/or hemorrhagic stroke using
mRNA expression profiling directly from whole blood within a processing time <20 min to
accommodate effective therapeutic treatment of this disease. This will be achieved by developing
a fluidic bio-processor fabricated in polymers via micro-replication technology and integrating
task specific modules on a fluidic motherboard. Chapters 2, 3, 5 provide an indepth elucidation
of this project.
In chapter 2, cell isolation module is described in detail. This microfluidic cell isolation module
enabled the isolation the multiple leukocyte subsets (T-cells and neutrophils) relevant for stroke
diagnosis based on the differential expression of several genes in these cell types. Cell recoveries
and purities of isolated cells were reported. Fluid dynamics and microfluidic design architectures
were emphasized. Solid phase extraction (SPE) module for purification of RNA extracted from
the isolated T-cells and neutrophils (as discussed in chapter 2) using photoactivated
polycarbonate SPE bed remains the focus of chapter 3. RNA purification results in a single step
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by serially connecting the cell isolation and SPE modules were also discussed. Finally in chapter
5 details on the proposed integration of aforementioned modules in addition to some other
modules are discussed as the future work.
Chapter 4 describes the investigation of surface charge density, zeta potential and
electroosmotic flow in surface modified nanofluidic systems (nanoslits and nanochannels).
Surface modification of these nanofluidic devices via plasma modification and amination and
relevant surface characterization studies were elucidated in this chapter.
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CHAPTER 2. PARALLEL AFFINITY-BASED ISOLATION OF
LEUKOCYTE SUBSETS USING MICROFLUIDICS: APPLICATION FOR
STROKE DIAGNOSIS*
2.1 Introduction
Isolation of pure leukocyte subsets and their molecular analysis from whole blood is
challenged by the presence of numerous interfering cells. 1 The use of conventional isolation
methods such as density gradient centrifugation, sedimentation, and fluorescence assisted cell
sorting (FACS) are typically time consuming, require large volumes of blood and employ
sophisticated equipment. Microfluidics, however, are extremely attractive for blood analysis
because of the potentially short assay turnaround times and the ability to scale devices for pointof-care applications.2, 3
The use of microfluidics to isolate a certain type of leukocyte has attracted wide interest. For
example, Cheng et al. reported a two-stage microfluidic for the isolation of CD4+ T-cells; a
purity of ~90% was achieved.4-6 Lee and coworkers constructed a functionalized silicon and
quartz nanowire array to separate CD4+ T-cells from mouse splenocytes.7,

8

Thorslund et al.

fabricated a glass/PDMS/anti-CD4 microfluidic chip containing different architectural features
for CD4+ T-cell isolation.9 Warner et al. reported a microfluidic neutrophil-capture device
followed by gene expression analysis to observe changes after trauma injury. 10 They obtained
purities of 95% by processing 150 µL of whole blood through the chip that isolated ~25,000 cells
and yielded 69 ng of RNA. Common to these elegant examples was that only a single cell type
was isolated from the sample.
Stroke is the third leading cause of disability and death in the United States. 11 There are two
*Reproduced with permission from Analytical Chemistry
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types of stroke: (i) Ischemic stroke caused by vessel occlusion and occurs at a frequency of 8085%; and (ii) hemorrhagic stroke resulting from vessel rupture and is identified in 15-20% of all
stroke-related cases. Unfortunately, these two conditions cannot be differentiated using existing
clinical tests, which typically employ CT or MRI. Additionally, a third of all patients presenting
stroke-like symptoms actually suffer from non-vascular disease.12 It is imperative that stroke
diagnosis be made quickly and accurately because treatments for ischemic and hemorrhagic
stroke differ and there is a short time window (~3 h) for effective treatment. 13-17
Because head-related trauma or stroke tissue is not easily acquired, researchers have looked
for markers in the peripheral blood due to its accessibility, 18-20 and there have been ongoing
efforts to find reliable blood-based stroke biomarkers that afford high clinical sensitivity and
specificity.21 Several potential biomarker candidates that can be measured in serum or plasma
have been identified with their role in the underlying pathophysiology investigated. 22
Reports have shown that T-lymphocyte mediated anti-inflammatory responses in ischemic
brain injury23-26 and the expression of nearly 5,700 genes related to T-cell function change in
cases of head trauma.27 mRNA can be harvested from specific types of blood cells and used as
biomarkers that reflect the systemic changes in stroke.28 Transcripts of promise for detecting and
differentiating between ischemic and hemorrhagic stroke include S100A9 and IL1R2.29-32 Gene
expression studies conducted by Adamski et al. identified differential expression across different
leukocyte subsets, such as CD4 T-cells and neutrophils.33 These cells are known to express genes
found in stroke-related expression profiles.34 Therefore, the ability to rapidly isolate these
leukocyte subsets and secure their mRNA expression profile without interference from other
leukocyte subsets could provide a viable test for diagnosing various types of stroke. 35-38 Isolation
of pure fractions of these subsets is critical to provide unbiased expression data.
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In this study, we report a microfluidic device that can simultaneously isolate different types
of cells using affinity agents. As an example, we show the positive selection of CD4+ T-cells and
CD66b+ neutrophils from minute amounts of unprocessed and unfractionated blood. The device
design allowed for simultaneous isolation of up to four types of cells. The device architecture
and flow parameters allowed for the isolation of very pure subsets (>90%). Total RNA (TRNA)
was extracted from the isolated cells and reverse transcribed to monitor mRNA expression
changes from the isolated cells. To the best of our knowledge, this is the first report on the
simultaneous isolation of multiple leukocyte subsets. The selected subsets were used to
expression profile certain genes that possess diagnostic value for stroke. The figures-of-merit for
two device geometries were evaluated as well as the applicability of two different polymers,
poly(methyl methacrylate), PMMA, and cyclic olefin copolymer, COC, for optimizing antibody
load and cell recovery. We also introduce a chemical–based polymer surface activation method
that utilized sodium hydroxide and isopropanol, which provided efficient and simple polymer
surface activation resulting in high antibody loads.
2.2 Materials and Methods

2.2.1 Buffers and Reagents
PMMA (cover plates and substrates), 6013S-04 COC cover plates and 5013L-10 COC
substrates were purchased from Plaskolite (Columbus, OH) and TOPAS Advanced Polymers
(Florence, KY). Reagent-grade isopropyl alcohol (IPA), 1-ethyl-3-[3-dimethylaminopropyl]
carbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), and 2-(4-morpholino)-ethane
sulfonic acid (MES), bovine serum albumin (BSA), Triton X-100, and paraformaldehyde (PFA)
were obtained from Sigma-Aldrich (St. Louis, MO). Phosphate buffered saline (PBS, pH = 7.4)
was purchased from Life Technologies (Grand Island, NY). Sodium dodecyl sulfate (SDS),
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Micro-90, sodium hydroxide (NaOH) and histological and laboratory grade IPA were received
from Fisher Scientific (Houston, TX) and toluidine blue O (TBO) from Carolina Biological
Supply (Burlington, NC). Cy3-labeled oligonucleotides (5ʹNH2-C6-TTT-TTT-TTT-TTC-CGACAC-TTA-CGT-TTT-TTT-T-Cy3-3ʹ) were purchased from Integrated DNA Technology
(Coralville, IA). Low endotoxin anti-human CD4 antibodies (clone RPA-T4), FITC-conjugated
anti-human CD20 antibodies (clone AT80), and PE-conjugated anti-human CD14 antibodies
(clone TÜK4) were purchased from AbD Serotec (Raleigh, NC). FITC-conjugated anti-CD66b
(clone CLB-B13.9) antibody was obtained from Abcam (Cambridge, MA). Anti-human CD66b
antibodies (clone- G10F5) and 4ʹ, 6-diamidino-2-phenylindole (DAPI) were obtained from BD
Biosciences (San Jose, CA).
2.2.2 Microfluidic Device Fabrication and Assembly
Microfluidic devices were hot embossed into COC or PMMA substrates via microreplication from a metal mold master as previously reported.39 Two architectures (Figure 2.1)
were tested in these studies, both possessing four independent cell isolation beds comprised of
parallel arrays of curvilinear cell isolation channels with an 8 x 13 mm2 footprint.40 Prior to
device assembly, inlet and outlet reservoirs (d = 0.85 mm) were drilled into both chip designs
followed by cleaning with 10% Micro-90 and IPA and then drying at 60ºC. A 250 µm thick
cover plate and the device substrate were activated for 15 min in a home-built UV chamber
equipped with a low pressure Hg lamp (22 mW/cm2 at 254 nm) to generate carboxylic acid
scaffolds on the microchannel surfaces. 41 Thermal fusion bonding of the cover plate to the
substrate was performed at 132ºC and 100ºC (~25 min) for UV-modified COC and PMMA
devices, respectively. PEEK tubing of 175/335 µm id/od (IDEX Health & Science LLC) was
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inserted into the reservoirs and glued in place with epoxy. A constant flow programmable
syringe pump (Harvard Instruments) was used to introduce fluids into the devices.
The architectures for the 2 devices evaluated herein differed in terms of their addressing of
the selection beds (4 per device) employing either a bifurcation network or Z-configuration
(Figures 2.1A,C and Figure 2.5). In the Z-configuration device (Figure 2.1C), each cell isolation
unit consisted of 64 curvilinear channels that were 9,000 x 25 x 80 µm (l x w x h) with a centerto-center spacing of 200 µm. Two 150 µm wide inlet and outlet channels poised orthogonally to
the isolation channels addressed the selection bed. The surface area of a single bed including
inlet and outlet channel was 132.3 mm2 (1.9 mm2, 1.15 µL per channel).

Figure 2.1 An autoCAD drawing of (A) the bifurcated device with the cell isolation bed
containing 16 curvilinear channels spaced by 330 µm. (C) Z-configuration isolation bed
containing 64 curvilinear channels spaced by 200 µm. All curvilinear channel dimensions were
25 × 80 µm (w × h). (B, D) SEM’s of the isolation beds bifurcated and Z devices respectively.
The bifurcated device contained isolation beds with 16 curvilinear channels that were 11,000
x 25 x 80 µm (l x w x h) with a center-to-center spacing of 330 µm between channels (Figure
2.1A). Each isolation bed’s surface area was 36.8 mm2 (2.3 mm2/channel) with a volume of 352
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nL. Addressing each bed required four bifurcations with an additional two bifurcations for the
four independent isolation units. All four isolation beds shared a common inlet port with
different outlet ports for each cell isolation unit (Figures 2.1B). The total surface area, including
the bifurcation network, was 43.4 mm2.
2.2.3 Antibody (Ab) Immobilization to Activated Polymer Surfaces
Ab immobilization was a two-step process. In the first step, 50 mg/mL EDC and 5 mg/mL
NHS in 100 mM MES (pH = 4.8) was introduced into the device and incubated for 15 min at
room temperature followed by flushing with PBS. Then, a 15 µL aliquot of 0.5 mg/mL mouse
anti-human CD4 or anti-human CD66b monoclonal antibody (mAb) was introduced into the
device and incubated overnight at 4ºC. The selection bed was then rinsed with 1 mL PBS (pH =
7.4).
2.2.4 Fluorescence Staining of MOLT-3 Cells and Flow Cytometry Analysis
MOLT-3 cells (human acute lymphoblastic leukemia) were cultured as a suspension in 25
cm2 culture flasks (Cell Treat Scientific, Shirley, MA) containing RPMI 1640 Medium (Life
Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Life
Technologies, Grand Island, NY). FC was performed using a Beckman-Coulter CyAn instrument
equipped with a 25 mW, 488 nm Coherent sapphire (blue) laser.
Prior to staining of the MOLT-3 cells for determining CD4 expression, Fc receptors were
blocked with 5 µL of 1 mg/mL human IgG-Fc blocker (R&D Systems, Minneapolis, MN) and
incubated at 4ºC for 15 min. The following samples were prepared for analysis: (i) Unstained
cells serving as an autofluorescence control; (ii) cells stained with 10 µL of 0.1 mg/mL isotype
control, IgG1-FITC mAbs ( R&D Systems, Minneapolis, MN) and incubated in the dark at 4ºC
for 30 min; and (iii) cells stained with 10 µL of 0.1 mg/mL CD4-FITC Abs (BD Biosciences,
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Franklin Lakes, NJ) and incubated in the dark at 4ºC for 30 min. Cells were then washed three
times: One mL of cold PBS-0.5% BSA was added; the cells were centrifuged for 4 min at 350x
g; supernatants were decanted and resuspended in 1 mL PBS. Propidium iodide staining (1
µg/mL) was performed on all the samples (except for the autofluorescence control) just prior to
the analysis for the determination of cell viability as detected by red fluorescence. Samples were
then analyzed on a CyAn flow cytometer (Beckman-Coulter) equipped with 25 mW 488 nm
laser within 2 h after staining. Gain and amplitude settings were set and kept constant throughout
the analysis. Ten thousand events were counted for all samples. Data acquisition and analysis
was performed using Summit software (Dako, Carpineteria, CA).
2.2.5 Cell Isolation from Whole Blood, Staining and Enumeration
Whole blood samples were obtained from anonymous healthy donors at the UNC Blood
Bank in accordance with UNC Institutional Review Board (IRB) procedures. Peripheral blood
samples were collected by venipuncture in Vacutainer tubes containing EDTA (7.5% in 0.06
mL; Tyco Health Care). Samples were processed within 4 h following collection.
The microfluidic device was connected to the syringe pump with PEEK tubing via a luer lock
syringe connector (Hamilton, Reno, NV). A pre-isolation rinse of the chip was performed using
PBS/0.5% BSA at 4 mm/s. Fifty µL of whole blood was infused at 3.8 µL/min and 15.3 µL/min
for the bifurcation and Z-configuration devices, respectively, yielding nominal linear velocities
of 2 mm/s in the isolation beds. A post-isolation rinse was performed at 4 mm/s with 100-200 µL
PBS/0.5% BSA to remove blood and unbounded cells. Affinity-bound cells were fixed on-chip
with 4% PFA/PBS for 15 min and then rinsed with 50 µL PBS/0.5% BSA. Surface antigens of
fixed T-cells and neutrophils were stained with anti-CD3-FITC Abs and anti-CD66b-FITC Abs,
respectively, in the dark for 1 h. Then, the chip was rinsed with PBS/0.5% BSA for 10 min (8
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µL/min). Cells were permeabilized with 0.1% Triton-X for 5 min and nuclei stained with 1
µg/mL DAPI in PBS for 5 min followed by a rinse with 50 µL PBS/0.5% BSA at 8 µL/min.
Finally, cells were identified based on staining results with the total number of isolated cells
determined by scanning across the cell selection regions using a fluorescence confocal
microscope.
Cell characterization was performed by acquiring images on an Olympus IX71-DSU
Spinning Disk Confocal inverted microscope with DAPI, FITC, and Texas Red filter sets, a
mercury burner arc lamp and a high sensitivity Hamamatsu EMCCD and high resolution
Hamamatsu ORCA-03G CCD cameras. Metamorph software was used for analyzing and
processing images. Exposure times for DAPI, FITC and Texas Red were 10, 300, and 500 ms,
respectively.
2.2.6 Evaluation and Quantification of Carboxylic acid Surface Densities
Cy3-modified oligonucleotides containing a 5ʹ pendant amino group served as fluorescent
reporters by covalently labeling surface confined carboxylic acids. Carboxylic acid surface
densities were also quantified by a colorimetric assay using TBO.
An incubation chamber (BioRad) was glued to the substrate’s surface and filled with 0.1%
(w/v) toluidine blue O (TBO) in carbonate buffer (50 mM, pH = 10.5). After 15 min, the
substrate was submersed in the same buffer for 15 min and air dried. TBO was desorbed using
40% acetic acid (d = 1.0196 g mL-1), collected in a pre-weighed microfuge tube and analyzed
with an Ultrospec 4000 UV/Vis spectrophotometer (Pharmacia Biotech) against a 40% acetic
acid blank.
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2.2.7 Contact Angle Measurements
Changes in surface hydrophobicity were measured via sessile drop water contact angle
measurements performed using a VCA 2000 contact angle system (AST Products). Two µL of
18 MΩ·cm deionized water was dispensed onto substrates, images were collected and contact
angles were measured using the manufacturer’s software. Five measurements were averaged for
all reported values.
2.2.8 Fluorescence Imaging
Cy3-labeled oligonucleotides (40 µM) modified with an amino group at their 5ʹ end were
suspended in PBS buffer (100 mM, pH = 7.4) containing EDC (20 mg/mL) and incubated
overnight at 4oC within the appropriately activated microfluidic device. The chip was then rinsed
with ~2 mL of 0.1% SDS and PBS to remove unreacted molecules. All images were acquired
(230 ms acquisition time) with a 200M inverted microscope (Zeiss) that contained an XBO 75
Xe arc lamp, a single band filter set (Omega Optical), and a Cascade 1 K EMCCD camera
(Photometrics). Images were analyzed using Image-J software.
2.2.9 Chemical Surface Modification
Assembled devices were filled with a mixture of 5:1 (v/v) 2 M NaOH/100% IPA using
input/output tubing sealed to the chip. Once filled, the chips were incubated with the activating
solution in a hybridization oven (Boekel Scientific) for 12 h at 65ºC for COC and 30 min at room
temperature for PMMA unless otherwise noted. Chips were rinsed with 1 mL nanopure water.
2.2.10 Reverse Transcription (RT) and Polymerase Chain Reaction (PCR)
CD4+ T-cells and neutrophils isolated on-chip were lysed by infusing ~20 µL lysis solution
(GenElute Mammalian Total RNA Miniprep Kit, Sigma, St. Louis, MO) through the cell
selection bed. The effluent was collected into a microfuge tube and purified using a total RNA
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miniprep kit (Sigma) according to the manufacturer’s protocol with DNase treatment (OnColumn DNase I, Sigma, St. Louis, MO). After purification of TRNA, reverse transcription (RT)
was accomplished using a ProtoScript II First Strand cDNA Synthesis Kit (New England
BioLabs, Ipswich, MA). Samples were prepared by mixing 10 µL reaction mix, 2 µL poly-T
primer, 2 µL enzyme (no enzyme, 2 µL of water for RT) and 6 µL of TRNA. The samples were
then incubated at 42˚C for 1 h and heated to 80˚C for 5 min to deactivate the RT enzyme.
2.2.11 Polymerase Chain Reaction (PCR)
PCR was performed with cDNA in a total volume of 20 µL using Taq 2X Master Mix (New
England Biolabs, Ipswich, MA). PCR cocktails consisted of 2 µL of primers (final concentration
500 nM), 10 µL Taq 2X Master Mix, 6 µL nuclease free water and 2 µL cDNA. PCR was carried
out in a commercial thermal cycler (MJ Research Inc., Waltham, MA) with the following steps:
Initial denaturation at 94˚C for 2.5 min followed by 40 cycles of denaturation at 94˚C for 15 s;
annealing for 30 s at 63˚C for GAPDH primers and 55˚C for S100 primers; and extension at
72˚C for 30 s. A final extension at 72˚C for 7 min was followed by a cooling step at 4˚C. All
primers were obtained from Integrated DNA Technologies, Inc. The sequences (5ʹ-3ʹ) were
GAPDH:

forward

(F)

–

CTTTTGCGTCGCCAGCCGAG;

reverse

(R)

–

TGACCTTGGCCAGGGGTGCT42; S100A9 F – CTCGGCTTTGACAGAGTGCAAGAC; R –
TCCCCGAGGCCTGGCTTATGG42; TCRB F – GTTTTCTTTCAGACTGTGGCTTC; R –
CACGGCATACAAGGTGGC;

and

FPR1

F

–

TTTGCCTGTAACGCCAC;

R

–

ATGCTCTATGTC TTCATGGG (www.ncbi.nih.gov).
PCR products were electrophoresed at 4.8 V/cm in 1X TBE (Tris–boric acid/EDTA, Bio-Rad
Laboratories) on a 4% agarose gel with ethidium bromide (Lonza) staining. Amplicons were
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indexed against a DNA sizing ladder 50 – 766 bp (New England Biolabs, Ipswich, MA). Images
were collected using a Logic Gel imaging system (Eastman Kodak Company).
2.2.12 Statistical Analysis and Computational Methods
Data were analyzed using a student’s two-tailed T-test (ANOVA). Statistical significance
was assigned where p < 0.0500. Shear stress and flow uniformity through the bifurcated device
was evaluated using COMSOL Multiphysics 4.3b. 43

Flow distribution analysis in the Z-

configuration device employed a custom numerical algorithm detailed elsewhere. 44
2.3 Results and Discussion
2.3.1 Polymer Surface Activation for Ab Attachment
Stable attachment of Abs to the surfaces of the selection bed, which were made from a
polymer, is critical for efficient recovery and purity of the target cells. Ab density and uniformity
throughout the selection channel is dependent on the activation protocol employed in cases
where the Ab concentration exceeds the surface functional group number (see Figure 2.6).
We have reported that activating microchannel surfaces via UV/ozone irradiation causes two
effects: (i) Optical absorption by the bulk polymer with transmission decreasing with higher dose
levels, which can cause functional group surface densities to become increasingly non-uniform
as the aspect ratio of the channel is increased; and (ii) fragmentation of the polymer during
irradiation reducing functional group surface density, especially during thermal fusion bonding.
UV and thermally treated COC devices were less susceptible to these artifacts compared to
PMMA.43
We sought to avoid these effects by filling assembled devices with an activating chemical
solution. Therefore, we investigated the use of a chemical modification protocol following
thermal assembly of the device as this could potentially produce more uniform modification
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throughout the channel cross-section and avoid thermal effects that would bury the surface
functional groups for UV-activated surfaces.43
Microchannels were chemically activated via incubation in 5:1 (v:v) 2 M NaOH:IPA. In the
case of PMMA, it has been reported that it’s ester groups can be hydrolyzed to carboxy groups
by incubation with 10M NaOH at 40ºC for 16 h. 45 However, the covalent attachment of Cy3labeled oligonucleotides containing a pendant amino group serving as a fluorescent reporter of
surface-confined carboxylic acids did not indicate the carboxylic acid group formation using this
procedure. We hypothesized that the addition of IPA (similar to methanol by Patel et al.46) would
encourage interaction with the hydrophobic polymer (water contact angle of PMMA = 76.4
±1.4º) and/or solvation of methoxide byproducts.46,

47

Treatment of PMMA microfluidic

channels with 1/1 (v/v) 2M NaOH/IPA for 3 min at 60ºC and 10 min at room temperature
resulted in some channel roughening and deformation (Figures 2.2C, D). However, it was found
that channel integrity was preserved up to 30 min at 65ºC in 5:1 (v:v) 2M NaOH:IPA (Figure
2.2E). Thus we restricted PMMA modification using the aforementioned conditions to 30 min
using 5:1 NaOH:IPA.
Chemical activation of PMMA did not change the water contact angle or carboxylic acid
surface density as determined by a TBO assay relative to the pristine surface; this was likely due
to poor sensitivity of the TBO assay in comparison to fluorescence assays using Cy3-labeled
oligonucleotides containing a pendant amino group that served as a fluorescent reporter of
surface-confined carboxylic acids. Chemically activated PMMA microchannels derivatized with
Cy3-labeled oligonucleotides showed 232 ±47 cps compared to 503 ±72 cps for UV-activated
and thermally treated PMMA microchannels (Figures 2.2A, E).
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Figure 2.2 Line plots created from 20X fluorescence images for (A) PMMA and (B) COC
curvilinear channels modified with 40 μM 3ʹ-Cy3-labeled, 5ʹ-amino modified oligonucleotides
that were covalently bound to surface-confined carboxylic acids generated by UV (grey lines) or
chemical activation (black lines) of the polymer surface. For controls (dotted lines colored
corresponding to their treatments), fluorescently-labeled oligonucleotides were immobilized to
identical surfaces without EDC coupling reagents to measure nonspecific adsorption and
autofluorescence. UV activation was identical for the two polymers, but chemical activation
protocols differed in incubation times, where a 5/1 (v/v) 2 M NaOH/IPA solution was incubated
at 65oC for 30 min for PMMA devices and 12 h for COC devices. Fluorescence images of
oligonucleotides immobilized to PMMA devices that were chemically treated with (C) 1/1 (v/v)
2 M NaOH/IPA for 3 min at 60oC and (D) 1/1 (v/v) 2 M NaOH/IPA for 10 min at room
temperature, and (E) 5/1 (v/v) 2M NaOH/IPA for 5 min at 60oC
COC microchannels were subjected to a similar treatment (5:1 (v:v); 2 M NaOH:IPA)
Chemical activation decreased COC’s water contact angle from 95.5 ±1.8º (pristine) to 63.3
±3.2º and increased the carboxyl surface density to 0.6 ±0.2 nmol/cm2 as determined by the TBO
assay, which approached a theoretical monolayer (0.83 nmol/cm2). Carboxyl formation was also
evident by fluorescence analysis, where the surface fluorescence intensity (4369 ±437 cps) for
chemical modification was significantly greater than that observed for the UV activated and
thermally treated COC microchannels (2357 ±218 cps, see Figure 2.2B). The mechanism for
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carboxyl formation for COC using these chemical conditions is currently unknown; literature
precedence necessitates a radical-forming catalyst, such as Cu, Fe or other heavy metals to
convert alkanes, such as those found in COC, directly to carboxylic acid groups. 48 We suspect
that additives incorporated into the COC polymer during manufacturing assist in forming the
surface carboxylic acids. Based on covalent labeling of surface-confined carboxylic acid,
chemical treatment of COC resulted in the highest production of these functional groups.
2.3.2 Flow Uniformity in Bifurcated and Z-configuration Microfluidic Devices
The uniformity of flow in the two devices, which consisted of four selection units, with each
unit containing an array of parallel, curvilinear isolation channels addressed by either a
bifurcation or Z-configuration, were studied using fluid dynamic simulations and video
microscopy. COMSOL Multiphysics 4.3a was utilized49 to confirm uniform flow distribution
within the devices. The velocity field in Figure 2.3A indicated that flow was uniformly
distributed within each bifurcated, cell isolation bed (Figure 2.3B) and also between the four
beds. Furthermore, because the Z-configuration device employed the same addressing
architecture for the four isolation beds as the bifurcation device, the flow was uniformly
distributed between the four Z-configuration cell isolation beds, but the flow was slightly nonuniform within each bed (Figure 2.3B).
The flow distribution simulations were compared to empirical observations acquired by
filling the devices with red dye.44 Time lapse images were extracted from the videos (Figure 2.4).
As shown in images depicted in Figure 2.4A-D, the dye front was nearly linear across the four
bifurcation beds, indicating uniform flow between and within the bifurcation beds, which agreed
with the simulation results (Figures 2.3A and 2.3B). Flow was uniform between the Zconfiguration isolation beds, but showed a parabolic profile within each bed (Figure 2.3B). As
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shown in the images depicted in Figure 2.4E-G, dye filled more rapidly in the outer channels
than the central channels, similar to that depicted in Figure 2.3B. Similar flow profiles were
observed for filling devices with blood. These data agreed with previous results using a similar
type of device, but consisting of a single cell isolation bed. 44

Figure 2.3 (A) COMSOL simulation showing the velocity field of buffer through the bifurcated
cell isolation device. (B) Linear velocities normalized to an average of 2 mm/s acquired by
(filled bars) 14 groups of the parallel channels in the Z-configuration device based on the results
depicted in Figure. 2.4E-H and (solid line) compared to theoretical predictions via numerical
simulation (solid black line).Dashed line indicates the distribution of linear flow velocities
through all four beds of the simulated in bifurcation device in Figure 2.3A.

Figure 2.4 Time-lapse images of dye filling the (A-D) bifurcated device and (E-H) Zconfiguration device. Images A-D and E-H were taken at 0, 15, 30, and 60 s, respectively.
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2.3.3 Microfluidic Architectures and Performance Evaluation
Two microfluidic devices were fabricated both of which contained four separate isolation
beds to facilitate the simultaneous positive selection of multiple types of cells. We chose to target
T-cells using CD4 and neutrophils were selected using anti-CD66b mAbs. In all cases, the
concentration of mAb used to optimize recovery was 0.5 mg/mL (see Figure 2.6). To facilitate
simultaneous isolation of T-cells within two beds and neutrophils in the remaining two beds from
a blood sample (Figures 2.5A, B), the beds were modified by introducing the EDC/NHS solution
through the common inlet followed by mAbs infusion through the individual isolation bed
outlets so that beds could be functionalized with different antibodies. This design also enabled
the lysis of each subset contained within a bed for downstream analysis, such as mRNA
expression, by infusing a lysis solution through the common inlet and lysate collection from the
four separate outlets.

Figure 2.5 Photograph of the four isolation beds filled with red dye in A) bifurcated B) Zconfiguration devices
The two microfluidic devices differed in how the parallel channels were addressed. In the
first device (Figure 2.5A), a bifurcation network was utilized to address 16 channels, thereby
requiring four bifurcations per isolation unit. The second device (Figure 2.5B) employed a Zconfiguration, where inlet and outlet channels were poised orthogonal to the cell selection
channels (64 per device).43, 44 Due to the larger number of channels within the Z-configuration,
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this device had a higher throughput; 50 µL of blood could be processed in 3 min maintaining a 2
mm/s linear velocity to optimize recovery40 compared to 13 min for the bifurcated design. Using
a previously reported and experimentally validated numerical algorithm, 44 we calculated the flow
distribution through the Z-configuration and found that the linear velocity ranged between 1.7
and 2.5 mm/s for each isolation bed in the parallel arrangement (Figure 2.3B). For the bifurcation
device (Figures 2.3A and 2.4), the fluid velocity within each isolation bed was uniform. The
variability in the flow velocity seen within each isolation bed of the Z-configuration can result in
variable cell recoveries.
To evaluate the performance of the two microfluidic designs and surface activation
chemistry, T-cells and neutrophils were isolated from blood and their recoveries determined. All
cell counts and purities are summarized in Table 2.1. In this discussion, we differentiate the UV
and chemical activation modalities by UV- and CH-, respectively. For COC chips and the
bifurcated or Z-configuration, these were designated as UV-COCbif and UV-COCZ, respectively,
when UV activated and CH-COCbif and CH-COCZ when chemically activated.
To ensure Ab concentration was not a limiting factor and cell recovery results reflected the
number density of the generated surface-confined carboxylic acids, we quantified cell recovery
as a function of the antibody concentration in the COC bifurcated devices. The concentration of
anti-CD4 Abs was varied at 0.1, 0.25, 0.5, and 1 mg/mL. Figure 2.6 suggested reduction in
recoveries when Ab concentrations were set <0.5 mg/mL and comparable recoveries between 0.5
and 1 mg/mL. Therefore, 0.5 mg/mL was selected to be the optimal concentration for Ab
immobilization for all subsequent experiments.
Initial testing of the bifurcated design indicated that with either activation protocol, COC out
performed PMMA devices. UV-COCbif isolated 798 ±167 CD4+ T-cells cells compared to 325
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±85 cells for UV-PMMAbif from a 50 µL blood sample (Table 2.1). These agree with our
previous results, which indicated efficient and uniform activation in COC microchannels
providing a higher Ab load and thus, higher recoveries. 43 CH-PMMAbif devices demonstrated
extremely poor performance (7 ±3 cells), which reflected the inability to chemically activate
PMMA without degrading microstructures (see Figure 2.2). Results for CH-COCbif devices (702
±386 cells) showed no statistical difference (p = 0.631) to UV-COCbif devices (798 ±167)
(Figure 2.7). Chemical activation was as efficient as UV activation for the bifurcated COC
devices as well.

Figure 2.6 T-cell recoveries from healthy donor blood using UV-COCbif devices modified with
anti-human CD4 Abs at different concentrations.
Both UV-COC devices produced nearly equal recovered T-cells; 798 ±167 and 596 ±154
using UV-COCbif and UV-COCZ devices, respectively. Considering nearly the same cell
recovery and more rapid blood sample processing, the Z-type architecture was determined to be
the most efficient from a throughput perspective. Hence, Z-configuration devices were used for
simultaneously isolating T-cells and neutrophils.
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Figure 2.7 Box plot comparing CD4+ T-cell recoveries from 50 µL healthy human blood in UV
and chemically modified PMMA and COC devices utilizing either bifurcated or Z-configuration.
(*) indicates statistically significant difference (student’s two tailed t-test p< 0.0500), while (**)
implies no statistically different results. Solid lines in the boxes represent median; the dotted line
represents mean; the upper and lower edges of the boxes indicate third and first quartiles,
respectively; and error bars show maximum and minimum values.
We observed higher cell recovery using CH-COCZ devices; absolute cell counts increased
from 596 ±25 for UV-COCZ to 2565 ±1194 for the CH-COCZ devices for T-cell isolation. In the
case of neutrophils, 1096 ±537 cells were selected for the UV-COCZ device compared to 2949
±901 for the CH-COCZ device. However, we observed no difference between the activation
modalities for bifurcated COC devices, which can be explained by shear stress considerations. 50
In bifurcated devices, ~40% of cells were isolated in the bifurcation regions (Figure 2.8B-E),
whereas only 4% were observed in the inlet and outlet addressing channels of the Zconfiguration. Inspection of the bifurcation network showed that fluidic shear stress was reduced
from 11 dynes/cm2 in the parallel channels to 6-7 dynes/cm2 through the bifurcation network,
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where ~17.7% of the device’s surface area accounted for ~40% of cell isolation. Conversely,
shear stress through the Z-configuration inlet and outlet channels ranged between ~1 and 38
dynes/cm2 along the channel’s length and was <11 dynes/cm2 in ~19% of the length of the inlet
and outlet channels.
For the Z-configuration, recovery occurred predominantly in the cell isolation channels,
where optical absorption of the activating UV radiation may lead to reduced Ab loads; activating
polymer surfaces using chemical modification is not sensitive to device aspect ratio. These
effects may be precluded in bifurcated devices due to cell isolation in the low aspect ratio
bifurcation regions (Figure 2.8A).

Figure 2.8 (A) Computational simulations showing the shear stresses in the parallel channels of
the bifurcated device. (B- E) T-cells isolated from blood from the left in the 3, 2, 1, and 0
bifurcation levels of the bifurcated microchip. All curvilinear channel dimensions are 25 × 80
µm (w × h) and the SEM scale bars are 1 mm for all micrographs.
2.3.4 Determination of CD4 Expression of MOLT-3 Cells by Flow Cytometry
Expression of CD4 antigen on MOLT-3 cells was measured after subtracting isotype controlFITC and CD4-FITC double positive events as shown in the histograms in Figure 2.9.

87

Figure 2.9 (A) Overlay of histograms generated by integration of negative isotype control
(vertical lines), CD4- MOLT-3 cells (diagonal lines), and CD4+ MOLT-3 cells (hatched lines).
The histogram for the CD4+ MOLT-3 cells was generated by the Overton subtraction method.
(B) Visualization of CD4-FITC labelled MOLT-3 cells on a microscope.
The low fluorescence signal observed for CD4+ MOLT-3 cells in flow cytometry (Figure
2.9A) indicated these cells have much lower CD4 expression than T-cells (46,000-202,000 CD4
molecules/cell; mean = 100,000 molecules/cell). 51-53
2.3.5 Recovery of Different Leukocyte Subsets
Initial recovery tests were performed with MOLT-3 cells (average cell diameter 9.3 ±2.4 µm)
using isolation beds modified with anti-CD4. However, we observed very poor recovery of these
cells; 0.36 ±0.3% for UV-COCbif, 0.13 ±0.1% for CH-COCbif and 0.52 ±0.1% for CH-COCZ.
After correcting for the CD4-MOLT-3 expression from the flow cytometry analysis (see Figure
2.9), the recoveries were 1.4 ±0.3 %, 0.5 ±0.1% and 2.0 ±0.1%, for the UV-COCbif, CH-COCbif
and CH-COCZ devices, respectively. These efficiencies were lower than that observed for the
human T-cells (~10%), but exhibited similar patterns between the activation modality and device
design; chemically activated COCZ devices isolated the highest absolute number of cells.
The two primary factors contributing to the low recovery of MOLT-3 cells were likely the
small cell size relative to the channel width and the low CD4 expression levels for these cells.
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Because the 9.3 ±2.4 µm diameter MOLT-3 cells were isolated in 25 µm wide channels, we
would expect low recovery as there is a low probability of cell/surface-confined Ab interactions.
Reduction in channel width to slightly larger than the MOLT-3 cell diameter should improve
their recovery.40 However, the use of much narrower channels may be problematic for blood
processing due to the risk of device failure arising from clogging because of the presence of large
leukocytes (~15 µm). If the Ag expression level is low, shear forces in the channel may also
remove isolated cells from the selection bed due to the small adhesion force and thus, produce
lower recovery. These considerations were also true for human T-cell isolation from whole
blood; in spite of their smaller size (~7 µm average diameter) compared to MOLT-3 cells, these
cells showed higher recovery most likely because of the higher expression of CD4 producing
better cell/surface adhesion forces.
We observed higher recoveries for CD4 T-cells (10.3 ±0.5%) compared to CD66b
neutrophils (1.5 ±0.1%) in the CH-COCZ devices, assuming relative abundances of 25,000 and
200,000 cells/50 µL of blood for T-cells and neutrophils, respectively.54 This difference in
recovery may be related to the number of Ab molecules immobilized to the surface. With the
size of anti-CD4 and anti-CD66b being 150 kDa IgG1 and 900 kDa IgM, respectively, they will
form monolayers where IgM is ~36x less abundant than a monolayer of IgG, possibly leading to
lower neutrophil recovery.43, 55
Flow cytometric analysis was performed on T-cells and neutrophils isolated from a buffy
coat as described previously. For T-cells, CD4-FITC fluorescence intensity was 5.3 times greater
than the IgG isotype control and for neutrophils, CD66b-FITC showed 4.6 times greater intensity
compared to its IgM control. However, due to the surface area of neutrophils (~707 µm2)
compared to smaller T-cells (113 µm2), antigen density (
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) of CD4 on T-cells is roughly 7

times denser than CD66b on neutrophils. Consequently, the rate of adhesion (

) of T-cells to

surface antibodies is ~7 times greater than for neutrophils as stipulated by Chang and Hammer; 55
(1)
where ( ) is the effective antibody-antigen binding rate and (

) is the antibody number.

Thus, the ~10 times lower recovery observed for neutrophils could be attributed to lower surface
density of the IgM anti-CD66b selection antibody and/or reduced surface densities of CD66b on
neutrophil cells.

Figure 2.10 (A) Distribution of T-cells and neutrophils in Z-configuration parallel channels,
which have varying linear velocities. (B) Scatter plot of the data in (A) showing strong, negative
correlation between the percentage of cells isolated in a parallel channel with the linear velocity
in that channel.
We also inspected the distribution of isolated cells throughout the parallel channels of the Zconfiguration device to relate cell counts to linear velocity (Figure 2.10A). To discern the effects
of varying linear velocity on absolute recovery, we normalized the recovered cell counts to the
total input cell counts and plotted these results as a function of linear velocity (Figure 2.10B). A
strong, negative correlation between linear velocity and cell recovery was observed for both Tcells (Pearson’s correlation r = -0.65) and neutrophils (r = -0.72). However, the magnitude of the
slope suggests that neutrophils (m = -10.03 cells/mm/s) are more sensitive to linear velocity and
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fluidic shear stress than T-cells (m = -5.17 cells/mm/s) due to the effects of lower CD66b antigen
surface density as noted by Eq. (1).
2.3.6 Purity of Isolated Leukocytes
When designing systems for mRNA expression analysis of cell subsets isolated from blood,
it is critical to isolate pure fractions of the targets. For T-cell isolation via CD4 positive selection,
this is challenged by the fact that CD4 is also expressed on the surface of monocytes,
macrophages, and dendritic cells at a frequency of 3-8% of the total leukocyte population in
blood, albeit, CD4 expression is lower compared to T-cells (46,000-202,000 molecules/cell) and
thus, their kad lower as noted by Eq. (1).4, 51-53 This means that fluidic shear stress can be used to
remove from the selection surface cells with low kad values.
Purity of isolated CD4+ T-lymphocytes was assessed by immunostaining with CD66b,
CD14, and CD20 Abs to identify neutrophils (comprising 40-66% of total leukocyte population),
monocytes (4-8%), and B-cells (8-12%), respectively.3 Purity was defined as the ratio of DAPI+,
CD14-, CD66b-, and CD20- cells to the total number of nucleated cells. Fluorescence images
(Figures 2.11A-C) showed the absence of cells labeled with CD14/66b/20 Abs. Isolated cells
showed intact structures without an obvious change in morphology. It was also observed that Tcells and neutrophils were distributed randomly within the channel (outer and inner curvatures of
the curvilinear channels, Figure 2.8A) unlike circulating tumor cells, which we have reported to
be predominantly isolated along the inner curvature. 40 To confirm proper identification of Tcells, an anti-CD3 marker was chosen because 87% of T-cells are CD3+ and CD4+ (Figures
2.11D-F).56 For the UV-COCbif devices, purities were 97 ±1%, and CH-COCbif purities were 92
±5% (Table 2.1). The lack of contaminating cells most likely resulted from their low CD4
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expression and the application of a shear stress between 6 to 11 dynes/cm2.51, 52, 57, 58 The purity
for the CH-COCZ for the CD4+ T-cells was found to be 98 ±1%.

Figure 2.11 (A-F) Fluorescence microscopy images of CD4+ T-cells isolated from whole blood
using a bifurcated microfluidic device immobilized with anti-CD4 Ab and stained with (A, D)
DAPI (nuclear stain); (B) CD20/CD66b-FITC specific for B-lymphocytes and neutrophils,
respectively; (C) CD14-PE specific for monocytes; (E) CD3-FITC specific for T-cells; and (F)
no antibody used. Purity of CD4+ T cells was defined as positive for DAPI and negative for PE
and FITC stains in (A-C), while specificity was demonstrated by dual staining of cells with CD3FITC and DAPI (D-F). (G-I) Fluorescence microscopic images of isolated neutrophils: (G) DAPI
stained; (H) CD66b-FITC stained; (I) no Ab used; and (J-L) a neutrophil that was (J) DAPI
stained with neutrophil morphology, (K) showed lack of CD66b-FITC signal, and (L) no Ab
used. Neutrophils were identified only if positive for both DAPI and CD66b
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Lastly, we assessed neutrophil purity by counting double positive DAPI and CD66b-FITC
cells (Figure 2.11G-I). We observed that some cells were DAPI+ but very faint for CD66b-FITC,
but the dimensions and morphology of these cells were consistent with neutrophils (Figure 2.11JL).59 These cells were counted as neutrophils and it is plausible that some neutrophils possessed
very low CD66b expression and thus, could not be detected thereby artificially lowering purity
levels. Neutrophil counts isolated from 50 μL of blood using the UV-COCbif devices averaged
918 ±91 with a purity of 94 ±3 % and CH-COCZ yielded purities of 97 ±2% (see Table 2.1)
Table 2.1 Enumeration values for isolated T-cells and neutrophils from whole blood using COC
and PMMA microfluidic devices with different geometries and activation protocols.
Cell type

T-Cells

Chip Design

Bifurcated

Modification
-substrate

Cell count (n= 4)
Mean ± SD (Median)

Negative
control

Purity

UV-PMMA

325 ±85 (342)

---

---

UV-COC

798 ±168(723)

19 ±5

97 ±1

CH-PMMA

7 ±3 (8)

---

---

CH-COC

703 ±386 (846)

16 ±3

92 ±5

Neutrophils

Bifurcated

UV-COC

918 ±91 (888)

---

94 ±3

Neutrophils

Zconfiguration

UV- COC

1096 ±537 (1112)

---

---

CH-COC

2949 ±901

---

97 ±2

Zconfiguration

UV-COC

596 ±154 (585)

7 ±1

---

CH-COC

2565 ±1194 (2139)

30 ±9

98 ±1

T-cells

2.3.7 Reverse Transcription –Polymerase Chain Reaction (RT-PCR)
The total number of isolated cells in the CH-COCZ devices ranged from 500 to 2,000 CD4+
T-cells and CD66b+ neutrophils. Considering an average of 10 pg of TRNA per leukocyte, we
expected to obtain 5 – 20 ng TRNA (0.25-1 ng of mRNA) per bed, which should provide
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sufficient material for cDNA synthesis and gene expression analysis. To make sure that
sufficient mRNA was harvested from the T-cells and neutrophils, two beds were used for each
cell type. T-cells and neutrophils were isolated from the same blood sample using the CH-COCZ
chip and because of the high purity of isolated fractions, cell lysis was performed directly on
chip. Following lysis and TRNA isolation, an RT reaction was performed. cDNA was then used
for PCR with expression analysis of 4 genes; S100A9, which has been shown to be
overexpressed following stroke38 and plays a prominent role in the regulation of inflammatory
processes and immune response,60-62 TCRB and FPR1 genes, which are specific to T-cells and
neutrophils,63-65 respectively, and GAPDH, a housekeeping gene used as a reference. Figure
2.12A shows fluorescence images of the amplicons. Although the expression of GAPDH can
vary between different types of cells, 66 for these initial results we normalized the amplicon
intensities to the intensity of the GAPDH product.
As shown in Figure 4B for the T-cell population, we observed significantly lower expression
(22x) of S100A9 than in the neutrophil subset for the same healthy donor.T-cells showed a higher
expression of the TCRB gene compared to neutrophils as supported from the literature. However,
some studies demonstrated neutrophils populations also expressing TCRB mRNA as well.67
FPR1 gene was 7x higher expressed in neutrophils, similar to that reported in the literature.68 It is
important to emphasize that in the case of mRNA profiling, it is imperative that cell perturbation
and handling is reduced to eliminate any phenotypic changes.69, 70 By using microfluidics, we
obtained pure populations of cells and cell lysate within 12 min from the time of blood sample
introduction into the microfluidic device. Fast processing allows for securing high quality
mRNA (data not shown), lack of centrifugation, and unnecessary storage of blood specimens.
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Figure 2.12 (A) Gel electrophoresis inverted image of amplicons generated from cDNA reverse
transcribed from TRNA extracted from isolated neutrophils. Negative control (-) and positive (+)
amplification reactions for tested genes were performed with products from negative (-) RT
(without RT enzyme) and positive (+) RT. Amplicon lengths are shown in the figure. Separation
performed at 4.8 V/cm in a TBE buffer. (B) Normalized to GAPDH gene signals (n=3) from the
amplicons identified on an agarose gel stained with ethidium bromide for T-cells and
neutrophils.
2.4 Conclusions
We have demonstrated an affinity-based microfluidic system capable of isolating highly pure
subsets of leukocytes from whole blood. Processing 50 µL of whole blood within 6.6 min
provided sufficient genetic material for gene expression profiling. Special emphasis was placed
on the fluid dynamics and design architecture of the device for T-cell and neutrophil isolation to
obtain high purity leukocytes fractions using a single step. The isolation of two types of cells
from whole blood was accomplished with purity >90%.
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We assessed the effects of polymeric substrate and surface activation modalities on cell
isolation and discovered a chemical activation method for COC, which can be useful for ultrahigh aspect ratio microfluidic devices. The demonstrated results are not limited only to CD4+ Tcells and CD66b+ neutrophils but can be expanded to analyze other cell types simply by
choosing different affinity agents for the cells of interest. Furthermore, our microfluidic device
contains four individually addressable beds, permitting simultaneous isolation of four individual
cell sub-populations from the same blood sample with sufficient material to perform mRNA
expression analysis on the isolated cells.
2.5 References
1.

Feezor, R. J.; Baker, H. V.; Mindrinos, M.; Hayden, D.; Tannahill, C. L.; Brownstein, B.
H.; Fay, A.; MacMillan, S.; Laramie, J.; Xiao, W.; Moldawer, L. L.; Cobb, J. P.;
Laudanski, K.; Miller-Graziano, C. L.; Maier, R. V.; Schoenfeld, D.; Davis, R. W.;
Tompkins, R. G. Whole Blood and Leukocyte Rna Isolation for Gene Expression
Analyses. Physiol Genomics 2004, 19, 247-54.

2.

Gao, Y.; Li, W.; Pappas, D. Recent Advances in Microfluidic Cell Separations. Analyst
(Cambridge, U. K.) 2013, 138, 4714-4721.

3.

Toner, M.; Irimia, D. Blood-on-a-Chip. Annu. Rev. Biomed. Eng. 2005, 7, 77-103, 3
plates.

4.

Cheng, X.; Irimia, D.; Dixon, M.; Sekine, K.; Demirci, U.; Zamir, L.; Tompkins, R. G.;
Rodriguez, W.; Toner, M. A Microfluidic Device for Practical Label-Free Cd4+ T Cell
Counting of Hiv-Infected Subjects. Lab Chip 2007, 7, 170-178.

5.

Cheng, X.; Liu, Y.-s.; Irimia, D.; Demirci, U.; Yang, L.; Zamir, L.; Rodriguez, W. R.;
Toner, M.; Bashir, R. Cell Detection and Counting through Cell Lysate Impedance
Spectroscopy in Microfluidic Devices. Lab Chip 2007, 7, 746-755.

6.

Rodriguez, W. R.; Christodoulides, N.; Floriano, P. N.; Graham, S.; Mohanty, S.; Dixon,
M.; Hsiang, M.; Peter, T.; Zavahir, S.; Thior, I.; Romanovicz, D.; Bernard, B.; Goodey,

96

A. P.; Walker, B. D.; McDevitt, J. T. A Microchip Cd4 Counting Method for Hiv
Monitoring in Resource-Poor Settings. PLoS Med. 2005, 2, 663-672.

7.

Kim, S. T.; Kim, D.-J.; Kim, T.-J.; Seo, D.-W.; Kim, T.-H.; Lee, S.-Y.; Kim, K.; Lee, K.M.; Lee, S.-K. Novel Streptavidin-Functionalized Silicon Nanowire Arrays for Cd4+ T
Lymphocyte Separation. Nano Lett. 2010, 10, 2877-2883.

8.

Kim, D.-J.; Seol, J.-K.; Wu, Y.; Ji, S.; Kim, G.-S.; Hyung, J.-H.; Lee, S.-Y.; Lim, H.;
Fan, R.; Lee, S.-K. A Quartz Nanopillar Hemocytometer for High-Yield Separation and
Counting of Cd4+ T Lymphocytes. Nanoscale 2012, 4, 2500-2507.

9.

Thorslund, S.; Larsson, R.; Bergquist, J.; Nikolajeff, F.; Sanchez, J. A Pdms-Based
Disposable Microfluidic Sensor for Cd4+ Lymphocyte Counting. Biomed Microdevices
2008, 10, 851-7.

10.

Warner, E. A.; Kotz, K. T.; Ungaro, R. F.; Abouhamze, A. S.; Lopez, M. C.; Cuenca, A.
G.; Kelly-Scumpia, K. M.; Moreno, C.; O'Malley, K. A.; Lanz, J. D.; Baker, H. V.;
Martin, L. C.; Toner, M.; Tompkins, R. G.; Efron, P. A.; Moldawer, L. L. MicrofluidicsBased Capture of Human Neutrophils for Expression Analysis in Blood and
Bronchoalveolar Lavage. Lab. Invest. 2011, 91, 1787-1795.

11.

Feigin, V. L.; Lawes, C. M. M.; Bennett, D. A.; Barker-Collo, S. L.; Parag, V.
Worldwide Stroke Incidence and Early Case Fatality Reported in 56 Population-Based
Studies: A Systematic Review. The Lancet Neurology 2009, 8, 355-369.

12.

Hand, P. J.; Kwan, J.; Lindley, R. I.; Dennis, M. S.; Wardlaw, J. M. Distinguishing
between Stroke and Mimic at the Bedside: The Brain Attack Study. Stroke 2006, 37, 76975.

13.

Norris, J. W.; Hachinski, V. C. Misdiagnosis of Stroke. Lancet 1982, 1, 328-31.

14.

Goldstein, L. B.; Simel, D. L. Is This Patient Having a Stroke? JAMA, J. Am. Med. Assoc.
2005, 293, 2391-2402.

15.

Furlan, A.; Higashida, R.; Wechsler, L.; Gent, M.; Rowley, H.; Kase, C.; Pessin, M.;
Ahuja, A.; Callahan, F.; Clark, W. M.; Silver, F.; Rivera, F. Intra-Arterial Prourokinase

97

for Acute Ischemic Stroke. The Proact Ii Study: A Randomized Controlled Trial. JAMA,
J. Am. Med. Assoc. 1999, 282, 2003-2011.

16.

Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Dvalos, A.; Guidetti, D.; Larrue, V.;
Lees, K. R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von, K. R.; Wahlgren, N.; Toni,
D. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N. Engl. J.
Med. 2008, 359, 1317-1329.

17.

Goldstein, L. B. Improving the Clinical Diagnosis of Stroke. Stroke 2006, 37, 754-5.

18.

Whiteley, W.; Tseng, M.-C.; Sandercock, P. Blood Biomarkers in the Diagnosis of
Ischemic Stroke: A Systematic Review. Stroke 2008, 39, 2902-9.

19.

Hasan, N.; McColgan, P.; Bentley, P.; Edwards, R. J.; Sharma, P. Towards the
Identification of Blood Biomarkers for Acute Stroke in Humans: A Comprehensive
Systematic Review. Br. J. Clin. Pharmacol. 2012, 74, 230-240.

20.

Jickling, G. C.; Sharp, F. R. Blood Biomarkers of Ischemic Stroke. Neurotherapeutics
2011, 8, 349-360.

21.

Saah, A. J.; Hoover, D. R. “Sensitivity” and “Specificity” Reconsidered: The Meaning of
These Terms in Analytical and Diagnostic Settings. Annals of Internal Medicine 1997,
126, 91-94.

22.

Maas, M. B.; Furie, K. L. Molecular Biomarkers in Stroke Diagnosis and Prognosis.
Biomarkers Med. 2009, 3, 363-383.

23.

Yilmaz, G.; Arumugam, T. V.; Stokes, K. Y.; Granger, D. N. Role of T Lymphocytes and
Interferon-Gamma in Ischemic Stroke. Circulation 2006, 113, 2105-12.

24.

Marsh, B. J.; Williams-Karnesky, R. L.; Stenzel-Poore, M. P. Toll-Like Receptor
Signaling in Endogenous Neuroprotection and Stroke. Neuroscience (Amsterdam, Neth.)
2009, 158, 1007-1020.

25.

Tang, S.-C.; Arumugam, T. V.; Xu, X.; Cheng, A.; Mughal, M. R.; Jo, D. G.; Lathia, J.
D.; Siler, D. A.; Chigurupati, S.; Ouyang, X.; Magnus, T.; Camandola, S.; Mattson, M. P.
98

Pivotal Role for Neuronal Toll-Like Receptors in Ischemic Brain Injury and Functional
Deficits. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 13798-13803.

26.

Gee, J. M.; Kalil, A.; Shea, C.; Becker, K. J. Lymphocytes: Potential Mediators of
Postischemic Injury and Neuroprotection. Stroke 2007, 38, 783-8.

27.

Laudanski, K.; Miller-Graziano, C.; Xiao, W.; Mindrinos, M. N.; Richards, D. R.; De, A.;
Moldawer, L. L.; Maier, R. V.; Bankey, P.; Baker, H. V.; Brownstein, B. H.; Cobb, J. P.;
Calvano, S. E.; Davis, R. W.; Tompkins, R. G. Cell-Specific Expression and Pathway
Analyses Reveal Alterations in Trauma-Related Human T Cell and Monocyte Pathways.
Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 15564-15569.

28.

Baird, A. E. Blood Biologic Markers of Stroke: Improved Management, Reduced Cost?
Curr Atheroscler Rep 2006, 8, 267-75.

29.

Moore, D. F.; Goldin, R.; Violet, W. Using Peripheral Blood Mononuclear Cells to
Determine a Gene Expression Profile of Intra-Cerebral Hemorrhage. Annals of Neurology
2007, 62, S8.

30.

Moore, D. F.; Li, H.; Jeffries, N.; Wright, V.; Cooper, R. A.; Elkahloun, A.; Gelderman,
M. P.; Zudaire, E.; Blevins, G.; Yu, H.; Goldin, E.; Baird, A. E. Using Peripheral Blood
Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke.
Circulation 2005, 111, 212-221.

31.

Oh, S.-H.; Kim, O.-J.; Shin, D.-A.; Song, J.; Yoo, H.; Kim, Y.-K.; Kim, J.-K. Alteration
of Immunologic Responses on Peripheral Blood in the Acute Phase of Ischemic Stroke:
Blood Genomic Profiling Study. Journal of Neuroimmunology 2012, 249, 60-65.

32.

Tang, Y.; Xu, H.; Du, X.; Lit, L.; Walker, W.; Lu, A.; Ran, R.; Gregg, J. P.; Reilly, M.;
Pancioli, A.; Khoury, J. C.; Sauerbeck, L. R.; Carrozzella, J. A.; Spilker, J.; Clark, J.;
Wagner, K. R.; Jauch, E. C.; Chang, D. J.; Verro, P.; Broderick, J. P.; Sharp, F. R. Gene
Expression in Blood Changes Rapidly in Neutrophils and Monocytes after Ischemic
Stroke in Humans: A Microarray Study. J Cereb. Blood Flow Metab. 2006, 26, 10891102.

33.

Mateusz G. Adamski, Y. L., Erin Wagner, Hua Yu, Chloe Seales-Bailey, Steven A.
Soper, Michael Murphy, Alison E. Baird. J Biomolecular Screening 2013, submitted for
publication.
99

34.

Du, X.; Tang, Y.; Xu, H.; Lit, L.; Walker, W.; Ashwood, P.; Gregg, J. P.; Sharp, F. R.
Genomic Profiles for Human Peripheral Blood T Cells, B Cells, Natural Killer Cells,
Monocytes, and Polymorphonuclear Cells: Comparisons to Ischemic Stroke, Migraine,
and Tourette Syndrome. Genomics 2006, 87, 693-703.

35.

Siliciano, R. F.; Lawton, T.; Knall, C.; Karr, R. W.; Berman, P.; Gregory, T.; Reinherz,
E. L. Analysis of Host-Virus Interactions in Aids with Anti-Gp120 T Cell Clones: Effect
of Hiv Sequence Variation and a Mechanism for Cd4+ Cell Depletion. Cell (Cambridge,
Mass.) 1988, 54, 561-75.

36.

O'Brien, W. A.; Hartigan, P. M.; Daar, E. S.; Simberkoff, M. S.; Hamilton, J. D. Changes
in Plasma Hiv Rna Levels and Cd4+ Lymphocyte Counts Predict Both Response to
Antiretroviral Therapy and Therapeutic Failure. Va Cooperative Study Group on Aids.
Ann Intern Med 1997, 126, 939-45.

37.

Yarchoan, R.; Tosato, G.; Little, R. F. Therapy Insight: Aids-Related Malignancies-the
Influence of Antiviral Therapy on Pathogenesis and Management. Nat. Clin. Pract.
Oncol. 2005, 2, 406-415.

38.

Adamski, M. G.; Li, Y.; Wagner, E.; Yu, H.; Seales-Bailey, C.; Soper, S. A.; Murphy,
M.; Baird, A. E. Next-Generation Qpcr for the High-Throughput Measurement of Gene
Expression in Multiple Leukocyte Subsets. J Biomol Screen 2013, 18, 1008-1017.

39.

Hupert, M. L.; Guy, W. J.; Llopis, S. D.; Shadpour, H.; Rani, S.; Nikitopoulos, D. E.;
Soper, S. A. Evaluation of Micromilled Metal Mold Masters for the Replication of
Microchip Electrophoresis Devices. Microfluid. Nanofluid. 2007, 3, 1-11.

40.

Adams, A. A.; Okagbare, P. I.; Feng, J.; Hupert, M. L.; Patterson, D.; Gottert, J.;
McCarley, R. L.; Nikitopoulos, D.; Murphy, M. C.; Soper, S. A. Highly Efficient
Circulating Tumor Cell Isolation from Whole Blood and Label-Free Enumeration Using
Polymer-Based Microfluidics with an Integrated Conductivity Sensor. J. Am. Chem. Soc.
2008, 130, 8633-8641.

41.

Wei, S.; Vaidya, B.; Patel, A. B.; Soper, S. A.; McCarley, R. L. Photochemically
Patterned Poly(Methyl Methacrylate) Surfaces Used in the Fabrication of Microanalytical
Devices. J. Phys. Chem. B 2005, 109, 16988-16996.

100

42.

Adamski, M. G.; Li, Y.; Wagner, E.; Yu, H.; Seales-Bailey, C.; Soper, S. A.; Murphy,
M.; Baird, A. E. Next-Generation Qpcr for the High-Throughput Measurement of Gene
Expression in Multiple Leukocyte Subsets. J Biomol Screen 2013.

43.

Jackson, J. M.; Witek, M. A.; Hupert, M. L.; Brady, C.; Pullagurla, S.; Kamande, J.;
Aufforth, R. D.; Tignanelli, C. J.; Torphy, R. J.; Yeh, J. J.; Soper, S. A. Uv Activation of
Polymeric High Aspect Ratio Microstructures: Ramifications in Antibody Surface
Loading for Circulating Tumor Cell Selection. Lab on a Chip 2014.

44.

Kamande, J. W.; Hupert, M. L.; Witek, M. A.; Wang, H.; Torphy, R. J.; Dharmasiri, U.;
Njoroge, S. K.; Jackson, J. M.; Aufforth, R. D.; Snavely, A.; Yeh, J. J.; Soper, S. A.
Modular Microsystem for the Isolation, Enumeration, and Phenotyping of Circulating
Tumor Cells in Patients with Pancreatic Cancer. Analytical Chemistry 2013.

45.

Holmberg, K.; Hyden, H. Methods of Immobilization
Polymethylmethacrylate. Prep. Biochem. 1985, 15, 309-19.

46.

Patel, S.; Thakar, R. G.; Wong, J.; McLeod, S. D.; Li, S. Control of Cell Adhesion on
Poly(Methyl Methacrylate). Biomaterials 2006, 27, 2890-2897.

47.

Holmberg, K.; Hyden, H. Methods of Immobilization of
Polymethylmethacrylate. Preparative biochemistry 1985, 15, 309-19.

48.

Kirillova, M. V.; Kirillov, A. M.; Kuznetsov, M. L.; Silva, J. A. L.; da Silva, J. J. R. F.;
Pombeiro, A. J. L. Alkanes to Carboxylic Acids in Aqueous Medium: Metal-Free and
Metal-Promoted Highly Efficient and Mild Conversions. Chem Commun 2009, 23532355.

49.

Soper, S. A.; Battle, K.; Jackson, J. M.; Witek, M. A.; Hupert, M.; Hunsucker, S.;
Armistead, P. Solid-Phase Extraction and Purification of Membrane Proteins Using a UvModified Pmma Microfluidic Bioaffinity [Small Micro]Spe Device. Analyst 2014.

50.

Murthy, S. K.; Sin, A.; Tompkins, R. G.; Toner, M. Effect of Flow and Surface
Conditions on Human Lymphocyte Isolation Using Microfluidic Chambers. Langmuir
2004, 20, 11649-11655.

101

of

Proteins

Proteins

to

to

51.

Beck, M.; Brockhuis, S.; van, d. V. N.; Breukers, C.; Greve, J.; Terstappen, L. W. M. M.
On-Chip Sample Preparation by Controlled Release of Antibodies for Simple Cd4
Counting. Lab Chip 2012, 12, 167-173.

52.

Davis, K. A.; Abrams, B.; Iyer, S. B.; Hoffman, R. A.; Bishop, J. E. Determination of
Cd4 Antigen Density on Cells: Role of Antibody Valency, Avidity, Clones, and
Conjugation. Cytometry 1998, 33, 197-205.

53.

Denny, T. N.; Stein, D.; Mui, T.; Scolpino, A.; Holland, B. Quantitative Determination of
Surface Antibody Binding Capacities of Immune Subsets Present in Peripheral Blood of
Healthy Adult Donors. Cytometry 1996, 26, 265-274.

54.

Toner, M.; Irimia, D. Blood-on-a-Chip. Annual Review of Biomedical Engineering 2005,
7, 77-103.

55.

Chang, K.-C.; Hammer, D. A. The Forward Rate of Binding of Surface-Tethered
Reactants: Effect of Relative Motion between Two Surfaces. Biophysical journal 1999,
76, 1280-1292.

56.

Egerton, M.; Scollay, R.; Shortman, K. Kinetics of Mature T-Cell Development in the
Thymus. Proceedings of the National Academy of Sciences 1990, 87, 2579-2582.

57.

Hultin, L. E.; Matud, J. L.; Giorgi, J. V. Quantitation of Cd38 Activation Antigen
Expression on Cd8+ T Cells in Hiv-1 Infection Using Cd4 Expression on Cd4+ T
Lymphocytes as a Biological Calibrator. Cytometry 1998, 33, 123-132.

58.

Lee, B.; Sharron, M.; Montaner, L. J.; Weissman, D.; Doms, R. W. Quantification of
Cd4, Ccr5, and Cxcr4 Levels on Lymphocyte Subsets, Dendritic Cells, and Differentially
Conditioned Monocyte-Derived Macrophages. Proc. Natl. Acad. Sci. U. S. A. 1999, 96,
5215-5220.

59.

Bainton, D. F.; Ullyot, J. L.; Farquhar, M. G. The Development of Neutrophilic
Polymorphonuclear Leukocytes in Human Bone Marrow: Origin and Content of
Azurophil and Specific Granules. The Journal of Experimental Medicine 1971, 134, 907934.

102

60.

Srikrishna, G. S100a8 and S100a9: New Insights into Their Roles in Malignancy. J.
Innate Immun. 2012, 4, 31-40.

61.

Brennan, R. M.; Petersen, J.; Neller, M. A.; Miles, J. J.; Burrows, J. M.; Smith, C.;
McCluskey, J.; Khanna, R.; Rossjohn, J.; Burrows, S. R. The Impact of a Large and
Frequent Deletion in the Human Tcr Β Locus on Antiviral Immunity. J. Immunol. 2012,
188, 2742-2748.

62.

Marrack, P.; Rubtsova, K.; Scott-Browne, J.; Kappler, J. W. T Cell Receptor Specificity
for Major Histocompatibility Complex Proteins. Curr. Opin. Immunol. 2008, 20, 203207.

63.

Murphy, P. M.; Tiffany, H. L.; McDermott, D.; Ahuja, S. K. Sequence and Organization
of the Human N-Formyl Peptide Receptor-Encoding Gene. Gene 1993, 133, 285-90.

64.

Devosse, T.; Guillabert, A.; D'Haene, N.; Berton, A.; De Nadai, P.; Noel, S.; Brait, M.;
Franssen, J.-D.; Sozzani, S.; Salmon, I.; Parmentier, M. Formyl Peptide Receptor-Like 2
Is Expressed and Functional in Plasmacytoid Dendritic Cells, Tissue-Specific
Macrophage Subpopulations, and Eosinophils. J. Immunol. 2009, 182, 4974-4984.

65.

Tunnacliffe, A.; Kefford, R.; Milstein, C.; Forster, A.; Rabbitts, T. H. Sequence and
Evolution of the Human T-Cell Antigen Receptor Β-Chain Genes. Proc. Natl. Acad. Sci.
U. S. A. 1985, 82, 5068-72.

66.

Reiter, M.; Kirchner, B.; Mueller, H.; Holzhauer, C.; Mann, W.; Pfaffl, M. W.
Quantification Noise in Single Cell Experiments. Nucleic Acids Res. 2011, 39, e124.

67.

Puellmann, K.; Kaminski, W. E.; Vogel, M.; Nebe, C. T.; Schroeder, J.; Wolf, H.;
Beham, A. W. A Variable Immunoreceptor in a Subpopulation of Human Neutrophils.
Chir. Forum Exp. Klin. Forsch. 2007, 247-249.

68.

Whitney, A. R.; Diehn, M.; Popper, S. J.; Alizadeh, A. A.; Boldrick, J. C.; Relman, D.
A.; Brown, P. O. Individuality and Variation in Gene Expression Patterns in Human
Blood. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1896-1901.

103

69.

Eggleton, P.; Gargan, R.; Fisher, D. Rapid Method for the Isolation of Neutrophils in
High Yield without the Use of Dextran or Density Gradient Polymers. J Immunol
Methods 1989, 121, 105-13.

70.

Watson, F.; Robinson, J. J.; Edwards, S. W. Neutrophil Function in Whole Blood and
after Purification: Changes in Receptor Expression, Oxidase Activity and Responsiveness
to Cytokines. Biosci. Rep. 1992, 12, 123-33.

104

CHAPTER 3. SOLID PHASE EXTRACTION OF RNA FROM ISOLATED
T-CELLS AND NEUTROPHILS USING COMBINED MICROFLUIDIC
MODULES
3.1 Introduction
Advancements in the field of genomics have allowed better understanding of gene expression
changes and provide accurate means of disease diagnosis by potential biomarker measurement. 1
Genomic profiling of peripheral blood samples could be of great value in identifying biomarkers
for various complex diseases, including stroke, as evident from the studies which utilized white
blood cells to identify discrete patterns of expression associated with the disease states.2,

3

Therefore, growing interest continues in isolation of pure population of relevant white blood cell
subsets and extraction of nucleic acids for applications in clinical diagnostics and forensics. In
addition to that, development of small footprint, self-contained, disposable, fast, and inexpensive
devices for cell isolation and nucleic acid isolation play a key role in the point-of-care testing
specially in resource-poor settings. Greatest areas of potential impact for these miniaturized
devices is in molecular diagnostics to facilitate fast diagnostics, low cost, operation by minimally
trained personnel, and low contamination risk.
Some of the previously reported cell separation strategies include density gradient methods,4
magnetic activated cell separation (MACS),5 micro-fabricated fluorescence activated cell
sorting,6 ultrasonic particle separation,7 mammalian cells sorted by optical force switching,8 cell
separation by dielectrophoresis chip.9 However some of the limitations associated with
aforementioned techniques are alteration in immunophenotype of leukocytes due to excessive
manipulation of sample such as repeating pipetting or centrifugation. Cells are prone to apoptosis
as they are very sensitive to the changes in the environment. 10 Although FACS and MACS offer
high throughput, however high cost and complexity of these systems limits their implementation
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in a clinical setting. Strong polarization charges in non-uniform electric field may cause damage
to the cells in dielectrophoresis methods which limits its wide clinical use.
A suitable sample preparation for molecular diagnostics consists of an efficient target
recovery, from a biologically relevant sample, preserving the integrity of the nucleic acid (NA)
molecules at the same time. Nucleic acid-based assays have been successfully implemented in
recent years in many fields exploiting their rapid and accurate analysis (e.g., medical diagnostics,
forensics, environmental analysis, and biodefense).11-14 These assays typically involve cell lysis
to release the small amount of NAs (DNA/RNA) present in the sample, purification of these
moieties followed by amplification to achieve detectable concentration, and detection using
hybridization or electrophoretic methods.15 The sensitivity of these analyses, among other things
depends on the purity and yield of NA obtained that can be transferred into amplification
reaction.
Earlier methods of DNA purification, CsCl gradient extraction method, 16 phenol-chloroform
phase separation17 were replaced by solid phase extraction (SPE) methods wherein analytes are
retained on a solid support and are subsequently eluted in a concentrated form, 18 thus eliminating
the need for the use of toxic chemicals and lengthy centrifuge times. Most of these methods rely on

adsorption of DNA with a solid surface, either via hydrogen bonding or via electrostatic
interactions.19 Commercially available NA binding columns require several centrifugation steps
and pipetting. Therefore, transition to micro-domain is more amenable to miniaturization than
the traditional extraction processes and the use of microfluidic SPE allows for more rapid and
straightforward on-chip sample preparation as demonstrated by Tian et al., who established a
capillary-based micro-SPE (iSPE).20 Microchip-based DNA purification was first demonstrated
by Christel et al. using pillars created in a microchannel using reactive ion etching to increase the
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silica surface area available for DNA adsorption but limited by the complexity of the fabrication
procedure.21 Various techniques of microfluidic SPE involved the use of functionalized
microparticles, filters, silica gels and beads, and micro- and nano-engineered surfaces.22
Microfluidic extraction systems are mostly designed for DNA sample preparation and
relatively less research has been reported on the RNA isolation and specifically using
microfluidics. This is due to difficulty in isolation and purification of RNA because of significant
chemical and biological lability and instability of RNA when compared to DNA. RNases are
extremely active enzymes present in human skin, body fluids, lab surfaces, and environment.
RNase contamination makes the isolation of RNA from common clinical and forensic samples
challenging. Also, RNA derived from complicated matrix like blood may be contaminated with
inhibitors of downstream molecular analyses. Therefore, the choice of RNA purification methods
is important for successful isolation of high quality of RNA for consistent performance in
downstream applications like reverse transcription RT quantitative PCR (RT-qPCR), microarray
analyses.
RNA has multiple advantages over DNA in some applications as a biological target material
since it is more closely related to cell’s machinery. To carry out a gene expression analysis, RNA
must be first isolated and purified from biological source of interest. Detection of RNA and
mRNA expression can be used for clinical diagnostics, as the increased/decreased levels of
expression of specific genes can be indicative of the disease. These methods are based on the
inherently variable mRNA expression from different cell types, producing gene-specific patterns
which can be verified by the presence of a unique mRNA expression pattern. 23 However, it is
known that, within minutes of collection, peripheral blood gene expression profiles change
significantly due to transcript degradation, and these purification processes further introduce
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changes in expressed transcripts.24 The correct interpretation of transcript abundance requires
stabilization of the transcriptome at the point of sample collection, through storage and transport,
in order for gene expression to be detected in a reproducible manner. 25 Traditional assays involve
multiple steps involving sample transfer which can cause the degradation of the sample by
exposure to outside environment. Microchip based extraction hence offers advantages by
providing a contamination free environment because material is isolated in enclosed
architectures with minute amount of the sample needed. Examples of microfluidic chips for the
SPE of RNA using silica beads as a solid phase, chitosan-coated silica, porous polymer monolith
have been demonstrated.26-29
To address some of the issues of the aforementioned methods and their applicability for the
purification of NAs in clinical settings such as 1) cost of device fabrication and substrate
material required for the device; (2) lengthy and labor intensive procedures for SPE bed
preparation and; (3) sample recovery, we have demonstrated the use of photoactivated
polycarbonate (PPC) devices containing micropillars. SPE active surface on these PC devices is
produced by simple UV-photoactivation protocol which generates high density of carboxylic
acids on the PC surface that serves as the affinity surface for NA.30, 31 The advantages of this
method include: (1) inexpensive device fabrication through micro-replication into PC; (2) quick
and simple bed activation procedure using UV irradiation; (3) scalability of the fabrication
process to high volume mass production; (4) versatility – various NAs can be selectively purified
by using the proper composition of immobilization buffer and; (5) very high target recoveries
with good removal of endogenous proteins.30-32
In this study, we present a reliable and fast method using combined microfluidic modules
that serve purpose of cell isolation, cell lysis and TRNA isolation. The strategy employed here is
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to capture target cells on cell isolation module and following lysis on microchip to isolate RNA
using SPE module. RNA extracted using this method was reverse transcribed and resulting
cDNA was amplified via PCR. Incorporation of cell isolation, lysis and RNA purification steps
into one platform has a potential for development of an on-site setting and reduces the potential
for contamination. These integrated modules can be adapted for automation to enable high
throughput and can be implemented into microfluidic systems that interface with downstream
components.
3.2 Materials and Methods
3.2.1 Surface Characterization Techniques
Surface characterization studies were performed on clean planar polymer substrates. For XPS
measurements, C 1s and O 1s photoelectron signals were acquired using an Axis Ultra DLD Xray photoelectron spectrometer (Kratos Analytical) under ultra-high vacuum conditions (10 -8 to
10-10 Torr) with a monochromatic Al Kα X-ray source, 20 eV pass energy, 370 s acquisition
time, 1,600 ms dwell time, and 20° electron take-off angle. Given an inelastic mean free path of
3-4 nm, ~95% of the resultant signal originated 9-12 nm from the surface. ATR-FTIR spectra
were scanned from 375-4000 cm-1 using an ALPHA FTIR spectrometer and a Platinum ATR
module (Bruker Optics).
3.2.2 Chemicals and Reagents
Polyethylene glycol (PEG, Mw 8000), NaCl, ethanol, 2-propanol, were all purchased from
Sigma Aldrich. Ethanol was purchased from Fisher Scientific (Houston, TX). The lysis solution,
DNase used was from GenElute mammalian genomic RNA Miniprep Kit (Sigma-Aldrich, St.
Louis, MO) and used as received. A stock solution of immobilization buffer (IB) was prepared
with nuclease-free water to yield an optimal buffer composition of 0.5 M NaCl, 5% PEG, 63%
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EtOH. RNA containing samples were suspended in the IB and processed using the SPE
microchip as described below. All the primers used in this work were purchased from Integrated
DNA Technologies, Coralville, IA.
3.2.3 Design and Fabrication of Microfluidic Modules
The microfluidic device fabrication involved three major steps: (1) Mold insert fabrication
using a micro-milling machine (Kern MMP, Kern Micro- and Feinwerktechnik, MurnauWestried, Germany); (2) hot embossing of the microfluidic structures (HEX02, JenOptik
Mikrotechnik, Jena, Germany) on 3 mm thick PMMA/PC substrates (Goodfellow, United
Kingdom); and (3) post-processing of the microfluidic device including drilling of sample
reservoirs, UV modification of the immobilization beds and cover plate assembly.
The microfluidic devices for cell isolation were hot embossed into cycloolefin copolymer
(COC) substrates, via micro replication from a metal mold master as reported earlier.33 The Zconfiguration device, consisted of 64 curvilinear channels (see Figure 3.3A) that were 9,000 x 25
x 80 µm (l x w x h) with a center-to-center spacing of 200 µm. Each isolation bed’s surface area
was 132.3 mm2. Addressing each bed required four bifurcations, with an additional two
bifurcations for the four individual isolation units. All four capture beds shared a common inlet
port, with different outlet ports for each capture bed (Figure 3.3 B).
SPE module for isolation and purification of RNA, was embossed into PC substrate in a
single step. This device consisted of six, 24 mm long and 1.4 mm wide channels with
microposts. The channel (capture bed) dimensions were 100 μm height, 100 μm diameter, a 50
μm spacing. The extraction bed consisted of series of ~3600 microposts (see Figure 3.2 C, D)
which provided a high surface area allowing high mass load of RNA. Each affinity bed had a
surface area of 110 mm2 and volume 260 nL.
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3.2.4 Assembly of the Microfluidic Modules
For the device assembly, both COC and PC, inlet and outlet reservoirs were drilled (d=0.85
mm) in both microchip devices, followed by cleaning and then drying at 60ºC. A 250 µm thick
coverslips and devices were modified for 15 min in a home built UV chamber equipped with a
low pressure Hg lamp (1.5cm from light source, 22 mW/cm2 measured at 254 nm) to generate
carboxylic acid scaffolds on microchannel surfaces. 34 In order to enclose the microfluidic
structures, thermal fusion bonding was performed at 132˚C and 144oC (~25 min) for UVmodified COC and PC microdevices, respectively. PEEK tubing, IDEX Health & Science LLC
(175/335 µm id/od) was inserted into the drilled reservoirs and glued with epoxy resin to
facilitate sealed junction. Constant flow programmable syringe pump (Harvard Instruments) with
attached syringe introduced fluids into the device.
3.2.5 Cell Isolation on COC Microfluidic Devices
Following device assembly, Ab immobilization was carried out in two-step process. In the
first step, 50 mg/mL EDC and 5 mg/mL NHS in 100 mM MES (pH= 4.8) was introduced into
the freshly fabricated device and incubated for 15 min at room temperature to obtain the
succinimidyl ester intermediate. EDC/NHS solution was then removed from the device by
flushing with PBS, and a 15 µL aliquot of 0.5 mg/mL (unless stated otherwise) mouse antihuman CD4 (T-cell isolation) or mouse anti-human CD66b (neutrophil isolation) was introduced
into the device and incubated overnight at 4˚C. The capture bed was then rinsed with 1 mL PBS
(pH = 7.4) to remove unreacted molecules.
Whole blood samples were obtained from anonymous healthy donors at UNC Cancer
Hospital Blood Bank in accordance with the UNC Institutional Review Board (IRB) procedures.
Peripheral blood samples were collected by venipuncture technique in Vacutainer tubes

111

containing EDTA (K3) 7.5%, 0.06 mL, (Tyco Health Care). Collected samples were processed
within 4 h.
The microfluidic device was connected to the syringe pump with PEEK tubing via a luer lock
tuberculin syringe connector (Hamilton, Reno, NV). A precapture rinse of the chip was
performed using PBS/0.5% BSA at 4 mm/s. 200 µL of whole blood was infused through the
common inlet, at 3.8 µL/min which yielded nominal linear velocities of 2 mm/s in the isolation
bed. A post capture rinse was performed at 4 mm/s with 100-200 µL PBS/0.5% BSA to remove
blood and unbounded cells.
3.2.6 Cell Lysis
T-cells and neutrophils isolated in the bifurcated COC chip. Numbers of isolated cells were
enumerated using bright field microscopy. 200 µl of lysis solution was then introduced through
the common inlet of the bifurcated device and the lysate is collected into four different
microfuge tubes from the outlets. The cell lysate was then suspended in the appropriate IB ready
to be introduced to the SPE module.
3.2.7 Operation of Microchip Solid Phase Extraction
The extraction procedure consisted of load, wash, and elution steps. In the load step a
cocktail of 50 μL of IB buffer (0.5 M NaCl, 5% PEG, 63 % Ethanol) , 50 µl cell lysate (Tcells/neutrophils) and 170 µl of ethanol (63%), was infused through the SPE bed using a
programmable syringe pump at 5 µL/min followed by a 200 µL of wash buffer (85% ethanol) at
5 μL/min.

This washing step ensures complete removal of any proteins or possible PCR

inhibitors that were adsorbed onto the SPE bed during the load step. Air was drawn through the
other end of the SPE bed to remove ethanol and dry the bed. Ethanol removal is critical, because
residual amounts of ethanol may serve as a PCR inhibitor. Finally, the RNA was eluted with ~20
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μL H2O pumped through the SPE bed at 5 μL/min and was collected from the SPE bed into PCR
tubes. Then, isolation of pure RNA was achieved by a secondary enrichment, through enzymatic
removal of genomic DNA (DNase treatment), using DNase 1 digestion set (Sigma Aldrich, St.
Louis, MO. The DNase cocktail was prepared by addition of DNase I (10% of the total eluted
volume) and buffer (10% of the total eluted buffer). After incubation at room temperature for 15
minutes, the same volume of EDTA stop solution was added and the mixture was incubated at
70˚C for 10 minutes. This solution was then used for subsequent reverse transcription and PCR
analysis.
3.2.8 Reverse Transcription
After the purification of total RNA (TRNA), using SPE unit, reverse transcription (RT) of
RNA was accomplished using a ProtoScript II First Strand cDNA Synthesis Kit (New England
BioLabs, Ipswich, MA). Samples were prepared by mixing 10 µL reaction mix, 2 µL poly-T
primer, 2 µL enzyme (no enzyme, 2 µL of water for RT-) and 6 µL of TRNA. The samples were
then incubated at 42˚C for 1 h and heated to 80˚C for 5 min to deactivate the RT enzyme.
3.2.9 Polymerase Chain Reactions (PCR)
PCR was performed with synthesized cDNA in a total volume of 20 µL using Taq 2X Master
Mix (New England Biolabs, Ipswich, MA). PCR cocktails consisted of 2 µL of primers mix
(final concentration 500 nM), 10 µL Taq 2X Master Mix, 6 µL nuclease free water and 2 µL
cDNA. PCR was carried out in a commercial thermal cycler (MJ Research Inc., Waltham, MA)
with following steps: an initial denaturation at 94˚C for 2.5 min followed by 40 cycles of
denaturation at 94˚C for 15 s, annealing for 30 s at 63˚C for GAPDH primers, 55˚C for S100A9
and GUSB primers, 58˚C for TCRB primers, and 54˚C for FPR1 primers, and elongation at 72˚C
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for 30 s. A final extension at 72˚C for 7 min was followed by a cooling step at 4˚C. The list of
primers used is tabulated below.
Table 3.1 List of primers used for amplification of cDNA.

3.2.10 Gel Electrophoresis
PCR products were electrophoresed at 8.3 V/cm in 1X TBE (Tris–boric acid/EDTA) (BioRad Laboratories) on a 4% agarose gel with ethidium bromide (Lonza). Amplicons were indexed
against a DNA sizing ladder 50–766 bp (New England Biolabs, Ipswich, MA). Images were
collected using a Logic Gel imaging system (Eastman Kodak Company).
3.2.11 Fluorescence Spectroscopy
Following the SPE protocol described above with known total RNA concentrations of 50, 20,
4, 0.5, 0.3, 0.2 ng, quantification was done with RiboGreen Reagent (excitation 480 nm/
emission 520 nm, Molecular Probes). The emission spectra were acquired using FLUOROLOG3 spectrofluorometer (Jobin Yvon Inc., Edison, NJ) equipped with a 450 W xenon lamp and a
cooled Hamamatsu R928 photomultiplier (Bridgewater, NJ) operated at 900 V in a photon163
counting mode with the resulting emission spectra used for determining the RNA concentration
in the samples. A calibration curve was constructed using RiboGreen stained RNAs of
concentrations ranging from 1 ng/ μL to 1 µg/μL for RNA standards and correlation coefficient
for RNA standards were determined.
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3.3 Results and Discussion
3.3.1

Surface Characterization of UV Activated Polycarbonate

To identify the photo-products generated on the UV modified PC surface, we employed both
XPS and ATR-FTIR spectroscopies. After UV-activation, a 0.33-fold increase in the O/C ratio
was observed due to the appearance of several oxidized carbon species, which were
deconvoluted based on previously published functional group binding energies. 35-37
Pristine PC’s C 1s spectrum was deconvoluted into the following peaks: (1) 284.5 eV
aromatic C-C and C-H; (2) 285.0 eV aliphatic C-C and C-H; (3) 290.4 eV carbonate C=O; (4)
291.8 π-π* shake-up satellite; and (5) 286.2 eV aromatic C-O. The ratio of peak areas of C 1s
(1):(2):(3):(5) was 8.42:2.85:1.00:1.99, and matches reasonably well with the theoretical ratio of
10:3:1:2.
UV modified PC spectra were deconvoluted by calibrating the C 1s (2) peak to 285.0 eV,
fixing the C 1s (3) and C 1s (4) peaks at their pristine positions, adjusting the C 1s (1) peak
within ±0.2 eV of its pristine position, and adding C 1s (5), C 1s (6), and C 1s (7) peaks
corresponding to phenols, alcohols, or ethers, aldehyde or ketone carbonyls, and ester or
carboxylic acid carbonyls, respectively.
ATR-FTIR peak areas indicated the presence of several new oxidized functionalities,
such as an increase of 0.5 au·cm-1 and 6.3 au·cm-1 for the C=O (1650-1850 cm-1) and O-H
(3200-3700) regions, respectively. More specifically, using the work of Rivaton, et al., we were
able to identify several photo-products shown in Figure 3.1 along with their corresponding
carbonyl stretching energies, which are matched to the pristine-subtracted UV-PC.
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Figure 3.1 Structures and carbonyl stretching frequencies of PC’s photo-Fries rearrangement and
photo-oxidation products. Reproduced with permission from [39].
Despite being convoluted, we were able to identify several peaks in addition to the pristine
carbonate stretch (1767 cm-1) that were generated by UV-activation. The photo-Fries
rearrangement products, 2,2’-dihydroxybenzophenone (1627 cm-1) and phenylsalicylate (1687
cm-1), were apparent along with their associated O-H ring substitutions (1617 and 1585 cm-1) and
H-bonded carbonate groups (1748 cm-1).35 The constant level of atomic oxygen and ozone in the
UV modification chamber may have also led to photo-oxidation of the gem dimethyl side chains,
producing aliphatic carboxylic acids (1713 cm-1) and benzoic acids (1696 cm-1). There was also a
very small peak at 1840 cm-1, which could have originated from ring scissions producing
aliphatic carboxylic acids that can rearrange to form cyclic anhydrides at the elevated
temperatures present in our system. Rivaton, et al. observed this rearrangement from 45°C to
75°C , and these conditions occurred within the modification chamber, which was heated to
50°C after a 15 min UV exposure time. 35 However, this peak is small enough that it could be an
artifact of background subtraction.
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3.3.2 Operation of Serially-connected Micromodules
The combined fluidic system presented here consists of two task-specific modules connected
in series to facilitate leukocyte subset isolation, cell lysis and RNA isolation. As demonstrated
recently by Wang et. al.,38 the modular design approach offers some appealing advantages
compared to monolithic designs, including: (1) flexibility in materials used for designing
individual modules to optimize performance of each processing step imposed on that module; (2)
the ability to reconfigure the assay format without requiring re-engineering; (3) the ability to use
different fabrication schemes optimized for each module; and (4) high production yields of
integrated systems, because each module is fabricated and tested separately. Modules fabricated
in different thermoplastic materials with desired structures can be custom-designed.
We have demonstrated COC’s superb ability to generate COOH functionalities upon
exposure to UV light.39 Probability of COOH functional group generation on COC microchannel
surfaces do not decrease with the increase in microchannel’s aspect ratio unlike PMMA.
Furthermore, COC microdevices were less susceptible to photo-fragmentation upon irradiation.
These factors are critical for accessibility and covalent attachment of antibodies to microchannel
surfaces via carboxylic acid (COOH) scaffolds leading to efficient attachment of antibody and
therefore efficient cell isolation. The cell isolation data shown in chapter 2 clearly indicates that
COC devices exhibited superior performance compared to PMMA devices. Chemically modified
Z-configuration devices immobilized with anti-CD4 and anti-CD66b yielded 2565 ±1194 T-cells
and 2949 ±901 neutrophils respectively (Figure 3.2 A, B).
SPE module was constructed using polycarbonate (PC) due to its unique characteristic to
allow the isolation and purification of nucleic acids. 30,

31

Generation of polymer phenyl

salicylates, hydroxybenzophenones and a wide range of carbonyl/carboxyl-containing groups
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upon UV irradiation (254-300nm) of PC can serve as a capture medium for the isolation,
purification and preconcentration of a wide range of molecular weight-sized NA’s present in
complex biological samples.

Figure 3.2 Bright field images of (A) T-cells (60X) and (B) neutrophils (40X) captured within
the COC microfluidic device immobilized with CD4 and CD66b antibodies respectively.
A

C
B

B

D
B

Figure 3.3 (A) SEM image of isolation bed of Z-configuration device with dimensions 25 µm
wide and 80 µm deep (B) Photograph of Z-configuration device filled with red dye (C), (D) SEM
images of SPE immobilization capture bed, post diameter =100 µm, center-to-center post
spacing =50 µm (E) Picture showing the connected micromodules.
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Two modules were connected in series using a glass connector (see Figure 3.3 E). T-cells and
neutrophils captured on individual cell selection units were lysed by infusing cocktail solution
containing 50 µl IB, 50 µl lysis solution, 170 µl EtOH through leukocyte isolation module. The
lysate is directed to the SPE module on which RNA is purified and eluted with water for cDNA
synthesis and further amplification.
3.3.3 DNase Treatment of the Lysate.
A potential problem with RT-PCR is DNA contamination in RNA sample. DNA removal is
therefore critical especially for RT-PCR applications since DNA can serve as a template during
the PCR resulting in false positives, background, etc. Therefore, DNase treatment was performed
on the RNA isolated from SPE, prior to RT for cDNA synthesis. “Minus RT controls” (without
RT enzyme) were performed to identify erroneous signal due to genomic DNA contamination.
To demonstrate the effectiveness of SPE in removing the contaminated DNA, we chose to
perform DNase treatment on TRNA that was isolated from MCF-7 cells, a human breast cancer
cell line. Following cell lysis and considering 10 pg of TRNA per cell, 2 µl of lysate containing
8,000 cells i.e. 80 ng of TRNA was used for SPE. A cocktail mixture of 2 µl of this lysate, 50 µl
IB, 48 µl nuclease-free water, 170 µl of ethanol was infused through SPE bed and the TRNA
was eluted with 20 µl water. Following elution from SPE bed, DNase treatment for 15 minutes,
an RT reaction was performed. cDNA was then PCR amplified using GAPDH and GUSB
primers.
To eliminate amplification of gDNA, PCR primers can be designed to span introns or bridge
an exon-exon junction only in cDNA. Primers for GAPDH were designed that way, therefore,
PCR will not amplify gDNA and thus, any possible DNA contamination could not be identified.
GUSB primers, however, were not spanning introns and the absence of amplicons clearly

119

indicates the lack of DNA contamination. PCR products separated on gel for GUSB gene (Figure
3.4) indicate that DNase treatment was shown to efficiently degrade contaminating gDNA, since
no PCR product was amplified from samples that were DNase-treated but not reverse-transcribed
(minus RT controls), whereas the DNase treated and reverse transcribed mRNA show the
products of 528 bp and 122 bp for GAPDH and GUSB, respectively.

Figure 3.4 Gel electrophoresis images showing DNase treatment after SPE.RNA from MCF-7
cells was DNase treated for 15 min, reverse transcribed and PCR was performed on cDNA with
(A) GAPDH primers and (B) GUSB primers The absence of product for the negative RT
controls indicates the absence of DNA contamination.
3.3.4 Evaluation of RNA Extraction Efficiency
An efficient cell isolation method will not guarantee successful molecular analysis. In order
to perform an analytical assay, preconcentration of target (i.e., DNA or RNA) must be
accomplished. Microfluidic chips are especially attractive for cellular-based assays because
many of the sample processing steps can be integrated into a single module, minimizing the
dilution of intracellular components following cell lysis.
Recovery of TRNA after purification on SPE bed was evaluated by examining the mass of
TRNA before and after purification on the microchip. Samples containing TRNA in a mass
range of 0.5–180 ng were examined. RNA concentration was determined by staining with
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RiboGreen (excitation 500 nm/ emission ~525 nm, Molecular Probes). Calibration curves were
constructed using concentrations ranging from 5 pg/ µL to 1000 pg/µL for RNA standards.
After TRNA elution, as judged by fluorescence, the efficiency of recovery for 5 ng TRNA
was estimated to be 57% (Figure 3.5 C). Based on the TRNA mass immobilized on chip surface
and the available surface area of the capture bed, the surface loading density of TRNA was
determined to be 2.6 ng/cm2. It was observed that the efficiency of recovery decreased as the
mass load of TRNA introduced on a SPE bed increased. Efficiency of the recovery was less than
10% for aliquots containing 180 ng of TRNA. This indicates that the amount of TRNA
introduced onto bed exceeded the load capacity of the capture bed (i.e. available –COOH sites).
The amount of TRNA captured on previously reported 96-well PPC chip was determined to be
582 ± 286 ng/cm2.30 This significant difference in the surface load can be explained by use of a
different architecture chip. In previous work, SPE bed contained 3,800 20 μm diameter posts
with 20 μm spacing and 50 μm depth and surface area of 28.4 mm2. Such geometry provides
advantage for more efficient solid phase extraction because provides higher density of posts and
reduced inter-post spacing, providing shorter diffusional distance for RNA to reach surface.
As we could not determine the efficiency of the purification process for samples containing
less than 5 ng of TRNA, most likely due to instability of the RNA, we chose to test if TRNA is
present in the effluent of these samples by performing RT-PCR. In a separate experiment, a
range of different masses of TRNA (0.2-50 ng corresponding to ~10-2,500 cells) was introduced
on chip and purified. Immediately after purification, RT was performed with collected TRNA,
followed by amplification of GAPDH gene. Products were separated and these results are
presented in Figure 3.5A.
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Figure 3.5 SPE was performed on commercial Jurkat T-cell TRNA and isolated RNA was
analyzed via RT-PCR with GAPDH PCR primers. (A) Fluorescence image of ethidium-stained
4% agarose gel showing decrease in RNA isolated with a decrease in total RNA input. (B) Band
volumes of product bands in part A were quantified using ImageQuant. (C) Efficiency of RNA
isolation for different input masses of TRNA evaluated using the RiboGreen assay.
The products were observed for all tested effluents after SPE purification. Even effluent from
purification of 0.2 ng of TRNA was successfully amplified, suggesting that purification can be
efficient for minute amount of sample. The integrated intensity of the amplicon bands from
Figure 3.5A was plotted vs amount of TRNA introduced on SPE bed. The data show linearity for
lowest mass loads of TRNA while saturation of the signal on the gel is observed for amplicons
generated from 4-50ng TRNA mass load. Even though the SPE process is less efficient for these
amounts of TRNA, it can still purify enough material for gene expression analysis in RT-PCR. It
is clear, that for a given sample and immobilization buffer, the RNA recovery efficiency will
depend on the extraction bed characteristics, including the active surface area and the inter-post
distance and post layout.
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3.3.5 RT-PCR of RNA Extracted from T-cells and Neutrophils
In previous work we demonstrated that the total number of isolated cells from 50μL blood
using the same microfluidic device as reported herein ranged from 500 to 2,000 CD4+ T-cells
and CD66b+ neutrophils. We increased blood volume processed to 200 μL to increase the load
of isolated cells. If at least 4 times more cells will be isolated, therefore, we expected to obtain
between 20 and 80 ng TRNA (1-4 ng of mRNA), which should secure enough material after SPE
purification for cDNA synthesis and gene expression analysis. T-cells and neutrophils were
isolated from the same blood sample and because of the high purity (94±3%) of isolated
fractions, cell lysis was performed directly on chip followed by SPE and RT-PCR analysis in
thermocycler. Figure 3.6 presents agarose gel image showing amplicons from amplified S100A9
and FPR1 gene. Presence of amplicon products after RT-PCR indicates that high quality TRNA
(mRNA) was obtained during processing on integrated cell isolation and SPE unit.

Figure 3.6 Fluorescence images of ethidium-stained 4% agarose gels showing RT-PCR products
of TRNA captured from CD4+ T-Cells or neutrophils isolated from 100 μl whole blood. RNA
was captured on SPE bed, and reverse transcription was performed. PCR was run with primers
targeting S100A9 and FPR1 genes. Negative RT controls were performed without RT enzyme.
We have previously demonstrated high quality of TRNA following SPE microchip
purification.30 We assessed integrity of TRNA by monitoring the electrophoretic band pattern for
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rRNAs. This method relies on the assumption that rRNA quality and quantity reflect that of the
underlying mRNA population.31 The rRNA species used for this assessment included the 18S
and 28S rRNAs for mammalian samples. Ratios of these band intensities of ~2 were indicative of
intact TRNA, while for degraded RNA samples, these bands appeared smeared in the
electrophoretic bands.
3.4 Conclusions
The use of the PPC-SPE devices along with cell isolation unit is advantageous for RNA
purification requiring disposable and one-time use devices for eliminating potential sample
contamination and protection of RNA from RNases or other factors that can cause RNA
hydrolysis. Chip fabrication method, which use of micro-replication techniques such as hot
embossing or injection molding can provide high-volume and low-cost production of these
devices which can allow for wide use of these in clinical applications.33,34
We demonstrated that RT-PCRs of the SPE purified mRNAs were successful with the
amounts of mRNA isolated. The SPE chip showed the ability to provide high quality material
from whole cell lysate that could be used for a variety of molecular assays i.e., gene expression
analysis, particularly in detection of stroke markers in subpopulations of leukocytes.
The incorporation of SPE protocols into microfluidic formats is very appealing because
microfluidics capture occurs in a closed architecture and, therefore, the potential risk of crosscontamination is significantly reduced. By combining NA purification with cell isolation on-chip
processing, fully integrated lab-on-a-chip systems can be realized with a concomitant reduction
in the time, complexity, and cost of carrying out the analysis.
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CHAPTER 4. INVESTIGATION OF SURFACE CHARGE AND
ELECTROSMOTIC FLOW IN POLYMER NANOSLITS AND
NANOCHANNELS
4.1 Introduction
Fluidic channels with one or two of its dimensions in the nanometer scale, nanoslits or
nanochannels, respectively, have recently generated great interest because of unique phenomena
that occur in nano-confined space such as nanocapillarity,1 concentration polarization2,

3

and

electrical double layer (EDL) overlap.4-7 These properties arise when the channel size is
comparable to either the length scales of the range of electrostatic interactions in solution or the
molecular size of the analytes. Some of the interesting applications that arise from the use of
nanochannels and nanoslits include single-molecule interrogations,8-11 molecular preconcentration,12 chemical analyses of mass-limited samples,13,

14

DNA electrophoresis,15-17

desalination,18 nanofluidic diodes,19 real-time probing of biomolecules,20-24 ionic transport,25 and
entropic trapping for DNA separations. 26 Nanochannels fabricated in a controlled fashion have
enabled the exploration of charge-related effects such as concentration enhancement and
depletion and surface-charge-governed transport.27, 28 Hence, nanofluidic channels have become
a fundamental and essential experimental platform for the study of nanoscale-molecular, -fluidic,
and -ionic transport properties that offer high throughput with low sample volume requirements.
As described by Chantiwas et al.,29 polymer-based nanoslits/nanochannels have provided an
attractive alternative to glass or silicon devices due to their diverse range of physiochemical
properties, low material cost and the availability of a plethora of fabrication techniques to design
the prerequisite structures. A commonly employed modality for the fabrication of thermoplastic
nanofluidic devices is nanoimprint lithography (NIL), a specific sub-type of hot embossing.30-33
This technique takes advantage of the deformability of the material at elevated temperatures to
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produce multi-scale nanostructures in a relatively high production mode over large areas and at
low-cost.34 A distinct benefit of using polymers for the fabrication of nanofluidic devices is the
diversity in their surface chemistry, which is determined by the identity of the monomer units
comprising the polymer chains. For example, poly(methylmethacrylate), PMMA, possesses
functional groups on its backbone that consists of methyl esters while polycarbonate, PC,
possesses carbonates. In addition, a diverse range of simple activation techniques can be
employed to generate surface functionalities appropriate for the desired application. 35-39
Common surface modification protocols reported for polymer fluidic devices are ultraviolet
(UV) and plasma oxidation.40-42 These activation techniques have been reported to generate a
host of oxygen-containing species, such as different carbonyls (aldehydes, ketones and
carboxylic acids) and alcohols on the polymer surface41, 43 following a sequence of free-radical
photo-initiated oxidation reactions. Photochemical activation of polymer substrates possessing
nanofluidic structures requires careful control of the dose to minimize activation induced
nanoscale roughness that may affect the operational characteristics of the device.44 Plasma
treatment has been the technique of choice for nanofluidic surface activation and lowtemperature assembly of the device as it induces minimal surface root-mean-square (RMS)
roughness, lacks diffraction limitations and shadowing effects, as reported for UV activation of
polymer substrates with microchannels,38 and allows for low temperature assembly of the
nanofluidic device while retaining the surface functionality and minimizing nanostructure
deformation.33 For example, by exposing PMMA to controlled plasma conditions, it is possible
to generate surface carboxyl functional groups,41 which remain accessible for reactions after
device thermal assembly.
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In a previous work, we reported the generation of positively charged surface moieties in
PMMA microchannels following both chemical (N-lithiodiaminoethane reaction)39 and
photochemical

(UV

-

[N-(3-dimethylaminopropyl)-N-ethylcarbodiimide

(EDC)]

–

[ethylenediamine (EDA)]) pathways.37 To the best of our knowledge, most of the work on
nanochannel surface modification has involved functionalization of surface silanol groups,28
immobilization of biomolecules on the channel walls25, 45, 46 and ion transport studies performed
in glass-based substrates. Glass possesses well-established surface chemistry, hydrophilicity,
non-conductivity, rigidity with minimal surface defects, non-deformability at high pressures,
excellent optical properties and well-established top-down fabrication techniques.47, 48 However,
with the growing interests in elastomeric, 49-52 thermoplastic31 and membrane-based53,

54

nanofluidic devices, it becomes necessary to understand the effects of surface modification on
the charge density and surface charge governed ion transport in polymer-based nanofluidic
channels, especially when considering such devices for many of the nanofluidic applications
discussed previously.28, 55
In this work, we report for the first time the surface modification of polymer nanoslits and
nanochannels and the investigation of the surface charge density and electroosmotic flow (EOF)
in these devices. The nanofluidic devices were fabricated in PMMA substrates using a modified
protocol that we previously reported. Carboxyl groups were generated on the walls of PMMA
nanoslits and nanochannels under controlled conditions of the plasma exposure time and oxygen
gas flow rate.41, 43 These groups were subsequently aminated by reaction of the surface carboxyl
groups with a solution of EDC and EDA. The extent of surface roughness induced by surface
activation was assessed in a nanoslit using atomic force microscopy (AFM). Surface
conductance plots were generated for the fluidic devices using a range of potassium chloride
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(KCl) concentrations. In agreement with our measurements, a modified model of ion transport in
nanofluidic devices, based on Schoch et al.55 is presented. It revealed the importance of
geometrical parameters of the nanometer-sized channels and a dominating surface charge density
inducing a conductance plateau at low ionic strength. In addition, we investigated the effects of
solution pH on the surface charge density, reported the electroosmotic flow (EOF) in these
devices.
4.2 Materials and Methods
4.2.1 Reagents and Buffers
PMMA sheets and cover plates used for the device fabrication were purchased from Good
Fellow (Berwyn, PA). Cycloolefin copolymer backbone (COC 6017) for nanoimprinting was
purchased from TOPAS Advanced Polymers (Florence KY). Si <100> wafer was purchased
from

University

carbodimide

wafers

hydrochloride

(Boston,
(EDC),

MA).

Isopropanol,

1-ethyl-3-[dimethylaminopropyl]

2-(4-morpholino)-ethane

sulfonic

acid

(MES),

Ethylenediamine (EDA), tripropylene glycol diacrylate (TPGA), trimethylolpropane triacrylate
(TMPA), Irgacure 651 (photo-initiator), 50% potassium hydroxide (KOH) and potassium
chloride (KCl) were purchased from Sigma-Aldrich (St. Louis, MO). Anti-adhesion monolayer
of (Tridecafluoro – 1,1,2,2 – Tetrahydrooctyl) Tricholorosilane (T-Silane) was purchased from
Gelest, Inc. Tris buffer (pH 8.0) was obtained from Fisher Scientific (Houston, TX). Phosphatebuffered saline (PBS, pH = 7.4) was purchased from Life Technologies (Carlsbad, CA). All
required dilutions were performed using 18 MΩ/cm milliQ water (Millipore technologies) and
all measurements were performed at 25°C unless specified otherwise.
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4.2.2 Fabrication of Nanofluidic Devices
Previously, we have reported the development of nanoslits and nanochannels in polymer
substrates following a single step fabrication scheme that is based on nanoimprint lithography
(NIL).31, 32 Briefly, the device fabrication involves four key steps. First, the silicon master was
developed by initially patterning two V-shaped access microfluidic channels, 55 µm wide, 12
µm deep 1.5 cm long in Si <100> wafer using standard photolithography followed by anisotropic
etching with 50% KOH solution. Next, nanofluidic channels were patterned across the
microchannels by FIB milling using a Helios NanoLab 600 DualBeam instrument (FEI
Company). The spot size (beam current) and sputtering rate were carefully controlled to ensure
that the desired channel dimensions were designed.
Following this, an anti-adhesion monolayer of T-Silane was coated on the Si master from gas
phase in a desiccator under vacuum for 2 h to facilitate the demolding process. The structures on
the Si master were then carefully transferred into a UV-curable resin polymeric blend, containing
68 wt% TPGA as the base, 28 wt% TMPA as the crosslinking agent and 4 wt% Irgacure 651 as
photo-initiator) coated onto a cyloolefin copolymer (COC) backbone, via UV-NIL to
produce polymer stamps with protrusive structures. To achieve this, the Si master (mold) was
initially coated with the UV resin by dispensing with a pipette, followed by gentle pressing of the
COC backbone on the resin-coated master to ensure complete filling of the resin into mold
cavities. This was followed by exposure to a 365nm UV light (10 J/m2) through the COC
backbone for 5 min in a CL-100 Ultraviolet Crosslinker. After curing, the UV-curable resin was
gently demolded from the Si mold to get the negative copy on UV-curable resin.
Next, the patterned UV-curable resin was used as the stamp to hot emboss into a 3 mm-thick
PMMA sheet (Lucite CP) with access holes for reservoirs, drilled prior to embossing. The
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imprinting was performed at a pressure of 1910 kN/m2 for 120 s with the top and bottom plates
maintained at a temperature of 125ºC using the Hex03 hot-embosser (JenOptik). Pressure was
applied after 30 s preheating of the stamp and the substrate at the desired molding temperature,
and was maintained during the imprinting process until the system was cooled down to 45°C.
Upon cooling, PMMA copy was easily demolded from the UV-resin stamp. A 175µm thick
PMMA sheet (Goodfellow Corporation) was used as the cover plate. Both the patterned PMMA
sheet and cover plate were pre-activated with oxygen plasma at 50W for 35 s and 5.5 sccm gas
flow rate. Thermal assembly was performed immediately at 80°C for 400 s under a 370 kN/m2
pressure. This approach not only helped with achieving a low temperature device assembly with
the desirable bond strength but also contributed to the effective functionalization of the
nanochannel surface with carboxyl (hydrophilic) functional groups necessary for amine
modification.

4.2.3 Surface Modification
The reaction was initially tested on pre-cut pieces of PMMA (1 cm x 1 cm) without micro or
nanostructures. Clean PMMA substrates were exposed to 50 W (5.5 sccm) oxygen plasma for 35
s to generate the carboxyl functional scaffolds necessary for amination reaction (Scheme 4.1a).
The plasma modified samples were then soaked in a solution containing 300 mg EDA and 250
mg EDC in 5 ml of 0.1 M MES buffer (pH 4.8) for 20 min at room temperature. The amide
linkage between the surface carboxyl group and a terminal –NH2 group from EDA was achieved
through EDC linker chemistry. EDA attachment onto the surface is possible under the buffer
conditions described (pH 5 to 9) as the molecule does not contain functional groups susceptible
to hydrolysis (Scheme 4.1b).56 After incubation, samples were thoroughly rinsed with deionized
water and air dried. These amine modified samples along with the pristine and plasma activated
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substrates were then subjected to XPS analysis to determine the surface chemical composition
and AFM analysis to probe changes in surface morphology (roughness) induced by plasma
etching or chemical swelling/dissolution. The same protocol was adopted for the amination of
the assembled PMMA devices containing nanoslits and nanochannels. In this case, the plasma
assembled devices were immediately filled with EDC-EDA and allowed to incubate for 20 min
in a closed chamber. All devices were rinsed with deionized water prior to experiments.

Scheme 4.1 Protocol for the surface modification of PMMA with (a) carboxyl groups by plasma
activation, and (b) amine groups by chemical reaction with ethylenediamine through EDC
coupling chemistry to the plasma activated PMMA.
4.2.4 Water Contact Angle and Surface Energy
The wettability of the unmodified and surface treated PMMA were assessed by water
contact-angle measurements using a VCA Optima instrument (AST Products). 3 mm thick
PMMA sheet was cut to 15 mm x 18 mm dimensions and the surface was modified as described
above. A volume of 2.0 µL nanopure water (18.2MΩ.cm at 25oC) was dispensed on to the
substrate and the photograph of each droplet was captured immediately for analysis using the
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software provided by the manufacturer. The measurements were repeated at least five times at
separate positions on the substrate, and the values reported as the mean ± one standard deviation.
4.2.5 Atomic Force Microscopy (AFM)
The topographies of unmodified, O2-PMMA and NH2-modified flat PMMA surface and the
bottom of PMMA nanoslits were investigated using the Asylum Research MFP-3D Atomic
Force Microscope (tip radius ~2nm) in repulsive tapping mode at a rate of 1.0 Hz. The
Tap300A1-G cantilever tips (Ted Pella) had a frequency of 300 kHz and force constant of 40
N/m. For the flat surfaces, the scans were taken over a 3.5 µm x 3.5 µm scan size, presented in
3D and RMS surface roughness computed using manufacturer’s software. In the nanoslit, a scan
size of 4 µm x 500 nm was taken and the RMS roughness computed for the entire area.
4.2.6 Spectroscopies
For XPS measurements, C 1s, O 1s and N 1s photoelectron signals were acquired using an
Axis Ultra DLD X-ray photoelectron spectrometer (Kratos Analytical) under ultra-high vacuum
conditions (10-8 to 10-10 Torr) with a monochromatic Al Kα X-ray source, 20 eV pass energy,
370 s acquisition time, 1,600 ms dwell time, and 20° electron take-off angle. Given an inelastic
mean free path of 3-4 nm, ~95% of the resultant signal originated 9-12 nm from the surface.57-59
To examine the molecular nature of the treated and untreated surfaces, IR studies were employed
using pre-cut Silicon wafers coated with 200 nm Au layer (Au wafer). Commercial PMMA sheet
was dissolved in dichloromethane and serially diluted to yield a solution with final concentration
of 0.5 mg of PMMA/mL of dichloromethane. This was spin coated on the Au wafer at 2500 rpm
for 60 s to yield a 5 nm thick polymer layer. The coated Au-wafers were allowed to dry in an
oven after which they are ready for surface modification and analysis. This approach helped to
minimize interference from bulk material in the IR spectra. IR spectra were collected at a
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resolution of 2 cm−1 scans on a 670-IR spectrophotometer (Varian, US) using a
monolayer/grazing-angle specular reflectance accessory. For SEM, COC stamp and PMMA
substrate were pre-coated with a 2-3 nm layer of Au/Pd and were imaged under high vacuum
with an FEI Quanta 200 field emission gun at a 10 kV accelerating voltage and an EverhartThornley detector.
4.2.7 Surface Charge Measurement
Following each step of surface modification of the nanofluidic vias, electrical conductance of
the nanochannels was investigated using different dilutions of KCl from 1M to 10 -6M in Tris
buffers, pH 7.8 for all devices. The DC electrical conductance of the nanochannels was
monitored through Ag/AgCl electrodes immersed in the access reservoirs at the ends of
microchannels using a low noise Axopatch 200B amplifier with real-time control and analysis
using pClamp10 software. The conductance values were determined by fitting the slope of the
ionic current as a function of the applied voltage, which was stepped from -1V to 1V with
100mV step size and 5 s delay time for each data point. We found that the delay time was
sufficient for the device to reach a steady state current. The measurement was performed in
triplicate with the mean conductance plotted against the electrolyte concentration in log-log plot
and the surface charge was determined from these graphs. This experiment was repeated at pH
range between 3 and 12 to investigate the pH effects on the surface charge. The solution pH was
adjusted using hydrochloric acid or potassium chloride. No pressure difference across the
nanochannel was induced during the measurements.
To equilibrate the system, the fluidic device was first flushed with a binary mixture
of methanol/ultrapure water (50% v/v) by capillary force assisted with vacuum from the outlet
port to ensure complete filling and the elimination of air-bubbles. Next, deionized water (18
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MΩcm) was used to rinse the previous solution from the fluidic network followed by the
addition of the chosen electrolyte solution until the resistance of the fluidic channels reached a
stable minimum. Each rinsing cycle took 5 to 10 min until the flow was stopped and the
measurements were made. To avoid errors from solution interference, each measurement was
performed using a new device.
4.2.8 Electroosmotic Flow (EOF) Measurement
The EOF was measured using the Axopatch 200B amplifier. Two devices, one possessing a
single PMMA nanoslit (138 µm long, 50 nm high, and 1 μm wide) and the other a single
nanochannel (138 µm long, 120 nm high and 120 nm wide), connecting two opposite V-shaped
access microchannels, were fabricated as described previously. Fluidic channels were activated
and the EOF was assessed using the current monitoring method. EOF values were measured
using 0.1 and 0.05 M KCl solution in 10mM Tris buffer at pH 7.8. First, the entire device was
primed with 50% v/v water/methanol then drained and flushed with deionized water for 5-10
min. Next, the device was filled with 0.1 M solution and allowed to equilibrate for 3 min under a
1V DC bias. Following equilibration, as evident by a constant current trace, one access reservoir
was emptied and 0.05 M KCl was introduced. Ag/AgCl electrodes were placed in the reservoirs
across the channels under a 200 mV DC bias. Signals were acquired using pClamp10 software
and Digidata 1440A digitizer set at 10 kHz sampling frequency.
4.3 Results and Discussion
4.3.1 Device Fabrication
The Silicon (Si) master, which consisted of micron-scale access channels (fabricated using
photolithography) and an array of connecting nanoslits or nanochannels (fabricated using
Focused Ion Beam (FIB) milling), was used to fabricate the protrusive polymer stamp, which
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was made from a UV-curable resin. Thermal imprinting was used to transfer the nanofluidic
structures into PMMA from the UV-curable resin stamp and the device was sealed with a
PMMA cover plate using low-temperature plasma assisted bonding to build the enclosed mixedscale polymer device. UV-NIL conditions were carefully controlled to ensure that patterns from
the Si master were transferred with high fidelity and minimum deformations into the resin stamp.
Figure 4.1 shows scanning electron microscope (SEM) images of the original Si master, cured
UV-resin stamp and thermally imprinted PMMA substrate with an array of four nanoslits (Figure
4.1a – 4.1c) and seven nanochannels (Figure 4.1d – 4.1f).

Figure 4.1 Scanning electron micrographs (SEM) of the Si master, resin stamp and PMMA
substrate for the nanoslits (a, b, c) and nanochannel (d, e, f), respectively. – Inset shows the off–
axis (52°) cross section SEM images of the Si masters. The dimensions (l × w × h) were 21 µm x
1µm x 50 nm for each of the 4 nanoslits and 46 µm × 120 nm × 120 nm for each of the 7
nanochannels. (Note that the roughness on the SEM image of the stamp and substrate are
artifacts from coating with 3 nm AuPd for imaging).
The original channel fabricated by FIB milling into the Si master was purposely designed
with dimensions (width × depth) of 980 nm × 53 nm and 110 nm × 125 nm for the nanoslit and
nanochannel, respectively, to account for slight deformation of the UV resin stamp during the
high pressure and temperature thermal imprinting.32 The final PMMA devices had the
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dimensions of 1 µm × 50 nm and 120 nm × 120 nm, with the same polarity as the structures in
the Si master. Although we have previously reported the nanochannels in PMMA with the width
& depth <80 nm but for proof-of-concept, we deliberately chose these channel dimensions. The
UV resin stamp possessed a thermal expansion coefficient similar to PMMA (6 × 10 −5/°C) and
was chosen due to its capability to fabricate micro- and nano-scale patterns via UV-NIL and
reduce thermal stress following thermal-NIL production of the nanofluidic device. 60,61 A single
UV resin stamp was used for thermal imprinting for up to 10 times without any noticeable
damage to the structures.

Figure 4.2 (a) Photograph of the thermally assembled nanofluidic devices fabricated in PMMA.
The fluorescence images for the sealed nanoslit (b) and nanochannel (c) devices seeded with 5
mM FITC in 0.5X TBE buffer. The images shows channel continuity and the absence of
leakages. (d) IV plot generated between -0.9V to 0.9V for the nanofluidic devices filled with 1
mM KCl solution revealing an electrical resistance of 266.4 MΩ and 908.5 MΩ for the nanoslits
and nanochannels, respectively. The measured currents have similar absolute values for the
respective voltages of opposing polarities; hence, the channels are symmetric (absence of
rectification)
The PMMA substrates were sealed using plasma assisted low temperature thermal fusion
bonding (Figure 4.2a). The formation of leak-free fluidic devices or discontinuities due to
channel collapse during assembly was evaluated by introducing 5 mM fluorescein isothiocyanate
(FITC) solution in 0.5X TBE buffer into the fluidic network and allowing the channels to be
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filled by capillarity. As shown in Figure 4.2b and 4.2c, the fluidic channels did not show any
leakage between the substrate and the cover plate. Current-voltage plots acquired after filling
with 1 mM KCl as shown in Figure 4.2d revealed that the measured currents for voltages of
opposite polarity had similar absolute values and showed good linearity (non-rectification). The
absence of voltage gating and rectification indicated homogeneity in surface charge along the
walls of the PMMA nanoslits and nanochannels when using symmetrical electrolyte conditions.
Using low thermal bonding temperatures (~80oC) also minimized the amount of surface
reorganization of the polar functional groups following plasma treatment. (Figure 4.3).
4.3.2 Surface Characterization
4.3.2.1 Effects of Annealing Temperature on the Wettability of Plasma-activated PMMA
Previous reports have shown that thermal annealing for nanofluidic device assembly affects
the surface wettability/solid surface tension of polymer surfaces. 38 Here, we investigated the
effects of temperature on the wettability of PMMA activated under oxygen plasma (50 W, 5.5
sccm gas flow rate for 35 s) by measuring the water contact angle between 75 ˚C and 100˚C, the
typical temperature range reported for thermal assembly of PMMA nanofluidic devices. As
represented by Chai et al.41 the interpretation of contact angles in terms of the solid surface
tension relies on the validity of Young’s equation, which interrelates the Young’s contact angle,
θY, with the interfacial tension of the liquid-vapor , γlv, solid-vapor, γsv, and solid-liquid, γsl,
interface;
γlv cos θY = γsv - γsl

(1)

Typically, θY is expected to be a good approximation of the measured contact angle for a
surface with RMS roughness ≤ 5 nm.62 The solid surface tension (surface energy) γ sv can be
calculated from the water contact angle using;62
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2

γsl = γlv + γsv - 2√γlv γsv(1 - β(γlv - γsv) )

(2)

where β is 1.057 x 10-4 (m2/mJ)2 and γlv is the surface tension of water (72.70 mJ/m2).

Figure 4.3 Variation of surface energy with annealing temperature for plasma activated PMMA
substrate. As shown, there was no significant change in the surface energy at temperatures below
80ºC. At temperatures above 85ºC, the wettability significantly reduced as indicated by an
increase in the water contact angle. Each reported value represents the average of five values
measured at different positions on the substrate and the vertical bars represent the error of one
standard deviation.
As shown in Figure 4.3a, there was a gradual increase in the water contact angle as the
temperature of the plasma-activated PMMA was increased. Heating the plasma activated
substrate at temperatures ≤ 80˚C did not result in a significant change in the solid surface
tension/wettability. However, at temperatures ≥ 85˚C, there was a significant increase in surface
tension at the solid-liquid interface. As described by Jackson et al.,38 this increase arises because
the functional groups generated after plasma activation (≤ 10 nm from the surface) undergo
thermally induced rearrangement and are buried into the bulk substrate when heated. To avoid
this, we performed thermal fusion bonding of the nanofluidic device at 80˚C for 400 s. The
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wettability was retained at this condition and allowed the devices to be fill easily with aqueous
solvents by capillary action and low pressure suction.
The surface wettability and solid surface tensions for the unmodified, plasma and aminemodified PMMA samples were then assessed using water contact angle measurements (see
equations 1& 2). Unmodified PMMA showed a contact angle of 78.0 ±1.5°, which corresponds
to a solid-vapor surface tension (surface energy) of ~36.8 mJ/m2. After plasma treatment, the
contact angle decreased to 50.1 ±1.1° implying an increase in surface energy to ~54.6 mJ/m2.
Amine modification led to an increase in the water contact angle to 62.92 ±2.0° with an
associated surface energy of 45.8 mJ/m2. The observed trends are consistent with literature
values.39
4.3.2.2 XPS Analysis
X-ray photoelectron spectra (XPS) was used to analyze the surfaces of the unmodified,
plasma activated and amine-terminated PMMA sheets for the chemical composition. The O/C
and N/C ratio was used to assess the extent of surface modification of different tested schemes
(Figure 4.4c). For convenience, we designate unmodified, plasma activated and amine
terminated PMMA as u-PMMA, O2-PMMA and NH2-PMMA, respectively. The modification
scheme employed will determine the type of functional moieties generated. XPS was used to
monitor the O/C and N/C ratio on plasma-activated and amine-modified PMMA surfaces. In all
XPS spectra acquired here, a Shirley background was subtracted by averaging at least 10 end
points associated with the background. As shown in Figure 4.4c, plasma activation of PMMA led
to an increase in the O/C ratio confirming the addition of oxygen containing functional groups. 41
For amination of the plasma activated polymer, several schemes involving EDC or EDC-NHS
coupling chemistries were tested with concentrations between 0.1 and 1 M EDA; in all cases,
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there was a decrease in the O/C ratio (Figure 4.4c). However, the amount of nitrogen containing
groups differed with different conditions. As depicted in Figure 4.4d, the highest N/C ratio (and
lowest O/C ratio) was observed for animation involving the reaction of O 2-PMMA with a
solution of 1 M EDA in EDC.
To identify the surface groups generated after treatment of PMMA, the C1s spectra for all
treated surfaces was deconvoluted based on previously published work.63 Pristine PMMA C1s
spectrum showed the presence of four Gaussian components: (1) 284.6 eV aliphatic C-C and CH; (2) 285.2 eV quaternary C-C α to the pristine ester; (3) 286.4 eV methoxy C-O ester; and (4)
288.7 eV carbonyl C=O ester (Figure 4.4e). The theoretical peak area ratio of the C1s
components (1) - (4) of 2:1:1:1 was found to be 1.90:1.18:1.20:1.00 in our data. The slight
deviation may have been attributed to additives and plasticizers introduced into the substrate by
the manufacturer.64 Furthermore, in addition to the peaks listed above for u-PMMA, the
deconvoluted C1s peak of O2-PMMA showed the presence of a peak at a binding energy of
289.7 eV (Figure 4.4f). This peak corresponds to the OC=O for a carboxylic acid group. After
amination, the deconvoluted C1s peak showed the absence of the carboxylic acid peak and the
presence of two peaks; 285.8 eV, C-N bond of an amine, and 287.9 eV for a O=C-N bond
associated with an amide (Figure 4.4g).
The combined survey spectra are shown in Figure 4.4a. The trace for u-PMMA showed the
presence of only two peaks at 284.8 eV and 532.0 eV, indicative of C1s and O1s core levels,
respectively. After exposure to 50 W (5.5 sccm) oxygen plasma for 35 s, there were observable
changes in the individual intensities of the C1s and O1s peaks when compared to the untreated
samples (red trace in Figure 4.4a). There was an increase in the O/C atomic ratio from 0.331
±0.006 for u-PMMA to 0.403 ±0.003 for O2-PMMA, indicating the incorporation of oxygen
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containing polar functional groups onto the surface. The survey spectrum taken from the amineterminated PMMA (blue trace) shows the presence of a new peak centered at 399.69 eV in
addition to the C1s and O1s peaks. This peak is characteristic of surfaces possessing nitrogencontaining functionalities (N1s core level) and is in agreement with literature values. 39,65

Figure 4.4 (a) Full XPS survey spectrum of unmodified (black trace), plasma activated (red
trace) and amine modified (blue trace) PMMA (b) N 1s deconvoluted spectrum showing two
forms of nitrogen atoms (insert shows the chemical structure of aminated PMMA surface with
the forms of nitrogen labeled N1 and N2 .Bar graphs showing the (c) O/C ratio and (d) N/C ratio
for different surface modification schemes C-H tested for both unmodified-PMMA and O2PMMA (plasma treated PMMA), obtained from XPS data. Deconvoluted C1s spectra for (e)
unmodified, (f) O2-PMMA and (g) NH2-PMMA obtained by reacting the plasma activated
PMMA with 1 M ethylenediamine in the presence of EDC. PMMA peaks are labeled and
assigned to the polymer’s monomer. Spectra for the plasma activated PMMA contained an
additional peak for COOH functionalities and the amine modified surface showed the presence
of two peaks corresponding to the C-N amine and amide carbon atoms.
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Further analysis of the XPS data revealed that the atomic ratio of the peak area of the O1s
peak to the C1s peak was 0.309 ±0.006 with the ratio of the O1s to C1s peak areas ~10.9% less
for NH2-PMMA compared to u-PMMA. This result demonstrated that not only was nitrogen
successfully incorporated onto the surface of the PMMA but the amount of oxygen present on
the surface was less than what was present for the u-PMMA or O2-PMMA. The N/C ratio was
0.025 ±0.001. The N1s peak obtained was deconvoluted as shown in Figure 4.4b. This peak
consisted of two individual peaks, one centered at 399.1 eV and the other at 400.9 eV. The peak
at the lower binding energy corresponded to the N1s core level of an amine (N1), while the
higher energy peak was assigned to an amide (N2). 39 The deconvoluted C1s peaks for u-PMMA,
O2-PMMA and NH2- PMMA are presented in Figure 4.4e-g and described in detail.
The observations in the XPS data were in agreement with the infrared spectra shown in
Figure 4.6, which indicated the presence of fewer ester groups for the amine-terminated PMMA.
Collectively, these results indicated successful oxidation and amination reactions of the PMMA
surface, an outcome that is important for applications requiring surface modification of the
nanofluidic devices.

4.3.2.3 AFM Imaging
Typically, surface modification reactions induce not only chemical changes but also some
topographical changes. These changes are in the form of nanometer or sub-nanometer random
surface roughness on solid walls with roughness amplitude ar. Results obtained from previously
reported molecular dynamic simulations showed that the roughness may dramatically affect the
wettability of surfaces and EOF in nanofluidic channels depending on the magnitude of ar.66 For
the case where λD/ar << 1, where λD is the Debye length, the EOF can be significantly different
compared to λD/ar ~ 1; the presence of a rough surface that is comparable to the double layer
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thickness can alter the electrical double layer near the surface and significantly reduce the EOF67
and streaming potential.68 For a homogeneously charged rough channel (such as considered
here), the EOF is expected to decrease when the roughness is larger than 5% of the channel
width.69 However, this effect becomes insignificant for surfaces with λD/ar > 1.70,66 Also, the
water contact angle (wettability) is expected to be larger for very rough surfaces than a smooth
surface with identical chemical properties. 71,62
First, we investigated the surface topography of PMMA substrates to monitor any changes in
surface roughness induced by surface treatment. Figure 4.5 a-c shows representative AFM scans
for unmodified, plasma and amine-modified PMMA nanoslit devices following assembly of the
cover plate to the substrates. The measured RMS roughness for u-PMMA nanoslit devices was
1.16 nm, which originated from the Si master due to ion sputtering. The RMS roughness values
increased to 1.42 nm for O2-PMMA and 1.63 nm for NH2-PMMA nanoslit devices.

The roughness of PMMA nanoslits was measured by AFM only because the bottom surface
could be easily profiled without interference due to tip-wall interactions. Figure 4.5d shows a
representative AFM image of a nanoslit. AFM scans of 4 µm × 500 nm were acquired for the
bottom surfaces of the unmodified, plasma and amine modified nanoslits. For the u-PMMA
nanoslit shown in Figure 4.5e, the measured RMS surface roughness was 0.80 nm. This value
was approximately equal to the measured roughness obtained from the bottom surface of the FIB
milled nanoslit in the original Si master (data not shown). After surface modification, there was
an increase in RMS surface roughness to 1.15 nm and 1.23 nm for the plasma and aminemodified PMMA, respectively. This increase in surface roughness of O 2-PMMA is due to
etching by the oxygen plasma. However, the increase in surface roughness for the aminated
surface can be attributed to slight swelling and/or dissolution of the PMMA by the EDC/EDA
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solution and the additional C-C bonds introduced onto the surface from EDA. (see Figure 4.5 ac). Nevertheless, because the experiments were performed at solution ionic strengths producing a
debye length which is smaller than ten times the channel dimension but larger than the wall
roughness (λD > 2.0 nm,)17,72 we expect the contributions of surface roughness to wettability and
EOF in our PMMA nanoslit and nanochannel devices to be insignificant relative to contributions
from changes in surface chemistry and/or charge.

Figure 4.5 AFM images acquired for (a) u-PMMA (b) O2-PMMA and (c) NH2-PMMA. All
images were scanned over a surface area of 3 µm x 3 µm (d) AFM characterization of the device
with 1 µm x 50 nm nanoslit. AFM surface scans of (e) unmodified (f) plasma activated and (g)
amine-terminated nanoslit in PMMA substrate. This was performed in the nanoslit (4 µm x
500nm scan size) since the bottom surface could be easily profiled without the interference of
tip-wall interactions. The measured root-mean-square (RMS) surface roughness was 0.80 nm,
0.95 nm and 1.03 nm, respectively
4.3.2.4 Fourier Transform Infra-red (FTIR) Spectroscopy
FTIR was employed to characterize the functional groups on pristine, plasma and amine
modified PMMA. The typical IR spectrum of pristine PMMA with characteristic peaks between
4000 and 650 cm-1 are shown in Figure 4.6a. The most prominent band was ν(C=O), at 1733 cm-1
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assigned to stretching of esters. The absorption bands at 1270, 1241 cm−1 and 1195, 1153
cm−1 could be assigned to ν(C–O) and ν(COC) stretching of an ester, respectively. This spectrum
correlated well with the absorbance spectrum of PMMA documented in the literature. 39 After
plasma treatment, bands appeared at 3430 cm-1 and at 1700 cm-1 assigned to the ν(O-H) and
ν(C=O) of a carboxylic acid (Figure 4.6b). Amination with EDA led to peaks at 3396 cm-1 and
1675 cm-1 corresponding to the ν(N-H) stretch of a primary amine and ν(C=O) of an amide
(Figure 4.6c). These support the XPS results and confirm successful surface modification of the
PMMA devices.

Figure 4.6 ATR-FTIR Spectra for (a) Untreated (b) Plasma activated (c) Amine modified PMMA
substrates
4.3.3 Surface Charge and pH Effects
Considering that a solid in contact with a liquid electrolyte will bear a surface charge, which
may be due to dissociation of surface groups or specific (nonelectric) adsorption of ions in
solution, one would expect that the contributions of the surface charge to fluid transport
dynamics and molecular interactions becomes significant in devices possessing high surface-to149

volume ratios. Depending on the solution pH and the surface chemistry, the solid can have either
a positive or negative surface charge density, σs, described as σs = ∑

⁄ ; where qi = zie and is

the net charge of ion i, zi is the valency of ion i, e is the electron charge, and A is the surface area.
This can be used to compute the number of charged sites per unit area Γ in nm-1.
Due to the fixed surface charge, an oppositely charged region called the electric double layer
(EDL), which consists of a layer of immobile surface charge and a layer of mobile counterions,
develops in the liquid to maintain the electroneutrality of the solid/liquid interface. 73 In
nanofluidic channels, the EDL can represent a significant fraction of the total channel volume.
For a channel filled with a symmetrical 1:1 electrolyte like KCl with ionic concentration c, the
EDL thickness or Debye length, λD, is represented as (ϵ0ϵrRT/2F2c)1/2, where F is the Faraday
constant (C·m-1), R is the molar gas constant (J·mol-1 K-1), ϵ0 is the permittivity of vacuum (F·m1

), ϵr is the dielectric constant of the medium, and T is the Kelvin temperature. Depending on the

ionic concentration, λD can vary from less than 1 nm at high ionic strength to a few tens of
nanometers at low ionic strength. 27
Electrical conductance measurements across nanofluidic channels filled with ionic salt
solutions have been an approach used to deduce the magnitude of the surface charge density.
Here, we present a modified electrokinetic model based on the report from Stein et al.28 for
deducing σs. When an external electric field is applied across a nanochannel filled with an ionic
salt solution, the measured electrical conductance (neglecting electroosmotic effects) is a sum of
the bulk conductance (GB) and the secondary surface conductance (GS);
(3)
At high salt concentrations, the surface charges in the nanochannel are shielded by the
mobile ions and have negligible influence on the ion concentration in the nanochannel. In this
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case, the ionic transport is dominated by the ions in the bulk solution and GT ≈

B.

The value of

GB depends on the nanochannel dimensions and electrolyte concentration according to the
following expression;55,72,45
103 (

K+

Cl-

)

(4)

where w, L and h are the nanochannel width, length and height, respectively, NA is the
Avogadro constant, c is the electrolyte concentration in mol/L, n is the number of nanochannels
and μK+ and µCl- are the ion mobilities of K+ and Cl- ions, respectively (μK+ = 7.619 × 10-8 m2/V s
and µCl- = 7.912 × 10-8 m2/V s). At low salt concentrations, the nanochannels are filled with
counterions. For electroneutrality inside the nanochannel, excess counterions in the EDL
compensate for the net surface charge, which governs the excess counterion concentration ce
(mol/L) inside the channel.74 GB becomes negligible and σ s governs the total ion conductance in
the nanochannel (GT ≈

S).

Considering that a nanochannel possesses four surfaces in contact

with the electrolyte solution and by the principle of charge conservation, ce is given by;
e

mol⁄L = 10-3

2 σs (

)

(5)

For 1D nanochannels (i.e., nanoslits), such as reported by Stein et al.,28 Schoch et al.,55
Karnik et al.,46 and Martins et al.,45 h << w; hence (w + h) ≈ w. However, for 2D nanochannels
with h ≤ w, the channel width also contributes to ce and GS. Therefore,
= 2

σs

(

)

(6)

Substituting equations (2) and (4) into equation (1) yields the expression;
103 (

K+

Cl-

)

2

σs

(

)

(7)

When GB ≈ GS, a transition ion concentration, ct is observed on the log-log plot of GT
versus the ion concentration.55
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We investigated the effects of surface modification of polymer nanofluidic devices by
experimentally measuring the surface charge density of modified PMMA nanoslits and
nanochannels by monitoring ionic conductance plots performed on nanofluidic devices. Figure
4.7a and 4.7b show the conductance traces for an array of surface modified nanoslits (22 µm × 1
µm × 50 nm) and nanochannels (45 µm × 120 nm × 120 nm) measured over the range of
concentrations between 10 -5 M and 1 M KCl in Tris buffer (pH 7.8). In both nanofluidic devices,
the conductance results obtained before and after surface modification differed essentially in the
low ionic concentration regime. This effect is characterized by a shift of the plateau conductance
suggesting a change in the surface charge dependent on the nature of the modification. When the
modified surfaces were in contact with a KCl solution at pH 7.8, ~99.9 % of the surface –COOH
groups (pKa = 4.66) would be deprotonated and ~99.0% of the –NH2 groups (pKa = 10.42)
would be protonated.75 At extreme pH values and very low buffer concentrations, the total
counterions in solution necessary to maintain electroneutrality are H + and K+ for the O2-PMMA
and Cl- and OH- for the NH2-PMMA devices. However, at pH 7.8 and KCl concentration ≥10 -5
M, [K+] >> [H+] and [Cl-] >> [OH-] ([H+] ≈ 1.6 × 10-8 M and [OH-] ≈ 6.31 × 10-7 M); hence, GS
is computed from equation (4) using µK+ and µCl- as µopp for the –COO- and –NH3+ surfaces,
respectively. Nevertheless, due to the different size of the K+ (0.27 nm) and Cl- (0.36 nm) and
the discreteness of the water molecules, we expect differences in surface conductance between
the positively and the negatively charged channel. 76
At a KCl concentration greater than 10 -2 M (geometry governed region), the measured ionic
conductance in both the nanoslits and nanochannels fit linearly with the theoretical bulk
conductance (Fig. 4.7) and was reproducible from one device to another. This confirmed that
there was no significant change in the dimensions of the fluidic channels during thermal
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imprinting, device assembly and surface chemical modification with EDC/EDA. However, at
low electrolyte concentrations (surface charge-governed regime), the nanochannel conductance
deviated from linearity and plateaued for both the plasma and amine treated PMMA nanoslits
and nanochannels with the measured surface conductance lower for the –NH3+ terminated
devices compared to the –COO- terminated devices.

Figure 4.7 Conductance plots obtained from surface modified devices consisting an array of (a)
four nanoslits (each 1 µm wide, 50 nm deep and 22 µm long), and (b) seven nanochannels (each
120 nm wide, 120 nm deep and 45 µm long) (square and circle markers represent the data
obtained for the plasma and amine modified surfaces, respectively. The solid blue line represents
the trace of the theoretical bulk conductance calculated with equation (2)). Each data point
represents the average of five measurements with a scatter in the data within 5-8% of the mean
value. From the graph, the effective surface charge density as calculated from the transition
concentration, ct, was 38.2 mC/m2 for plasma treated nanoslit, 28.4 mC/m2 for amine treated
nanoslit, 40.5 mC/m2 for plasma treated nanochannel and 22.9 mC/m2 for the amine treated
nanochannel.
For the nanoslit devices, the average surface conductance at this region was 7.5 × 10-10 S for
the O2-PMMA device. After amination, the conductance dropped to 3.8 × 10-10 S, ~50.7 % of its
original value (Fig. 4.7a). The transition concentration, ct, used to compute σs was approximately
6.60 mM and 3.52 mM for the plasma and amine modified surfaces, respectively. For plasma
treated PMMA nanoslits, we obtained |σs| of ~ 38.2 mC/m2, which was less than 60 mC/m2
reported by Stein et al.28 and 214 mC/m2 reported by Schoch et al.55 for glass-based nanoslits
measured at pH 8. For the amine modified nanoslit, |σs| was 28.4 mC/m2. In the nanochannels,
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the conductance in the low ionic strength region for the amine-modified device dropped to
~67.6% of its plasma modified counterpart. The surface charge densities were 40.5 mC/m2 and
22.9 mC/m2 for the plasma and amine devices, respectively.
We also monitored the effect of pH on the surface charge density of nanoslits and
nanochannels. As depicted in Figure 4.8 for both the plasma modified nanoslits and
nanochannels the surface charge gradually increased as the pH of the electrolyte solution
increased because at low pH (high H+ concentration), the surface carboxy groups are converted
to the protonated form. This leads to a corresponding measurable decrease in the surface
conductance as less counterions are attracted into the fluidic channel. On the other hand, at high
pH, the –COOH groups become deprotonated and are converted to the negatively charged –
COO- thereby increasing σs.

Figure 4.8 Plot showing the effect of pH on the surface charge density σ s, in plasma and amine
modified nanoslits and nanochannels
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For the amine modified surfaces, an opposite trend was observed. The measured surface
conductance was higher at low pH values and lower at high pH. This is due to the conversion of
the reactive –NH2 groups to the positively charged –NH3+ groups. At pH ≥ 8, the surfaces of the
O2-PMMA devices were fully deprotonated and the |σs| for the nanochannel was found to be
greater than the nanoslits. The values were 38.3 mC/m2 (Γ ≈ 4.2 nm-2) and 40.5 mC/m2 (Γ ≈ 4.0
nm-2) for the fully deprotonated PMMA nanoslit and nanochannel, respectively. These values
were found to remain relatively constant at pH > 10. In the nanochannel, the width was
comparable to the height and the implication is that the surface charge density contribution from
the vertical walls, which is typically neglected in the nanoslits, also contributed to ion transport
within the channel.77 Surplus counterions would be attracted into the nanochannel and more
coions will be excluded. Despite the contribution of vertical surfaces on the aminated surfaces, at
pH ≤ 8, |σ| was greater in the nanoslits than the nanochannels. This is likely due to incomplete
conversion of the carboxyl functional groups into the amine groups in the nanochannels for the
reaction conditions reported, a consequence of EDA depletion in the nanochannel with higher
surface-to-volume ratio when compared to the nanoslit.

4.3.4 Electrical Model of a Nanofluidic Device
Figure 4.9a shows the experimental setup of a nanofluidic device setup for conductance
measurements and the equivalent circuit (Figure 4.9b). The device contained two oppositely
placed V-shaped access microchannels (with equal dimensions) and two reservoirs placed at both
ends of the microchannel for introducing fluids into the nanochannels. We represented the total
voltage applied across reservoirs 1 and 3 as V and the voltage drops across the micro- and
nanochannel as Vm and Vn, respectively. In this study, it was important that the microchannel
dimensions were carefully controlled in such a way that most of the voltage drop across the
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device occurred within the nanochannel. The measured electrical resistance, R, across reservoirs
1 and 3 for a given electrolyte was expressed as a combination of the resistance of the
microchannels, Rm, and that of the nanochannel, Rn:
2

(8)

Figure 4.9 (a) Schematic showing the experimental setup for measuring the conductance of the
nanochannels. It shows the nanofluidic device interfaced to an axopatch 200B amplifier
connected to a Digidata 1440A and computer for readout. (b) Diagram showing the voltage drop
and resistances across micro- and nanochannels. (c) Current versus time trace showing the
current generated across the nanoslit arising from the replacement of a low ionic strength buffer
(0.05 M KCl in 10 mM Tris buffer phosphate buffer) with a higher ionic strength buffer (0.1 M
KCl in 10 mM Tris buffer) for the O2-PMMA nanoslit. The buffer replacement within the
nanochannel arises from the electroosmotic flow.
To assess the percent voltage drop across each nanofluidic array, the mixed-scale devices
were filled with 0.5 M KCl and the values of Rm and R measured using the Axopatch 200B
current amplifier. From these values, Rn/n was calculated for the nanoslits (n = 4) and
nanochannels (n = 7) using equation (8) and the voltage drop calculated from;
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%V = [( )⁄ ] ×100

(9)

The data is summarized in Table 4.1
Table 4.1. Measured and calculated electrical
nanoslit/nanochannel Rn and percent voltage drop.

resistances

across

the

microchannel

Dimensions of
Nanofluidic device
(l × w × h)

Rm (kΩ)

R (MΩ)

22 µm × 1 µm × 50 nm

501.7 ± 10.2

19.9 ± 1.2

18.9 ± 1.1

95.2 ± 1.1

Nanochannel 45 µm × 50 nm × 50 nm 997.2 ± 12.5

60.9 ± 1.8

58.9 ± 1.6

96.7 ± 1.2

Device
Nanoslit

(MΩ)

Rm,

Voltage
drop
(%V)

4.3.5 Electroosmotic Flow (EOF) Measurements
The electroosmotic flow is a surface driven fluidic transport that is generated when an
external electric field E, applied in the direction tangential to the wall of a channel filled with an
electrolyte solution, induces a fluid drag by motion of ions in the EDL. Because of its scalability
and ease-of-control, electroosmotic transport has been widely used in many nanofluidic systems.
The EOF can be described in terms of a mobility, µeof = υeof/E, where υeof is the steady-state bulk
EOF velocity. It is possible to derive an expression for µeof from the solvent viscosity η, and the
zeta potential ζ using the Helmholtz-Smoluchowski relation:78
=

ϵ0 ϵr ζ

(10)

η

The Zeta potential depends on σ s and λD for different electrolyte solutions as noted by the
nonlinear Poisson-Boltz-Mann equation:41, 79
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2

T)
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(11)

With ϵ0 and ϵr constants, conditions that cause a change in the σ s, ζ, λD, or η will alter the
magnitude of the EOF.
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Typically, µeof is measured using the well-established current monitoring method.80 In this
work, 0.1 M and 0.05 M KCl solutions were used for the measurement to allow for the
generation of a large amount of readable current and measurements at regions with the EDL (see
Figure 4.9c for a typical current trace). For this investigation, we fabricated PMMA devices
possessing a single nanofluidic channel, 138 µm long, interfaced across two access
microchannels as shown in Figure 4.1c and 4.1f. This single channel geometry eliminated errors
in migration time that may arise due to preferential filling across an array of nanochannels during
electrolyte replacement. A negative EOF value indicated that the solution flow was from cathode
to anode and consistent with a positively charged fluidic channel wall. Positive values indicated
a negatively charged wall and a reverse EOF.
Previously, we have shown that exposing PMMA to controlled plasma conditions can
generate carboxylate groups with a surface coverage of 2.7 ± 0.5 × 10-9 mol/cm2.43 We also
reported the EOF (pH 7.4) for carboxylated and NH2-terminated PMMA microfluidic devices to
be 4.43 ±0.58 × 10-4 cm2/ Vs and -1.34 ±0.21 × 10-4 cm2/Vs, respectively.37 As shown in Table
4.2, we obtained an EOF mobility of 0.93 ±0.03 × 10-4 cm2/Vs and -0.82 ±0.01 × 10-4 cm2/Vs for
plasma activated and NH2-terminated PMMA nanoslits, respectively. For the plasma and NH2terminated PMMA nanochannels, the EOF was found to be 1.02 ±0.02 × 10-4 cm2/Vs and -0.75
±0.02 × 10-4 cm2/Vs, respectively. The trend and magnitude of the EOF mobilites observed in the
PMMA nanofluidic devices scales with the measured surface charge density in the nanochannel
and was consistent with the molecular dynamic simulation results reported by Qiao et al.81 The
values reported above for the O2-PMMA nanochannels were similar to that reported by Menard
et al.17 for fused silica nanochannels (≤ 100 nm) measured using 2X TBE, with 2%
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polyvinylpyrrolidone (PVP) (0.79 ±0.01 × 10-4 cm2/Vs) and ~35.8 ±4.4% lower when compared
to the value obtained in fused silica measured with only 2X TBE (1.58 ±0.01 × 10-4 cm2/Vs).
Table 4.2 Measured and expected EOF mobility values as well as surface charge and zeta
potentials for the plasma activated and amine terminated devices investigated at pH 7.8.
µeof (cm2/Vs) × 10-4
Device

Terminating
groups

(mC/m2)

ζ (mV)

Expected*

Measured

O -PMMA

- 38.3

- 57.1

4.53

0.93 ± 0.025

NH -PMMA

28.4

45.8

- 3.63

- 0.82 ± 0.012

O -PMMA

- 40.5

- 59.8

4.74

1.02 ± 0.017

NH -PMMA

22.9

38.3

- 3.04

- 0.75 ± 0.021

2

Nanoslit
2

2

Nanochannel
2

*Calculated from equation (7) using the values for

s

and ζ

A possible reason for the low EOF observed in the PMMA nanofluidic device is the low ζ
potential of the surface (at the reported experimental conditions). This conclusion is supported by
the results from the continuum theory, based on the Poisson–Boltzmann equation for the ion
distribution and Navier–Stokes equations for the fluid transport, 78 and the atomistic
simulations.81 Both models show that the EOF in a nanofluidic channel varies almost linearly
with the ζ, with the latter model true for surface charge densities ≤ 80 mC/m2.81 As previously
described, the zeta potential depends on the chemistry of the solid–fluid interface and is related
to the surface charge density by parameters such as the ionic strength, density of chargeable sites
on the surface, their pKa values and the solution pH, which modulates the rate of dissociation of
the surface groups (see Figure 4.8). However, the difference in the EOF values observed for the
negatively charged O2-PMMA devices when compared to the positively charged NH 2-PMMA
devices is due to the difference in the distribution of counterions in both devices due to the
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different size of the K+ and Cl- ions.76 Therefore, at a fixed pH and electrolyte concentration, as
the surface σs reduces, ζ is lowered resulting in a corresponding lowering effect on the EOF.
Although the trend of the measured EOF mobilities in the PMMA nanofluidic devices
presented in Table 4.2 followed the results of the surface charge density, they remained less than
the expected values, which were similar to that observed in the microchannels. The expected
values were calculated using λD ≈ 1.5 nm and assuming that the µeof is independent of the size or
shape of the channels but rather on the charge distribution around several tens of nanometers
from the surface of the channels. However, recent reports have shown that downsizing the size of
fluidic channels from the micro- to nano- dimensions can result in reduction of the net flow
(EOF) within a channel due to the apparent increase in the viscosity of a fluid confined in the
charged nanochannel resulting from the induced counterflow of the streaming potential to the
electroosmotic flow.82-85 This phenomenon, termed electroviscosity, can cause the ratio apparent
viscosity to the true viscosity to be as high as 1.3 depending on the material of the channel wall,
with spatial size and shape of the channel, the ionic concentration, zeta potential, temperature,
dielectric constant and other properties of the liquid. 84 In the derivation of equation (6), the
electroviscous effect was not considered. However, due to relatively higher ζ in glass based
devices, large streaming potentials are generated resulting in greater electroviscosity in than
polymer devices. This can explain why the EOF measured in glass nanoslits at pH 8.5 (~1.3 × 10-3
cm2/Vs) was lower than that of fused silica and glass capillaries (5 × 10-4 cm2/Vs and 1.5 × 10-3
cm2/Vs, respectively)86 or glass microchannels (4.82 × 10 -4 cm2/Vs).87 It also described the
reason for low EOF observed in a glass microchannel device populated with nanopillars spaced
by ~700 nm (1 × 10-5 cm2/Vs).88 In PMMA nanoslits and nanochannels, the zeta potential was
lower for the conditions reported. The implication is that small streaming currents will be

160

generated and the contributions of electroviscosity to the EOF will be minimal; hence, the
measured EOF will be due majorly due to low surface charge densities.
In summary, our results reveal that in polymer nanofluidic devices (nanoslit or
nanochannels), the surface modification scheme adopted, pH and ionic strength of the electrolyte
play crucial roles in determining the magnitude of the surface charge density and the extent of
electroviscosity effects on the EOF. Parameters that take predominance will depend upon the
spatial size of the fluidic device. The effects of Joule heating on the solution viscosity in these
channels were considered negligible because very small electric currents were generated due to
the high nanochannel resistance compared to microchannels (see Table 4.1).
4.4 Conclusions
In this work, we reported the successful modification of thermoplastic nanoslits and
nanochannels for the first time to the best of our knowledge. Carboxyl moieties were generated
by plasma activation and amino groups were introduced by reaction with EDC and covalent
coupling of EDA molecules. The presence of the surface functional groups was confirmed by
wettability/surface energy studies and XPS/FTIR analysis. Changes in surface topography
induced from surface modification were assessed using AFM. The effect of pH on the surface
charge density σ s in the nanofluidic devices was reported and the EOF in the plasma activated
and amine-terminated devices was measured. The magnitude of σ s and ζ for the polymer
nanofluidic devices were carefully controlled by the choice of substrate, plasma dose and pH of
the electrolyte solution.
For the conditions reported in this work, the plasma treated polymer nanoslits and
nanochannels were observed to possess |σs| of 38.2 mC/m2 and 40.5mC/m2, respectively, at pH
7.8. These values were lower than that reported for the glass-based counterpart (60 mC/m2)
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thereby making polymer nanochannels a great prospect in applications involving molecular
separations. Also, low surface charge densities in fluidic devices help to minimize artifacts of ion
exclusion from concentration polarization. The ability to generate positively charged –NH3+
moieties in a simple modification scheme with |σs| of 28.4 mC/m2 in the nanoslits and 22.9
mC/m2 in the nanochannel offer a unique venue for performing nanochannel chromatography.
The substrate material can potentially serve as the stationary phase without the need for
appending different monolayer assemblies to the support and the solute/wall interactions of
biomolecules traversing through the nanochannels can be investigated.
The reduced EOF observed in the PMMA devices compared to polymer microchannels and
glass nanochannels was likely due to lower surface charge density (and zeta potential) for
polymer devices and electroviscosity effects due to confinement. Generally, low EOF is
desirable in applications involving DNA analysis for regulation of gene expression, mapping and
sequencing since it enables the introduction of these biomolecules into the fluidic channels
without the need of EOF suppressors. Polymer nanofluidic devices can be tuned to possess the
desired surface functionality and charge density by carefully controlling the modification
protocol that is employed. We are currently investigating the electrokinetic properties of other
viable thermoplastic substrates for the fabrication of nanochannels.
4.5 References
1.

van, H. J. W.; Brunets, N.; Tas, N. R. Capillarity at the Nanoscale. Chem. Soc. Rev. 2010,
39, 1096-1114.

2.

Anand, R. K.; Sheridan, E.; Knust, K. N.; Crooks, R. M. Bipolar Electrode Focusing:
Faradaic Ion Concentration Polarization. Analytical Chemistry 2011, 83, 2351-2358.

162

3.

Mani, A.; Zangle, T. A.; Santiago, J. G. On the Propagation of Concentration Polarization
from Microchannel−Nanochannel Interfaces Part I: Analytical Model and Characteristic
Analysis. Langmuir 2009, 25, 3898-3908.

4.

Wang, Y.-C.; Stevens, A. L.; Han, J. Million-Fold Preconcentration of Proteins and
Peptides by Nanofluidic Filter. Analytical Chemistry 2005, 77, 4293-4299.

5.

Kim, S. J.; Wang, Y.-C.; Lee, J. H.; Jang, H.; Han, J. Concentration Polarization and
Nonlinear Electrokinetic Flow near a Nanofluidic Channel. Physical Review Letters
2007, 99, 044501.

6.

Kim, S. J.; Li, L. D.; Han, J. Amplified Electrokinetic Response by Concentration
Polarization near Nanofluidic Channel. Langmuir 2009, 25, 7759-7765.

7.

Pu, Q.; Yun, J.; Temkin, H.; Liu, S. Ion-Enrichment and Ion-Depletion Effect of
Nanochannel Structures. Nano Letters 2004, 4, 1099-1103.

8.

Craighead, H. Future Lab-on-a-Chip Technologies for Interrogating Individual
Molecules. Nature (London, U. K.) 2006, 442, 387-393.

9.

Craighead, H. G. Nanostructure Science and Technology: Impact and Prospects for
Biology. J. Vac. Sci. Technol., A 2003, 21, S216-S221.

10.

Saleh, O. A.; Sohn, L. L. An Artificial Nanopore for Molecular Sensing. Nano Lett. 2003,
3, 37-38.

11.

Menard, L. D.; Mair, C. E.; Woodson, M. E.; Alarie, J. P.; Ramsey, J. M. A Device for
Performing Lateral Conductance Measurements on Individual Double-Stranded DNA
Molecules. ACS Nano 2012, 6, 9087-9094.

12.

Zangle, T. A.; Mani, A.; Santiago, J. G. Theory and Experiments of Concentration
Polarization and Ion Focusing at Microchannel and Nanochannel Interfaces. Chemical
Society Reviews 2010, 39, 1014-1035.

13.

Piruska, A.; Gong, M.; Sweedler, J. V.; Bohn, P. W. Nanofluidics in Chemical Analysis.
Chemical Society Reviews 2010, 39, 1060-1072.
163

14.

Tsukahara, T.; Mawatari, K.; Kitamori, T. Integrated Extended-Nano Chemical Systems
on a Chip. Chemical Society Reviews 2010, 39, 1000-1013.

15.

Keyser, U. F.; van Dorp, S.; Lemay, S. G. Tether Forces in DNA Electrophoresis.
Chemical Society Reviews 2010, 39, 939-947.

16.

Pennathur, S.; Baldessari, F.; Santiago, J. G.; Kattah, M. G.; Steinman, J. B.; Utz, P. J.
Free-Solution Oligonucleotide Separation in Nanoscale Channels. Analytical Chemistry
2007, 79, 8316-8322.

17.

Menard, L. D.; Ramsey, J. M. Electrokinetically-Driven Transport of DNA through
Focused Ion Beam Milled Nanofluidic Channels. Analytical Chemistry 2013, 85, 11461153.

18.

Kim, S. J.; Ko, S. H.; Kang, K. H.; Han, J. Direct Seawater Desalination by Ion
Concentration Polarization (Vol 5, Pg 297, 2010). Nat. Nanotechnol. 2013, 8, 609-609.

19.

Cheng, L.-J.; Guo, L. J. Nanofluidic Diodes. Chemical Society Reviews 2010, 39, 923938.

20.

Persson, F.; Tegenfeldt, J. O. DNA in Nanochannels-Directly Visualizing Genomic
Information. Chem. Soc. Rev. 2010, 39, 985-999.

21.

Levy, S. L.; Craighead, H. G. DNA Manipulation, Sorting, and Mapping in Nanofluidic
Systems. Chem. Soc. Rev. 2010, 39, 1133-1152.

22.

Liang, X.; Chou, S. Y. Nanogap Detector inside Nanofluidic Channel for Fast Real-Time
Label-Free DNA Analysis. Nano Letters 2008, 8, 1472-1476.

23.

Reccius, C. H.; Mannion, J. T.; Cross, J. D.; Craighead, H. G. Compression and Free
Expansion of Single DNA Molecules in Nanochannels. Physical Review Letters 2005, 95,
268101.

24.

Levy, S. L.; Mannion, J. T.; Cheng, J.; Reccius, C. H.; Craighead, H. G. Entropic
Unfolding of DNA Molecules in Nanofluidic Channels. Nano Letters 2008, 8, 38393844.
164

25.

Daiguji, H. Ion Transport in Nanofluidic Channels. Chemical Society Reviews 2010, 39,
901-911.

26.

Han, J.; Craighead, H. G. Separation of Long DNA Molecules in a Microfabricated
Entropic Trap Array. Science 2000, 288, 1026-1029.

27.

Plecis, A.; Schoch, R. B.; Renaud, P. Ionic Transport Phenomena in Nanofluidics:
Experimental and Theoretical Study of the Exclusion-Enrichment Effect on a Chip. Nano
Letters 2005, 5, 1147-1155.

28.

Stein, D.; Kruithof, M.; Dekker, C. Surface-Charge-Governed Ion Transport in
Nanofluidic Channels. Physical Review Letters 2004, 93, 035901.

29.

Chantiwas, R.; Park, S.; Soper, S. A.; Kim, B. C.; Takayama, S.; Sunkara, V.; Hwang,
H.; Cho, Y.-K. Flexible Fabrication and Applications of Polymer Nanochannels and
Nanoslits. Chemical Society Reviews 2011, 40, 3677-3702.

30.

Chou, S. Y.; Krauss, P. R.; Renstrom, P. J. Imprint of Sub‐25 Nm Vias and Trenches in
Polymers. Applied Physics Letters 1995, 67, 3114-3116.

31.

Chantiwas, R.; Hupert, M. L.; Pullagurla, S. R.; Balamurugan, S.; Tamarit-Lopez, J.;
Park, S.; Datta, P.; Goettert, J.; Cho, Y.-K.; Soper, S. A. Simple Replication Methods for
Producing Nanoslits in Thermoplastics and the Transport Dynamics of Double-Stranded
DNA through These Slits. Lab on a Chip 2010, 10, 3255-3264.

32.

Wu, J.; Chantiwas, R.; Amirsadeghi, A.; Soper, S. A.; Park, S. Complete Plastic
Nanofluidic Devices for DNA Analysis Via Direct Imprinting with Polymer Stamps. Lab
on a Chip 2011, 11, 2984-2989.

33.

Abgrall, P.; Low, L.-N.; Nguyen, N.-T. Fabrication of Planar Nanofluidic Channels in a
Thermoplastic by Hot-Embossing and Thermal Bonding. Lab on a Chip 2007, 7, 520522.

34.

Rotting, O.; Ropke, W.; Becker, H.; Gartner, C. Polymer Microfabrication Technologies.
Microsyst. Technol. 2002, 8, 32-36.

165

35.

Soper, S. A.; Henry, A. C.; Vaidya, B.; Galloway, M.; Wabuyele, M.; McCarley, R. L.
Surface Modification of Polymer-Based Microfluidic Devices. Analytica Chimica Acta
2002, 470, 87-99.

36.

Hawthorne, S. B.; Yang, Y.; Grabanski, C. B.; Miller, D. J.; Lee, M. L. Response to
Comments on Adsorption Versus Absorption of Polychlorinated Biphenyls onto SolidPhase Microextraction Coatings. Anal. Chem. 2000, 72, 642-643.

37.

Llopis, S. L.; Osiri, J.; Soper, S. A. Surface Modification of Poly(Methyl Methacrylate)
Microfluidic Devices for High-Resolution Separations of Single-Stranded DNA.
Electrophoresis 2007, 28, 984-993.

38.

Jackson, J. M.; Witek, M. A.; Hupert, M. L.; Brady, C.; Pullagurla, S.; Kamande, J.;
Aufforth, R. D.; Tignanelli, C. J.; Torphy, R. J.; Yeh, J. J.; Soper, S. A. Uv Activation of
Polymeric High Aspect Ratio Microstructures: Ramifications in Antibody Surface
Loading for Circulating Tumor Cell Selection. Lab on a Chip 2014, 14, 106-117.

39.

Henry, A. C.; Tutt, T. J.; Galloway, M.; Davidson, Y. Y.; McWhorter, C. S.; Soper, S.
A.; McCarley, R. L. Surface Modification of Poly(Methyl Methacrylate) Used in the
Fabrication of Microanalytical Devices. Analytical Chemistry 2000, 72, 5331-5337.

40.

Chan, C. M.; Ko, T. M.; Hiraoka, H. Polymer Surface Modification by Plasmas and
Photons. Surface Science Reports 1996, 24, 1-54.

41.

Chai, J.; Lu, F.; Li, B.; Kwok, D. Y. Wettability Interpretation of Oxygen Plasma
Modified Poly(Methyl Methacrylate). Langmuir 2004, 20, 10919-10927.

42.

Wei, S.; Vaidya, B.; Patel, A. B.; Soper, S. A.; McCarley, R. L. Photochemically
Patterned Poly(Methyl Methacrylate) Surfaces Used in the Fabrication of Microanalytical
Devices. J. Phys. Chem. B 2005, 109, 16988-16996.

43.

Xu, F.; Datta, P.; Wang, H.; Gurung, S.; Hashimoto, M.; Wei, S.; Goettert, J.; McCarley,
R. L.; Soper, S. A. Polymer Microfluidic Chips with Integrated Waveguides for Reading
Microarrays. Analytical Chemistry 2007, 79, 9007-9013.

44.

Yang, Z.; Min, Z. D. Cardiac Markers and Their Point-of-Care Testing for Diagnosis of
Acute Myocardial Infarction. Clin Biochem 2006, 39, 771-80.
166

45.

Martins, D. C.; Chu, V.; Conde, J. P. The Effect of the Surface Functionalization and the
Electrolyte Concentration on the Electrical Conductance of Silica Nanochannels.
Biomicrofluidics 2013, 7, -.

46.

Karnik, R.; Castelino, K.; Fan, R.; Yang, P.; Majumdar, A. Effects of Biological
Reactions and Modifications on Conductance of Nanofluidic Channels. Nano Letters
2005, 5, 1638-1642.

47.

Tas, N. R.; Berenschot, J. W.; Mela, P.; Jansen, H. V.; Elwenspoek, M.; van den Berg, A.
2d-Confined Nanochannels Fabricated by Conventional Micromachining. Nano Letters
2002, 2, 1031-1032.

48.

Menard, L. D.; Ramsey, J. M. Fabrication of Sub-5 Nm Nanochannels in Insulating
Substrates Using Focused Ion Beam Milling. Nano Letters 2011, 11, 512-517.

49.

Huh, D.; Mills, K. L.; Zhu, X. Y.; Burns, M. A.; Thouless, M. D.; Takayama, S. Tuneable
Elastomeric Nanochannels for Nanofluidic Manipulation. Nat. Mater. 2007, 6, 424-428.

50.

Chung, S.; Lee, J. H.; Moon, M.-W.; Han, J.; Kamm, R. D. Non-Lithographic Wrinkle
Nanochannels for Protein Preconcentration. Adv. Mater. (Weinheim, Ger.) 2008, 20,
3011-3016.

51.

Park, K. D.; Lee, S. W.; Takama, N.; Fujii, T.; Kim, B. J. Arbitrary-Shaped
Nanochannels Fabricated by Polymeric Deformation to Achieve Single DNA Stretching.
Microelectron. Eng. 2009, 86, 1385-1388.

52.

Park, S.-m.; Huh, Y. S.; Graighead, H. G.; Erickson, D. A Method for Nanofluidic
Device Prototyping Using Elastomeric Collapse. Proc. Natl. Acad. Sci. U. S. A. 2009,
106, 15549-15554, S15549/1-S15549/6.

53.

Shao, P. E.; van Kan, A.; Wang, L. P.; Ansari, K.; Bettiol, A. A.; Watt, F. Fabrication of
Enclosed Nanochannels in Poly(Methylmethacrylate) Using Proton Beam Writing and
Thermal Bonding. Applied Physics Letters 2006, 88, -.

54.

Kwak, R.; Kim, S. J.; Han, J. Continuous-Flow Biomolecule and Cell Concentrator by
Ion Concentration Polarization. Anal. Chem. (Washington, DC, U. S.) 2011, 83, 73487355.
167

55.

Schoch, R. B.; Renaud, P. Ion Transport through Nanoslits Dominated by the Effective
Surface Charge. Applied Physics Letters 2005, 86, 25311 1-3.

56.

Larson, R. A. Reaction Mechanisms in Environmental Organic Chemistry. Lewis
Publishers: Boca Raton, [Fla.], 1994.

57.

Seah, M. P.; Dench, W. A. Quantitative Electron Spectroscopy of Surfaces: A Standard
Data Base for Electron Inelastic Mean Free Paths in Solids. Surface and Interface
Analysis 1979, 1, 2-11.

58.

Mitchell, D. F.; Clark, K. B.; Bardwell, J. A.; Lennard, W. N.; Massoumi, G. R.;
Mitchell, I. V. Film Thickness Measurements of Sio2 by Xps. Surface and Interface
Analysis 1994, 21, 44-50.

59.

Powell, C. J.; Jablonski, A.; Tanuma, S.; Penn, D. R. Effects of Elastic and Inelastic
Electron Scattering on Quantitative Surface Analyses by Aes and Xps. Journal of
Electron Spectroscopy and Related Phenomena 1994, 68, 605-616.

60.

Chan-Park, M. B.; Yan, Y.; Neo, W. K.; Zhou, W.; Zhang, J.; Yue, C. Y. Fabrication of
High Aspect Ratio Poly(Ethylene Glycol)-Containing Microstructures by Uv Embossing.
Langmuir 2003, 19, 4371-4380.

61.

Becker, H.; Gärtner, C. Polymer Microfabrication Technologies for Microfluidic
Systems. Anal Bioanal Chem 2008, 390, 89-111.

62.

Kwok, D. Y.; Neumann, A. W. Contact Angle Measurement and Contact Angle
Interpretation. Advances in Colloid and Interface Science 1999, 81, 167-249.

63.

Seidel, C.; Kopf, H.; Gotsmann, B.; Vieth, T.; Fuchs, H.; Reihs, K. Ar Plasma Treated
and Al-Metalized Polycarbonate: A Xps, Mass Spectroscopy and Sfm Study. Appl. Surf.
Sci. 1999, 150, 19-33.

64.

Ben, A. S.; Baud, G.; Jacquet, M.; Nanse, G.; Fioux, P.; Nardin, M. Xps Characterization
of Plasma-Treated and Alumina-Coated Pmma. Appl. Surf. Sci. 2000, 153, 172-183.

168

65.

Gröning, P.; Collaud, M.; Dietler, G.; Schlapbach, L. Plasma Modification of
Polymethylmethacrylate and Polyethyleneterephthalate Surfaces. Journal of Applied
Physics 1994, 76, 887-892.

66.

Messinger, R. J.; Squires, T. M. Suppression of Electro-Osmotic Flow by Surface
Roughness. Physical Review Letters 2010, 105.

67.

Ziarani, A. S.; Mohamad, A. A. Effect of Wall Roughness on the Slip of Fluid in a
Microchannel. Nanoscale and microscale thermophysical engineering 2008, 12, 154-169.

68.

Park, H. M.; Lee, H. D. Effects of Wall Roughness and Velocity Slip on Streaming
Potential of Microchannels. International Journal of Heat and Mass Transfer 2012, 55,
3295-3306.

69.

Wang, M.; Wang, J.; Chen, S. Roughness and Cavitations Effects on Electro-Osmotic
Flows in Rough Microchannels Using the Lattice Poisson–Boltzmann Methods. Journal
of Computational Physics 2007, 226, 836-851.

70.

Kim, D.; Darve, E. Molecular Dynamics Simulation of Electro-Osmotic Flows in Rough
Wall Nanochannels. Physical Review E 2006, 73, 051203.

71.

Wenzel, R. N. Surface Roughness and Contact Angle. The Journal of Physical and
Colloid Chemistry 1949, 53, 1466-1467.

72.

Schoch, R. B.; Han, J.; Renaud, P. Transport Phenomena in Nanofluidics. Reviews of
Modern Physics 2008, 80, 839-883.

73.

Sonnefeld, J.; Göbel, A.; Vogelsberger, W. Surface Charge Density on Spherical Silica
Particles in Aqueous Alkali Chloride Solutions. Colloid Polym Sci 1995, 273, 926-931.

74.

Daiguji, H.; Yang, P.; Majumdar, A. Ion Transport in Nanofluidic Channels. Nano
Letters 2003, 4, 137-142.

75.

Meisenberg, G. Principles of Medical Biochemistry. Mosby Elsevier: Philadelphia, 2006.

169

76.

Qiao, R.; Aluru, N. R. Atomistic Simulation of Kcl Transport in Charged Silicon
Nanochannels: Interfacial Effects. Colloids and Surfaces A: Physicochemical and
Engineering Aspects 2005, 267, 103-109.

77.

Bhattacharyya, S.; Zheng, Z.; Conlisk, A. Electro-Osmotic Flow in Two-Dimensional
Charged Micro-and Nanochannels. Journal of Fluid Mechanics 2005, 540, 247-268.

78.

Slater, G.; Tessier, F.; Kopecka, K. The Electroosmotic Flow (Eof). In Microengineering
in Biotechnology, Hughes, M. P.; Hoettges, K. F., Eds. Humana Press: 2010; Vol. 583, pp
121-134.

79.

Kirby, B. J.; Hasselbrink, E. F., Jr. Zeta Potential of Microfluidic Substrates: 2. Data for
Polymers. Electrophoresis 2004, 25, 203-213.

80.

Huang, X.; Gordon, M. J.; Zare, R. N. Current-Monitoring Method for Measuring the
Electroosmotic Flow Rate in Capillary Zone Electrophoresis. Anal. Chem. 1988, 60,
1837-8.

81.

Qiao, R.; Aluru, N. R. Scaling of Electrokinetic Transport in Nanometer Channels.
Langmuir 2005, 21, 8972-8977.

82.

Tas, N. R.; Haneveld, J.; Jansen, H. V.; Elwenspoek, M.; van den Berg, A. Capillary
Filling Speed of Water in Nanochannels. Applied Physics Letters 2004, 85, 3274-3276.

83.

Kaji, N.; Ogawa, R.; Oki, A.; Horiike, Y.; Tokeshi, M.; Baba, Y. Study of Water
Properties in Nanospace. Anal Bioanal Chem 2006, 386, 759-764.

84.

Wang, M.; Chang, C.-C.; Yang, R.-J. Electroviscous Effects in Nanofluidic Channels.
The Journal of Chemical Physics 2010, 132, -.

85.

Neogi, P.; Ruckenstein, E. Viscoelectric Effects in Reverse Osmosis. Journal of Colloid
and Interface Science 1981, 79, 159-169.

86.

Hug, T.; Rooij, N. d.; Staufer, U. Fabrication and Electroosmotic Flow Measurements in
Micro- and Nanofluidic Channels. Microfluid. Nanofluid. 2006, 2, 117-124.

170

87.

Milanova, D.; Chambers, R. D.; Bahga, S. S.; Santiago, J. G. Effect of Pvp on the
Electroosmotic Mobility of Wet-Etched Glass Microchannels. ELECTROPHORESIS
2012, 33, 3259-3262.

88.

Yasui, T.; Kaji, N.; Mohamadi, M. R.; Okamoto, Y.; Tokeshi, M.; Horiike, Y.; Baba, Y.
Electroosmotic Flow in Microchannels with Nanostructures. ACS Nano 2011, 5, 77757780.

171

CHAPTER 5 FUTURE WORK: INTEGRATION OF TASK SPECIFIC
MODULES TO DEVELOP A MODULAR FLUIDIC BIOPROCESSOR FOR
POINT-OF-CARE DIAGNOSIS OF STROKE
5.1 Introduction
Emerging innovations of point-of-care (POC) diagnostic test devices is due to their ability to
provide rapid results on an ever expanding range of medical tests.1 The need for extremely
simple (in terms of use without need for trained personnel) devices in POC applications has
fueled an interest in the construction of field deployable instruments using microfluidics. 2 As
mentioned earlier in chapter 1, various biomarkers have been reviewed and their role in clinical
utility has been signified. The need for a POC device arises from the longer times required for
clinical distinction of subtypes of stroke with existing neuroimaging methods and shorter time
window available for treatment and patient management. POC devices also reduce the turnaround-time (TAT) for the identification of stroke subtype in a prehospital setting as a
confirmation test for diagnosis.
Attractive features offered by microfluidics like low consumption of reagents and samples,
miniaturization, and fast turnaround time for analysis to perform various laboratory functions
and assessments make them a perfect fit for point-of-care diagnostic devices. These devices are
fully enclosed due to which a there is a reduction in contaminant carryover, sample dilution and
losses. In addition, microfluidics is a versatile technology which offer features such as feasibility
of integrating electronics, reconfigurability, the possibility of automation and high throughput,
miniaturization of complex fluid handling and integrated detection. Various proof- of-concept
studies have shown the advantages of lab-on-a-chip (LOC) systems over laboratory testing. 3-6
Transformation of microfluidic systems into point-of-care diagnostic systems from a laboratory
into clinical setting requires automation and also efficient strategies for combining several
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individually tested modules including pumping, valving, mixing and sample preparation
obviating the need for moving or spinning components. The ultimate goal is to achieve
resolution & sensitivity similar to benchtop instruments.
5.2 Proposed Molecular Processing Strategy
We focus on developing a portable, automated instrument which would serve as a near patient
technology for the diagnosis of ischemic and/or hemorrhagic stroke using mRNA expression
profiling directly from whole blood within a processing time <20 min to accommodate effective
therapeutic treatment of this disease. This will be achieved by developing a fluidic bio-processor
fabricated in polymers via micro-replication technology and integrating task specific modules on
a fluidic motherboard. The material selected for each module will depend selected for each module
based upon the application needed to produce optimal performance. All the relevant steps required for

the molecular assay are depicted in Figure 5.1.

Figure 5.1 Processing pipelines using a conventional bench-top strategy for processing mRNAs
specifically for obtaining expression data and the processing pipeline that will be employed in
POC system for the rapid reporting of mRNA signatures associated with stroke.
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This includes i) cell isolation (i.e., positive selection of T-cells and neutrophils), ii) cell lysis of
isolated cells, extraction/purification of the target material (mRNA), iii) thermal enzymatic
reactions including reverse transcription (RT) to build cDNAs iv) Ligase detection reaction
(LDR) to generate molecular beacons unique to each mRNA biomarker using primers that carry
reporter sequences for the target and readout of successful ligation events using single pair
Fluorescence Resonance Energy Transfer (spFRET).The use of spFRET obviates the need for a
PCR step, which not only reduces processing time, but also produces exquisite analytical
sensitivity. The most important and notable feature of the molecular processing strategy
delineated in Figure 5.1, is the TAT. When compared to a conventional approach for mRNA
expression profiling, TAT is projected to be ~45 min for the proposed strategy compared to the
conventional approach, which may require nearly 11 h to secure similar information. Next
sections will provide a description of each processing step and the fluidic device for its
implementation. Detailed description of each of these modules will be given in the next sections.
5.3 Fluidic Bioprocessor for mRNA Expression Profiling
A fully integrated polymer-based fluidic bio-processor for mRNA expression profiling will
consist of individual or a group of processing steps poised on a single module and systems built
from modules connected to a fluidic motherboard. All these modules will be combined in plug
and play like setup.The primary advantages of this design approach include; (1) the ability to
match the material properties to the processing step(s) situated on the chip; (2) allow individual
testing of the modules to optimize performance; (3) simplify the fabrication process for
producing integrated systems; and (4) provide flexibility in assembling modules to accommodate
different assay strategies. Wang et al. demonstrated this approach for POC detection of
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Mycobacterium Tuberculosis (Mtb).7 This system could determine the multi-drug resistance of
Mtb resulting from strains that fail to respond to first-line drugs, such as rifampin.

Figure 5.2 Fluidic bio-processor for the analysis of mRNAs in PBMCs. The fluidic bio-processor
has 3 modules that are used for positive cell selection (T-cells and neutrophils), (2) SPE
isolation/purification of RNA (3) and spFRET readout (4). All these modules will be “plugged”
into a fluidic motherboard. Also shown are locations of on-chip valves (V) pumps (A-F) and
high-aspect ratio mixers (M). A – sample input; B – lysing buffer; C – SPE buffer; D – ethanol;
E – RT cocktail; F – LDR cocktail; G – connection to off-chip vacuum pump. Box in red shows
the modules which have been described in previous chapters.
The proposed fluidic bio-processor shown schematically in Figure 5.2 consists of different
modules. In chapters 2 & 3, we have focused our efforts to isolate T-cells and neutrophils. For
this application, cell sorting module was fabricated in COC due to its high optical transparency
and uniform modification of high aspect-ratio channels.8 We were able successfully isolate the
cells of interest and isolate TRNA from the lysate of these cells both by commercially available
silica columns and also by using UV activated PC SPE module. The RNA SPE module and
fluidic motherboard are made from PC due to its relatively high glass transition temperature to
allow it to withstand the temperatures required for the thermal reactions and also its unique
characteristic to allow the SPE of nucleic acids For the initial studies, TRNA was reverse
transcribed to cDNA and amplified via bench top PCR. 9-11 Gene expression studies were shown
for a housekeeping gene (GAPDH), a gene overexpressed in ischemic stroke event (S100A9), T175

cell specific gene (TCRB) and neutrophil specific gene (FPR1). However, gene expression of
mRNA’s specific for ischemic and hemorrhagic stroke are yet to be studied. In order to reduce
the final TAT, gene expression analysis can also be performed by carrying out reverse
transcription (RT) in a continuous flow mode on a microfluidic chip. An mRNA will be copied
to cDNA in continuous flow reverse transcription (CFRT) using an oligo dT primer. CFRT’s will
be used for the RT and LDRs with the devices optimized for processing speed and product yield.
Reaction time (RT phase) and the number of thermal cycles (LDR phase) required for obtaining
viable quantitative information from the mRNA transcripts required for the stroke diagnosis will
be investigated.
5.4 Fabrication of Microfluidic Modules
Polymer microchips can be replicated from metal masters using either hot embossing or
injection molding with the principle advantages of this fabrication protocol being; (1) the ability
to produce large quantities of microchips at low-cost; (2) once the master is made, a wide
selection of materials can be used for the final parts without requiring additional lithographic
processing; (3) mixed-scale, multi-level and double-sided molding can be used to fabricate the
prerequisite microchips. The metal masters can be made using a variety of techniques, including
UV-LiGA, X-ray LiGA or high precision micromilling, with the choice predicated on the
required structures and the stage of development of the microchip; we have developed the
infrastructure to generate masters using all of these techniques.10,

12-14

As the fluidic bio-

processor is to be used for diagnostic applications requiring one-time use operation, it is critical
to simplify the manufacturing of this fluidic processor to reduce chip cost.
As seen from Figure 5.2 the fluidic bioprocessor will consist of 3 modules with 1 made in
PMMA and another in the appropriate waveguiding material (blue, see Figure 5.2) and the third
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made from PC (light gray). The fluidic motherboard in which the modules will be inserted using
the appropriate interconnect technology will be made from PC. The modules and motherboard
will be replicated from metal masters fabricated by lithographic or non-lithographic techniques
with the selected technique based on the required dimensional features of each. These masters
will be then used to replicate parts in the appropriate polymeric substrate using hot-embossing.12,
14, 15

The spFRET readout module must be made of a polymeric material that has favorable

optical properties and also, supports waveguiding.
For structures possessing lateral dimensions below 20 μm and aspect ratios exceeding 5:1,
UV-LiGA must be used to make the mold master. For the hemispherical lenses, we will use Xray LiGA to fabricate the mold master. Whichever fabrication technique we use, the master is
used to replicate the appropriate parts via hot embossing (Jenoptik HEX02). Through-holes
required as the interconnects between modules can be made using excimer laser drilling, which
can machine holes ~50 μm in diameter through a substrate as thick as 2 mm.10 The exact channel
lengths and cross-sectional dimensions will be determined from experimental results. As can be
seen in Figure 5.2, several mixers in the fluidic motherboard are required. Because flow in
microchannels is laminar (Re << 100), the rate of mixing between two miscible fluids is
determined by molecular diffusion. To facilitate mixing between sample and reagents and to
keep the bio-processor operation simple, we will employ a Y-shaped, high-aspect ratio (AR,
where AR = channel height / channel width) passive micromixer configuration (see Figure 5.2).
In this type of mixer, input streams are fed into a narrow but deep channel, which effectively
increases the contact area between the two streams and reduces diffusional distances. The
increased channel depth also keeps the pressure drop low when feeding liquids into this narrow
channel.
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5.5 LDR/spFRET for mRNA Quantitation
The molecular assay’s foundation is based on the ability to identify unique sequences from
mRNAs (actually cDNA) using an LDR coupled to spFRET.16 In this project, we do not will
expression profile single cells, but detect single mRNA molecules through their respective
cDNA surrogates subjected to a LDR (superior sequence specificity for single base variations17)
to form molecular beacons undergoing spFRET that are digitally counted to provide
exquisite analytical sensitivity. The major advantages of this single molecule detection in
molecular analyses include; (1) the ability to alleviate the need for amplifying the target material
via PCR, which produces potential difficulties in obtaining quantitative information; (2) reduces
the number of processing steps and; (3) significantly reduces processing time and assay cost.

Figure 5.3 Illustration of LDR-spFRET assay18
LDR involves the use of two primers that recognize a reporter sequence of the target, which
in this case is a cDNA, and ligates the two primers only if there is complete complementarity
between the primers and the cDNA. If this condition is met, the primers are successfully ligated,
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forming a molecular beacon bringing the donor/acceptor dyes into close proximity to allow for
spFRET to occur (see Figure 5.3). If the primers are not perfectly matched to the reporter
sequence of the cDNA, no ligation occurs and consequently, no spFRET results. LDR-spFRET
provided the necessary specificity and sensitivity to detect single point mutations in as little as
~600 copies of human genomic DNA without PCR at a level of 1 mutant per 1,000 wild- type
sequences in less than 5 min.16
5.6 Inter and Intra Modular Assembly
In this phase of the project, the individual fluidic modules required for each processing
step of the molecular assay will be integrated to form a fluidic bio-processor consisting of taskspecific modules assembled to a fluidic motherboard using the appropriate interconnect
technologies. Super hydrophobic seals will be used to prevent “leakage” of fluid at the
interconnects. Various interconnect geometries and architectures will be evaluated as well. To
align the modules during assembly, V-grooves and pins (kinematic constraints) will be used.
Effective thermal isolation between modules will also be investigated and optimized.
While the proposed system is targeted for field diagnosis of stroke using mRNA biomarkers,
the system can be envisioned for other applications as well that require quantitative expression
analysis of mRNA. In the case of stroke diagnoses, the fluidic bio-processor can be configured to
detect other biomarkers necessary for the diagnoses, such as serum proteins, without hardware
reconfiguration.
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